|
G |
CHRNA4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
EXP |
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Lobeline inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Lobeline results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] |
CTD |
PMID:14645658 PMID:18448488 |
|
NCBI chr20:63,343,223...63,361,349
Ensembl chr20:63,343,223...63,378,401
|
|
G |
CHRNA7 |
cholinergic receptor nicotinic alpha 7 subunit |
affects response to substance multiple interactions |
EXP |
CHRNA7 protein mutant form affects the susceptibility to Lobeline Lobeline binds to and results in decreased activity of CHRNA7 protein; Lobeline binds to and results in increased activity of CHRNA7 protein mutant form |
CTD |
PMID:10082212 |
|
NCBI chr15:32,030,483...32,173,018
Ensembl chr15:31,923,438...32,173,018
|
|
G |
CHRNB2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
EXP |
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Lobeline inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Lobeline results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] |
CTD |
PMID:14645658 PMID:18448488 |
|
NCBI chr 1:154,567,778...154,580,013
Ensembl chr 1:154,567,778...154,580,013
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
EXP |
Lobeline results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Lobeline inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:18448488 PMID:20106947 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Lobeline inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:18448488 PMID:20106947 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Lobeline inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:18448488 PMID:20106947 |
|
NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568
|
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
[Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of ACTA2 mRNA] |
CTD |
PMID:34609854 |
|
NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339
|
|
G |
AIFM1 |
apoptosis inducing factor mitochondria associated 1 |
multiple interactions |
EXP |
Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium affects the localization of AIFM1 protein]; Selegiline inhibits the reaction [Oxidopamine affects the localization of AIFM1 protein]; Selegiline inhibits the reaction [Rotenone affects the localization of AIFM1 protein] |
CTD |
PMID:12880480 |
|
NCBI chr X:130,129,362...130,165,841
Ensembl chr X:130,124,666...130,165,879
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of AKT1 protein]; [Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of AKT1 protein Selegiline results in increased phosphorylation of AKT1 protein |
CTD |
PMID:22019741 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
BACH1 |
BTB domain and CNC homolog 1 |
multiple interactions |
EXP |
Selegiline inhibits the reaction [Smoke analog affects the localization of BACH1 protein] |
CTD |
PMID:28108387 |
|
NCBI chr21:29,298,922...29,361,894
Ensembl chr21:29,194,071...29,630,751
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Selegiline inhibits the reaction [linsidomine results in increased expression of BAX protein] |
CTD |
PMID:12880480 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO |
Selegiline inhibits the reaction [linsidomine results in decreased expression of BCL2 protein] |
CTD |
PMID:12880480 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP ISO |
Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 mRNA]; Selegiline inhibits the reaction [linsidomine results in increased expression of CASP3 mRNA]; Selegiline inhibits the reaction [linsidomine results in increased expression of CASP3 protein] Selegiline promotes the reaction [Hydroxyurea results in increased cleavage of CASP3 protein] |
CTD |
PMID:12880480 PMID:14724376 PMID:23696560 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CAT |
catalase |
multiple interactions |
ISO EXP |
Selegiline promotes the reaction [Rotenone results in increased activity of CAT protein] Selegiline inhibits the reaction [Smoke analog results in decreased activity of CAT protein] |
CTD |
PMID:16490285 PMID:28108387 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
[Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA] |
CTD |
PMID:34609854 |
|
NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632
|
|
G |
COL3A1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
[Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA] |
CTD |
PMID:34609854 |
|
NCBI chr 2:188,974,373...189,012,746
Ensembl chr 2:188,974,373...189,012,746
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
Selegiline inhibits the reaction [Smoke analog results in increased secretion of CXCL8 protein] |
CTD |
PMID:28108387 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions |
ISO |
Selegiline inhibits the reaction [linsidomine affects the localization of CYCS protein] |
CTD |
PMID:12880480 |
|
NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
affects metabolic processing |
EXP |
CYP1A2 protein affects the metabolism of Selegiline |
CTD |
PMID:16198659 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
multiple interactions decreases activity |
EXP |
Selegiline inhibits the reaction [CYP2B6 protein results in increased hydroxylation of Bupropion] Selegiline results in decreased activity of CYP2B6 protein |
CTD |
PMID:25656918 |
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of FOS mRNA] |
CTD |
PMID:14724376 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
GAPDH |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
EXP ISO |
Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of GAPDH mRNA] Selegiline inhibits the reaction [Paraquat affects the localization of GAPDH protein] Selegiline inhibits the reaction [Hydroxyurea affects the localization of GAPDH protein] |
CTD |
PMID:14724376 PMID:20478973 PMID:23696560 |
|
NCBI chr12:6,534,517...6,538,371
Ensembl chr12:6,534,512...6,538,374
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions |
EXP |
Selegiline inhibits the reaction [Smoke analog results in increased expression of HMOX1 protein] |
CTD |
PMID:28108387 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of JUN mRNA] Selegiline results in increased expression of JUN protein |
CTD |
PMID:14724376 PMID:16099847 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
MAOA |
monoamine oxidase A |
decreases activity |
EXP |
Selegiline results in decreased activity of MAOA protein |
CTD |
PMID:31323226 |
|
NCBI chr X:43,655,006...43,746,817
Ensembl chr X:43,654,907...43,746,817
|
|
G |
MAOB |
monoamine oxidase B |
affects binding decreases activity multiple interactions |
EXP ISO |
Selegiline binds to MAOB protein Selegiline results in decreased activity of MAOB protein [Selegiline results in decreased activity of MAOB protein] which results in decreased abundance of 3,4-Dihydroxyphenylacetic Acid; [Selegiline results in decreased activity of MAOB protein] which results in decreased abundance of Homovanillic Acid; [Selegiline results in decreased activity of MAOB protein] which results in increased abundance of Dopamine [Selegiline results in decreased activity of MAOB protein] which results in increased susceptibility to Methamphetamine; zonisamide inhibits the reaction [Selegiline binds to MAOB protein] Selegiline inhibits the reaction [MAOB protein results in decreased amination of Dopamine]; Selegiline inhibits the reaction [MAOB protein results in increased degradation of Dopamine]; Selegiline inhibits the reaction [Smoke analog results in increased activity of MAOB protein] |
CTD |
PMID:1905457 PMID:15178694 PMID:15545290 PMID:16012872 PMID:16252076 PMID:19948168 PMID:21405131 PMID:21696156 PMID:21923181 PMID:21923198 PMID:26721607 PMID:28108387 PMID:28302559 PMID:30036687 PMID:31323226 More...
|
|
NCBI chr X:43,766,610...43,882,450
Ensembl chr X:43,766,610...43,882,450
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Selegiline results in increased phosphorylation of MAPK1 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of MAPK1 protein]; [Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:16099847 PMID:22019741 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Selegiline results in increased phosphorylation of MAPK3 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of MAPK3 protein]; [Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:16099847 PMID:22019741 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MT1X |
metallothionein 1X |
multiple interactions |
ISO |
Selegiline inhibits the reaction [linsidomine results in increased expression of MT1 protein] |
CTD |
PMID:12880480 |
|
NCBI chr16:56,682,470...56,684,196
Ensembl chr16:56,682,470...56,684,196
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
increases phosphorylation multiple interactions |
EXP |
Selegiline results in increased phosphorylation of MYC protein MYC protein affects the reaction [Selegiline results in increased expression of TXN] |
CTD |
PMID:16099847 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases localization |
ISO EXP |
NFE2L2 mutant form inhibits the reaction [Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of NQO1 protein]]; NFE2L2 mutant form inhibits the reaction [Selegiline results in increased activity of NQO1 protein]; Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased localization of NFE2L2 protein] Selegiline inhibits the reaction [Smoke analog affects the localization of NFE2L2 protein] Selegiline results in increased localization of NFE2L2 protein |
CTD |
PMID:22019741 PMID:28108387 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases activity |
ISO EXP |
NFE2L2 mutant form inhibits the reaction [Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of NQO1 protein]]; NFE2L2 mutant form inhibits the reaction [Selegiline results in increased activity of NQO1 protein]; Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of NQO1 protein] Selegiline inhibits the reaction [Smoke analog results in increased expression of NQO1 protein] |
CTD |
PMID:22019741 PMID:28108387 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Selegiline inhibits the reaction [linsidomine results in decreased expression of PARP1 protein] |
CTD |
PMID:12880480 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PRKN |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
EXP |
Selegiline inhibits the reaction [linsidomine results in increased expression of PRKN protein] |
CTD |
PMID:12880480 |
|
NCBI chr 6:161,347,417...162,727,766
Ensembl chr 6:161,347,417...162,727,775
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Selegiline inhibits the reaction [Smoke analog affects the localization of RELA protein] |
CTD |
PMID:28108387 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
SIAH1 |
siah E3 ubiquitin protein ligase 1 |
multiple interactions |
ISO |
Selegiline inhibits the reaction [Paraquat affects the localization of SIAH1A protein] |
CTD |
PMID:20478973 |
|
NCBI chr16:48,360,531...48,387,246
Ensembl chr16:48,356,364...48,448,402
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
Selegiline inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
G |
SNCA |
synuclein alpha |
multiple interactions |
EXP |
Selegiline inhibits the reaction [1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA protein]; Selegiline inhibits the reaction [linsidomine results in increased expression of SNCA protein] |
CTD |
PMID:12880480 PMID:15114628 |
|
NCBI chr 4:89,724,099...89,838,304
Ensembl chr 4:89,700,345...89,838,315
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:34609854 |
|
NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568
|
|
G |
TH |
tyrosine hydroxylase |
multiple interactions decreases expression |
ISO |
Selegiline inhibits the reaction [Rotenone results in decreased expression of TH protein] Selegiline results in decreased expression of TH mRNA |
CTD |
PMID:11862330 PMID:16490285 |
|
NCBI chr11:2,163,929...2,171,815
Ensembl chr11:2,163,929...2,171,815
|
|
G |
TXN |
thioredoxin |
multiple interactions increases expression affects response to substance |
EXP ISO |
Dinitrochlorobenzene inhibits the reaction [Selegiline results in increased expression of TXN]; Dinitrochlorobenzene inhibits the reaction [TXN protein affects the susceptibility to Selegiline]; MYC protein affects the reaction [Selegiline results in increased expression of TXN] Selegiline results in increased expression of TXN protein |
CTD |
PMID:16099847 |
|
NCBI chr 9:110,243,810...110,256,507
Ensembl chr 9:110,243,810...110,256,507
|
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
decreases methylation increases hydroxylation increases metabolic processing |
EXP |
CYP1A1 protein results in decreased methylation of almotriptan CYP1A1 protein results in increased hydroxylation of almotriptan CYP1A1 protein results in increased metabolism of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
decreases methylation |
EXP |
CYP1A2 protein results in decreased methylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP2C19 |
cytochrome P450 family 2 subfamily C member 19 |
decreases methylation |
EXP |
CYP2C19 protein results in decreased methylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
|
|
G |
CYP2C8 |
cytochrome P450 family 2 subfamily C member 8 |
decreases methylation |
EXP |
CYP2C8 protein results in decreased methylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497
|
|
G |
CYP2D6 |
cytochrome P450 family 2 subfamily D member 6 |
decreases methylation increases hydroxylation |
EXP |
CYP2D6 protein results in decreased methylation of almotriptan CYP2D6 protein results in increased hydroxylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
increases hydroxylation decreases methylation |
EXP |
CYP3A4 protein results in increased hydroxylation of almotriptan CYP3A4 protein results in decreased methylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
FMO3 |
flavin containing dimethylaniline monoxygenase 3 |
increases oxidation |
EXP |
FMO3 protein results in increased oxidation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr 1:171,090,905...171,117,819
Ensembl chr 1:171,090,901...171,117,819
|
|
G |
HTR1B |
5-hydroxytryptamine receptor 1B |
multiple interactions |
EXP |
HTR1B affects the reaction [almotriptan inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11134654 |
|
NCBI chr 6:77,460,924...77,463,491
Ensembl chr 6:77,460,924...77,463,491
|
|
G |
MAOA |
monoamine oxidase A |
increases metabolic processing |
EXP |
MAOA protein results in increased metabolism of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr X:43,655,006...43,746,817
Ensembl chr X:43,654,907...43,746,817
|
|
|
G |
HTR1A |
5-hydroxytryptamine receptor 1A |
affects binding |
ISO |
alverine binds to HTR1A protein |
CTD |
PMID:11697552 |
|
NCBI chr 5:63,957,874...63,962,445
Ensembl chr 5:63,957,874...63,962,507
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
EXP |
alverine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
|
G |
AADAT |
aminoadipate aminotransferase |
affects expression |
ISO |
Amitriptyline affects the expression of AADAT mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 4:170,060,222...170,094,292
Ensembl chr 4:170,060,222...170,091,699
|
|
G |
ABAT |
4-aminobutyrate aminotransferase |
decreases expression |
ISO |
Amitriptyline results in decreased expression of ABAT mRNA |
CTD |
PMID:21820738 |
|
NCBI chr16:8,674,617...8,784,570
Ensembl chr16:8,674,596...8,784,575
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
affects transport affects expression increases transport |
ISO |
ABCB1A protein affects the transport of Amitriptyline Amitriptyline affects the expression of ABCB1 mRNA ABCB1A protein results in increased transport of Amitriptyline; ABCB1A protein results in increased transport of Amitriptyline metabolite |
CTD |
PMID:10700657 PMID:12082591 PMID:18355885 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCB11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of ABCB11 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
|
|
G |
ABCD2 |
ATP binding cassette subfamily D member 2 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of ABCD2 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr12:39,531,025...39,619,803
Ensembl chr12:39,550,033...39,619,803
|
|
G |
ABCG5 |
ATP binding cassette subfamily G member 5 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of ABCG5 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 2:43,806,211...43,839,231
Ensembl chr 2:43,812,472...43,838,865
|
|
G |
ABCG8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of ABCG8 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988
|
|
G |
ACE2 |
angiotensin converting enzyme 2 |
increases expression |
EXP |
Amitriptyline results in increased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236
|
|
G |
ACHE |
acetylcholinesterase (Yt blood group) |
decreases expression increases activity |
ISO |
Amitriptyline results in decreased expression of ACHE mRNA Amitriptyline results in increased activity of ACHE protein |
CTD |
PMID:21820738 PMID:29614332 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
ALDH1A1 |
aldehyde dehydrogenase 1 family member A1 |
affects expression |
ISO |
Amitriptyline affects the expression of ALDH1A1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442
|
|
G |
ANKRD1 |
ankyrin repeat domain 1 |
increases expression |
ISO |
Amitriptyline results in increased expression of ANKRD1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr10:90,912,096...90,921,087
Ensembl chr10:90,912,096...90,921,087
|
|
G |
ANO3 |
anoctamin 3 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of ANO3 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr11:26,188,808...26,663,289
Ensembl chr11:26,188,842...26,663,289
|
|
G |
AP1S1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of AP1S1 mRNA |
CTD |
PMID:17175557 PMID:17567588 |
|
NCBI chr 7:101,154,476...101,161,276
Ensembl chr 7:101,154,456...101,161,596
|
|
G |
APOA4 |
apolipoprotein A4 |
affects expression |
ISO |
Amitriptyline affects the expression of APOA4 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr11:116,820,700...116,823,304
Ensembl chr11:116,820,700...116,823,304
|
|
G |
ARG1 |
arginase 1 |
increases expression |
ISO |
Amitriptyline results in increased expression of ARG1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 6:131,573,226...131,584,329
Ensembl chr 6:131,470,832...131,584,332
|
|
G |
ASAH1 |
N-acylsphingosine amidohydrolase 1 |
increases expression |
EXP |
Amitriptyline results in increased expression of ASAH1 mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr 8:18,055,992...18,084,961
Ensembl chr 8:18,055,992...18,084,998
|
|
G |
ASNS |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
EXP |
Amitriptyline results in increased expression of ASNS mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr 7:97,851,677...97,928,441
Ensembl chr 7:97,851,677...97,872,542
|
|
G |
ATF3 |
activating transcription factor 3 |
increases expression |
ISO |
Amitriptyline results in increased expression of ATF3 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:212,565,407...212,620,777
Ensembl chr 1:212,565,334...212,620,777
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein] |
CTD |
PMID:19135049 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein] |
CTD |
PMID:19135049 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BHMT |
betaine--homocysteine S-methyltransferase |
affects expression |
ISO |
Amitriptyline affects the expression of BHMT mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 5:79,111,809...79,132,288
Ensembl chr 5:79,111,809...79,132,288
|
|
G |
C1QA |
complement C1q A chain |
increases expression |
ISO |
Amitriptyline results in increased expression of C1QA mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:22,636,463...22,639,678
Ensembl chr 1:22,635,077...22,639,678
|
|
G |
C1QC |
complement C1q C chain |
increases expression |
ISO |
Amitriptyline results in increased expression of C1QC mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:22,643,633...22,648,108
Ensembl chr 1:22,643,014...22,648,110
|
|
G |
CACNA2D1 |
calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
increases expression |
ISO |
Amitriptyline results in increased expression of CACNA2D1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 7:81,946,444...82,443,956
Ensembl chr 7:81,946,444...82,443,956
|
|
G |
CASP1 |
caspase 1 |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of CASP1 protein]; Amitriptyline inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of CASP1 protein]; Amitriptyline inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein] |
CTD |
PMID:28633109 |
|
NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases expression increases activity |
ISO |
Amitriptyline inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein] Amitriptyline results in increased expression of CASP3 mRNA Amitriptyline results in increased activity of CASP3 protein |
CTD |
PMID:16717317 PMID:19135049 PMID:19815060 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASR |
calcium sensing receptor |
decreases expression |
ISO |
Amitriptyline results in decreased expression of CASR mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 3:122,183,668...122,291,629
Ensembl chr 3:122,183,668...122,291,629
|
|
G |
CAT |
catalase |
decreases expression |
EXP |
Amitriptyline results in decreased expression of CAT protein |
CTD |
PMID:1937386 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CD74 |
CD74 molecule |
increases expression |
ISO |
Amitriptyline results in increased expression of CD74 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 5:150,401,639...150,412,910
Ensembl chr 5:150,401,637...150,412,969
|
|
G |
CDKN2C |
cyclin dependent kinase inhibitor 2C |
affects expression |
ISO |
Amitriptyline affects the expression of CDKN2C mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 1:50,968,706...50,974,634
Ensembl chr 1:50,960,745...50,974,634
|
|
G |
CES2 |
carboxylesterase 2 |
affects expression |
ISO |
Amitriptyline affects the expression of CES2 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr16:66,934,471...66,945,096
Ensembl chr16:66,934,444...66,945,096
|
|
G |
CHAT |
choline O-acetyltransferase |
increases expression |
ISO |
Amitriptyline results in increased expression of CHAT mRNA |
CTD |
PMID:21820738 |
|
NCBI chr10:49,609,095...49,667,942
Ensembl chr10:49,609,095...49,667,942
|
|
G |
CHRNA3 |
cholinergic receptor nicotinic alpha 3 subunit |
decreases expression |
ISO |
Amitriptyline results in decreased expression of CHRNA3 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr15:78,593,052...78,620,996
Ensembl chr15:78,593,052...78,621,295
|
|
G |
CHRNB2 |
cholinergic receptor nicotinic beta 2 subunit |
decreases expression increases response to substance |
ISO |
Amitriptyline results in decreased expression of CHRNB2 mRNA CHRNB2 protein results in increased susceptibility to Amitriptyline |
CTD |
PMID:21820738 PMID:21905669 |
|
NCBI chr 1:154,567,778...154,580,013
Ensembl chr 1:154,567,778...154,580,013
|
|
G |
CMTM6 |
CKLF like MARVEL transmembrane domain containing 6 |
affects expression |
ISO |
Amitriptyline affects the expression of CMTM6 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 3:32,481,312...32,502,852
Ensembl chr 3:32,481,312...32,502,852
|
|
G |
CPNE4 |
copine 4 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of CPNE4 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 3:131,533,569...132,039,606
Ensembl chr 3:131,533,555...132,285,410
|
|
G |
CPPED1 |
calcineurin like phosphoesterase domain containing 1 |
affects expression |
ISO |
Amitriptyline affects the expression of CPPED1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr16:12,659,799...12,803,887
Ensembl chr16:12,659,799...12,803,887
|
|
G |
CREM |
cAMP responsive element modulator |
affects expression |
ISO |
Amitriptyline affects the expression of CREM mRNA |
CTD |
PMID:18355885 |
|
NCBI chr10:35,126,846...35,212,958
Ensembl chr10:35,126,791...35,212,958
|
|
G |
CSRP3 |
cysteine and glycine rich protein 3 |
increases expression |
ISO |
Amitriptyline results in increased expression of CSRP3 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr11:19,182,030...19,201,983
Ensembl chr11:19,182,030...19,210,571
|
|
G |
CYBB |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of CYBB protein]; Amitriptyline inhibits the reaction [7-ketocholesterol analog affects the localization of CYBB protein] |
CTD |
PMID:28633109 |
|
NCBI chr X:37,780,059...37,813,461
Ensembl chr X:37,780,018...37,813,461
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
increases metabolic processing multiple interactions |
EXP |
Amitriptyline results in increased metabolism of CYP1A2 protein; CYP1A2 protein results in increased metabolism of Amitriptyline [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Amitriptyline |
CTD |
PMID:18359012 PMID:23397584 PMID:27320963 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP2A13 |
cytochrome P450 family 2 subfamily A member 13 |
affects expression |
ISO |
Amitriptyline affects the expression of CYP2A1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr19:41,088,451...41,096,195
Ensembl chr19:41,088,451...41,096,195
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
increases metabolic processing |
EXP |
CYP2B6 protein results in increased metabolism of Amitriptyline |
CTD |
PMID:27320963 |
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
CYP2C19 |
cytochrome P450 family 2 subfamily C member 19 |
multiple interactions increases metabolic processing |
EXP |
[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Amitriptyline CYP2C19 protein results in increased metabolism of Amitriptyline |
CTD |
PMID:23397584 PMID:27320963 |
|
NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
multiple interactions |
EXP |
[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Amitriptyline |
CTD |
PMID:23397584 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP2D6 |
cytochrome P450 family 2 subfamily D member 6 |
decreases activity multiple interactions increases metabolic processing |
EXP |
Amitriptyline results in decreased activity of CYP2D6 protein [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Amitriptyline Amitriptyline results in increased metabolism of CYP2D6 protein; CYP2D6 protein results in increased metabolism of Amitriptyline |
CTD |
PMID:16044105 PMID:18359012 PMID:18359183 PMID:23397584 PMID:27320963 |
|
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
increases metabolic processing multiple interactions |
EXP |
Amitriptyline results in increased metabolism of CYP3A4 protein [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Amitriptyline |
CTD |
PMID:18359012 PMID:23397584 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
increases metabolic processing |
EXP |
Amitriptyline results in increased metabolism of CYP3A5 protein |
CTD |
PMID:18359012 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
|
|
G |
CYP4F12 |
cytochrome P450 family 4 subfamily F member 12 |
affects expression |
ISO |
Amitriptyline affects the expression of CYP4F2 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr19:15,673,087...15,697,174
Ensembl chr19:15,673,018...15,697,174
|
|
G |
DCAF8 |
DDB1 and CUL4 associated factor 8 |
affects expression |
ISO |
Amitriptyline affects the expression of DCAF8 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 1:160,215,720...160,262,549
Ensembl chr 1:160,215,715...160,262,549
|
|
G |
DEPP1 |
DEPP autophagy regulator 1 |
increases expression |
EXP |
Amitriptyline results in increased expression of DEPP1 mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr10:44,976,128...44,978,809
Ensembl chr10:44,970,981...44,978,809
|
|
G |
DES |
desmin |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [Homocysteine results in increased expression of DES protein] |
CTD |
PMID:23024785 |
|
NCBI chr 2:219,418,377...219,426,734
Ensembl chr 2:219,418,377...219,426,735
|
|
G |
DNMT1 |
DNA methyltransferase 1 |
decreases activity |
ISO |
Amitriptyline results in decreased activity of DNMT1 protein Amitriptyline decreases activity of Dnmt1 protein in astrocyte nucleus |
CTD RGD |
PMID:19924110 PMID:22880885 |
RGD:9588218 |
NCBI chr19:10,133,346...10,194,953
Ensembl chr19:10,133,342...10,231,286
|
|
G |
DRD1 |
dopamine receptor D1 |
increases expression |
ISO |
Amitriptyline results in increased expression of DRD1 mRNA |
CTD |
PMID:16499906 |
|
NCBI chr 5:175,440,036...175,444,182
Ensembl chr 5:175,440,036...175,444,182
|
|
G |
DRD3 |
dopamine receptor D3 |
increases expression |
ISO |
Amitriptyline results in increased expression of DRD3 mRNA |
CTD |
PMID:21820738 |
|
NCBI chr 3:114,127,580...114,199,407
Ensembl chr 3:114,127,580...114,199,407
|
|
G |
ECEL1 |
endothelin converting enzyme like 1 |
increases expression |
ISO |
Amitriptyline results in increased expression of ECEL1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 2:232,479,827...232,487,834
Ensembl chr 2:232,479,827...232,487,834
|
|
G |
EIF4B |
eukaryotic translation initiation factor 4B |
affects expression |
ISO |
Amitriptyline affects the expression of EIF4B mRNA |
CTD |
PMID:18355885 |
|
NCBI chr12:53,006,456...53,042,215
Ensembl chr12:53,006,282...53,042,215
|
|
G |
EPHX1 |
epoxide hydrolase 1 |
affects expression |
ISO |
Amitriptyline affects the expression of EPHX1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563
|
|
G |
ERP29 |
endoplasmic reticulum protein 29 |
affects expression |
ISO |
Amitriptyline affects the expression of ERP29 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr12:112,013,426...112,023,449
Ensembl chr12:112,013,348...112,023,449
|
|
G |
FABP1 |
fatty acid binding protein 1 |
increases expression |
EXP |
Amitriptyline results in increased expression of FABP1 mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062
|
|
G |
FLRT3 |
fibronectin leucine rich transmembrane protein 3 |
increases expression |
ISO |
Amitriptyline results in increased expression of FLRT3 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr20:14,322,985...14,337,612
Ensembl chr20:14,322,985...14,337,614
|
|
G |
FMO3 |
flavin containing dimethylaniline monoxygenase 3 |
increases metabolic processing |
EXP |
FMO3 protein results in increased metabolism of Amitriptyline |
CTD |
PMID:27320963 |
|
NCBI chr 1:171,090,905...171,117,819
Ensembl chr 1:171,090,901...171,117,819
|
|
G |
FNDC4 |
fibronectin type III domain containing 4 |
increases expression |
EXP |
Amitriptyline results in increased expression of FNDC4 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 2:27,491,883...27,495,200
Ensembl chr 2:27,491,883...27,495,200
|
|
G |
GABRA1 |
gamma-aminobutyric acid type A receptor subunit alpha1 |
increases expression decreases expression |
ISO |
Amitriptyline results in increased expression of GABRA1 mRNA Amitriptyline results in decreased expression of GABRA1 mRNA |
CTD |
PMID:21820738 PMID:22341215 |
|
NCBI chr 5:161,847,191...161,899,971
Ensembl chr 5:161,847,063...161,899,981
|
|
G |
GABRA2 |
gamma-aminobutyric acid type A receptor subunit alpha2 |
increases expression |
ISO |
Amitriptyline results in increased expression of GABRA2 mRNA |
CTD |
PMID:21820738 |
|
NCBI chr 4:46,243,548...46,390,300
Ensembl chr 4:46,243,548...46,475,230
|
|
G |
GABRA4 |
gamma-aminobutyric acid type A receptor subunit alpha4 |
increases expression |
ISO |
Amitriptyline results in increased expression of GABRA4 mRNA |
CTD |
PMID:21820738 |
|
NCBI chr 4:46,918,900...46,993,581
Ensembl chr 4:46,918,900...46,993,581
|
|
G |
GABRB3 |
gamma-aminobutyric acid type A receptor subunit beta3 |
increases expression |
ISO |
Amitriptyline results in increased expression of GABRB3 mRNA |
CTD |
PMID:21820738 |
|
NCBI chr15:26,543,552...26,773,763
Ensembl chr15:26,543,552...26,939,539
|
|
G |
GADD45A |
growth arrest and DNA damage inducible alpha |
increases expression |
ISO |
Amitriptyline results in increased expression of GADD45A mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334
|
|
G |
GAL |
galanin and GMAP prepropeptide |
increases expression |
ISO |
Amitriptyline results in increased expression of GAL mRNA |
CTD |
PMID:22341215 |
|
NCBI chr11:68,684,544...68,691,175
Ensembl chr11:68,683,779...68,691,175
|
|
G |
GCKR |
glucokinase regulator |
affects expression |
ISO |
Amitriptyline affects the expression of GCKR mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 2:27,496,839...27,523,684
Ensembl chr 2:27,496,839...27,523,684
|
|
G |
GDPD3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
increases expression |
EXP |
Amitriptyline results in increased expression of GDPD3 mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr16:30,104,810...30,113,537
Ensembl chr16:30,104,810...30,113,537
|
|
G |
GFAP |
glial fibrillary acidic protein |
increases expression |
ISO |
Amitriptyline results in increased expression of GFAP mRNA |
CTD |
PMID:22954530 |
|
NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937
|
|
G |
GLS2 |
glutaminase 2 |
affects expression |
ISO |
Amitriptyline affects the expression of GLS2 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr12:56,470,952...56,488,161
Ensembl chr12:56,470,944...56,488,414
|
|
G |
GOT2 |
glutamic-oxaloacetic transaminase 2 |
affects expression |
ISO |
Amitriptyline affects the expression of GOT2 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr16:58,707,131...58,734,316
Ensembl chr16:58,707,131...58,734,342
|
|
G |
GRB14 |
growth factor receptor bound protein 14 |
affects expression |
ISO |
Amitriptyline affects the expression of GRB14 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 2:164,492,417...164,621,482
Ensembl chr 2:164,492,417...164,621,482
|
|
G |
GRIK1 |
glutamate ionotropic receptor kainate type subunit 1 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of GRIK1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr21:29,536,933...29,939,996
Ensembl chr21:29,536,933...29,940,033
|
|
G |
GSTP1 |
glutathione S-transferase pi 1 |
decreases activity |
EXP |
Amitriptyline results in decreased activity of GSTP1 protein |
CTD |
PMID:15094841 |
|
NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
|
|
G |
HAL |
histidine ammonia-lyase |
affects expression |
ISO |
Amitriptyline affects the expression of HAL mRNA |
CTD |
PMID:18355885 |
|
NCBI chr12:95,972,662...95,996,344
Ensembl chr12:95,972,662...95,996,365
|
|
G |
HLA-DRA |
major histocompatibility complex, class II, DR alpha |
increases expression |
ISO |
Amitriptyline results in increased expression of RT1-DA mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 6:32,439,887...32,445,046
Ensembl chr 6:32,439,878...32,445,046
|
|
G |
HLA-DRB1 |
major histocompatibility complex, class II, DR beta 1 |
increases expression |
ISO |
Amitriptyline results in increased expression of RT1-DB1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 6:32,578,775...32,589,848
Ensembl chr 6:32,577,902...32,589,848
|
|
G |
HMGB2 |
high mobility group box 2 |
affects expression |
ISO |
Amitriptyline affects the expression of HMGB2 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 4:173,331,376...173,334,358
Ensembl chr 4:173,331,376...173,334,432
|
|
G |
HMGCS1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
EXP |
Amitriptyline results in increased expression of HMGCS1 mRNA |
CTD |
PMID:16324787 |
|
NCBI chr 5:43,287,470...43,313,412
Ensembl chr 5:43,287,470...43,313,512
|
|
G |
HOXD1 |
homeobox D1 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of HOXD1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 2:176,188,668...176,190,907
Ensembl chr 2:176,188,668...176,190,907
|
|
G |
HPN |
hepsin |
increases expression |
EXP |
Amitriptyline results in increased expression of HPN mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr19:35,040,506...35,066,573
Ensembl chr19:35,040,506...35,066,573
|
|
G |
HPSE |
heparanase |
decreases expression |
ISO |
Amitriptyline results in decreased expression of HPSE mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 4:83,292,461...83,335,153
Ensembl chr 4:83,292,461...83,335,153
|
|
G |
HS3ST2 |
heparan sulfate-glucosamine 3-sulfotransferase 2 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of HS3ST2 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr16:22,814,162...22,916,338
Ensembl chr16:22,814,162...22,916,338
|
|
G |
HTR1A |
5-hydroxytryptamine receptor 1A |
increases expression |
ISO |
Amitriptyline results in increased expression of HTR1A protein |
CTD |
PMID:1589591 |
|
NCBI chr 5:63,957,874...63,962,445
Ensembl chr 5:63,957,874...63,962,507
|
|
G |
HTR1D |
5-hydroxytryptamine receptor 1D |
decreases expression |
ISO |
Amitriptyline results in decreased expression of HTR1D mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:23,191,895...23,217,502
Ensembl chr 1:23,191,895...23,217,502
|
|
G |
HTR2C |
5-hydroxytryptamine receptor 2C |
affects binding |
EXP |
Amitriptyline binds to HTR2C protein |
CTD |
PMID:18083778 |
|
NCBI chr X:114,584,086...114,910,061
Ensembl chr X:114,584,078...114,910,061
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [7-ketocholesterol results in increased expression of IL1B protein]; Amitriptyline inhibits the reaction [Cholesterol analog results in increased expression of IL1B protein] |
CTD |
PMID:28633109 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL33 |
interleukin 33 |
affects expression |
ISO |
Amitriptyline affects the expression of IL33 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 9:6,215,149...6,257,983
Ensembl chr 9:6,215,786...6,257,983
|
|
G |
INHBE |
inhibin subunit beta E |
increases expression |
EXP |
Amitriptyline results in increased expression of INHBE mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr12:57,455,307...57,458,025
Ensembl chr12:57,452,323...57,459,280
|
|
G |
ITGB6 |
integrin subunit beta 6 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of ITGB6 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 2:160,099,671...160,200,272
Ensembl chr 2:160,099,667...160,200,313
|
|
G |
KCNA4 |
potassium voltage-gated channel subfamily A member 4 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of KCNA4 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr11:30,009,730...30,017,030
Ensembl chr11:30,009,730...30,017,030
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
EXP |
Amitriptyline inhibits the reaction [KCNH2 protein results in increased transport of Thallium] |
CTD |
PMID:19583963 PMID:21158687 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
KCNN2 |
potassium calcium-activated channel subfamily N member 2 |
decreases activity |
ISO |
Amitriptyline results in decreased activity of KCNN2 protein |
CTD |
PMID:10915830 |
|
NCBI chr 5:114,055,978...114,496,496
Ensembl chr 5:114,055,926...114,496,500
|
|
G |
KCNS1 |
potassium voltage-gated channel modifier subfamily S member 1 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of KCNS1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr20:45,091,214...45,101,127
Ensembl chr20:45,091,214...45,101,127
|
|
G |
KCNS3 |
potassium voltage-gated channel modifier subfamily S member 3 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of KCNS3 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 2:17,877,847...17,932,958
Ensembl chr 2:17,877,847...18,361,616
|
|
G |
LOX |
lysyl oxidase |
affects expression |
ISO |
Amitriptyline affects the expression of LOX mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 5:122,063,195...122,078,259
Ensembl chr 5:122,063,195...122,078,413
|
|
G |
LSS |
lanosterol synthase |
increases expression |
EXP |
Amitriptyline results in increased expression of LSS mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr21:46,188,446...46,228,774
Ensembl chr21:46,188,141...46,228,824
|
|
G |
MACROH2A1 |
macroH2A.1 histone |
affects expression |
ISO |
Amitriptyline affects the expression of MACROH2A1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 5:135,334,381...135,399,887
Ensembl chr 5:135,334,381...135,399,914
|
|
G |
MANBA |
mannosidase beta |
affects expression |
ISO |
Amitriptyline affects the expression of MANBA mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 4:102,630,770...102,760,968
Ensembl chr 4:102,630,770...102,760,994
|
|
G |
MAOA |
monoamine oxidase A |
affects expression |
ISO |
Amitriptyline affects the expression of MAOA mRNA |
CTD |
PMID:21820738 |
|
NCBI chr X:43,655,006...43,746,817
Ensembl chr X:43,654,907...43,746,817
|
|
G |
MLX |
MAX dimerization protein MLX |
affects expression |
ISO |
Amitriptyline affects the expression of MLX mRNA |
CTD |
PMID:18355885 |
|
NCBI chr17:42,567,100...42,573,203
Ensembl chr17:42,567,072...42,573,239
|
|
G |
MMP16 |
matrix metallopeptidase 16 |
increases expression |
ISO |
Amitriptyline results in increased expression of MMP16 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 8:88,032,011...88,327,483
Ensembl chr 8:88,032,011...88,328,025
|
|
G |
MRPS18B |
mitochondrial ribosomal protein S18B |
affects expression |
ISO |
Amitriptyline affects the expression of MRPS18B mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 6:30,617,840...30,626,392
Ensembl chr 6:30,617,840...30,626,395
|
|
G |
MSMO1 |
methylsterol monooxygenase 1 |
affects expression |
ISO |
Amitriptyline affects the expression of MSMO1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 4:165,327,669...165,343,164
Ensembl chr 4:165,327,667...165,343,164
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of NLRP3 protein]; Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of NLRP3 protein] |
CTD |
PMID:28633109 |
|
NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,416,156...247,449,108
|
|
G |
NMB |
neuromedin B |
decreases expression |
ISO |
Amitriptyline results in decreased expression of NMB mRNA |
CTD |
PMID:22341215 |
|
NCBI chr15:84,655,132...84,658,199
Ensembl chr15:84,655,129...84,658,563
|
|
G |
NMUR1 |
neuromedin U receptor 1 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of NMUR1 mRNA |
CTD |
PMID:21820738 |
|
NCBI chr 2:231,518,455...231,530,445
Ensembl chr 2:231,523,187...231,530,445
|
|
G |
NOG |
noggin |
decreases expression |
ISO |
Amitriptyline results in decreased expression of NOG mRNA |
CTD |
PMID:22341215 |
|
NCBI chr17:56,593,699...56,595,611
Ensembl chr17:56,593,699...56,595,611
|
|
G |
NPHS2 |
NPHS2 stomatin family member, podocin |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [Homocysteine results in decreased expression of NPHS2 protein] |
CTD |
PMID:23024785 |
|
NCBI chr 1:179,550,539...179,575,948
Ensembl chr 1:179,550,539...179,575,952
|
|
G |
NPY |
neuropeptide Y |
increases expression |
ISO |
Amitriptyline results in increased expression of NPY mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 7:24,284,190...24,291,862
Ensembl chr 7:24,284,188...24,291,862
|
|
G |
NPY5R |
neuropeptide Y receptor Y5 |
increases expression |
ISO |
Amitriptyline results in increased expression of NPY5R mRNA |
CTD |
PMID:21820738 |
|
NCBI chr 4:163,343,892...163,352,403
Ensembl chr 4:163,343,892...163,351,934
|
|
G |
NR0B2 |
nuclear receptor subfamily 0 group B member 2 |
increases expression |
EXP |
Amitriptyline results in increased expression of NR0B2 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975
|
|
G |
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
affects response to substance |
ISO |
NR3C1 protein affects the susceptibility to Amitriptyline |
CTD |
PMID:11226678 |
|
NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512
|
|
G |
NR3C2 |
nuclear receptor subfamily 3 group C member 2 |
increases expression |
ISO |
Amitriptyline results in increased expression of NR3C2 mRNA |
CTD |
PMID:12393271 |
|
NCBI chr 4:148,078,764...148,445,508
Ensembl chr 4:148,078,762...148,444,698
|
|
G |
NREP |
neuronal regeneration related protein |
affects expression |
ISO |
Amitriptyline affects the expression of NREP mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 5:111,728,802...111,976,932
Ensembl chr 5:111,662,621...111,997,464
|
|
G |
NTNG1 |
netrin G1 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of NTNG1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:107,140,088...107,484,923
Ensembl chr 1:107,140,007...107,484,923
|
|
G |
NUPR1 |
nuclear protein 1, transcriptional regulator |
increases expression |
EXP |
Amitriptyline results in increased expression of NUPR1 mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr16:28,532,708...28,538,974
Ensembl chr16:28,532,708...28,539,008
|
|
G |
OAF |
out at first homolog |
affects expression |
ISO |
Amitriptyline affects the expression of OAF mRNA |
CTD |
PMID:18355885 |
|
NCBI chr11:120,211,032...120,230,334
Ensembl chr11:120,211,032...120,230,334
|
|
G |
PATJ |
PATJ crumbs cell polarity complex component |
decreases expression |
ISO |
Amitriptyline results in decreased expression of PATJ mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:61,742,480...62,163,915
Ensembl chr 1:61,742,477...62,178,675
|
|
G |
PC |
pyruvate carboxylase |
affects expression |
ISO |
Amitriptyline affects the expression of PC mRNA |
CTD |
PMID:18355885 |
|
NCBI chr11:66,848,420...66,958,383
Ensembl chr11:66,848,417...66,958,386
|
|
G |
PECR |
peroxisomal trans-2-enoyl-CoA reductase |
affects expression |
ISO |
Amitriptyline affects the expression of PECR mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 2:216,029,088...216,081,809
Ensembl chr 2:215,996,329...216,082,955
|
|
G |
PHYH |
phytanoyl-CoA 2-hydroxylase |
increases expression |
EXP |
Amitriptyline results in increased expression of PHYH mRNA |
CTD |
PMID:15342952 |
|
NCBI chr10:13,277,799...13,300,064
Ensembl chr10:13,277,796...13,302,412
|
|
G |
PLCD4 |
phospholipase C delta 4 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of PLCD4 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 2:218,607,899...218,637,175
Ensembl chr 2:218,607,855...218,637,184
|
|
G |
PLPP4 |
phospholipid phosphatase 4 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of PLPP4 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr10:120,456,954...120,592,065
Ensembl chr10:120,457,227...120,592,065
|
|
G |
POR |
cytochrome p450 oxidoreductase |
affects expression |
ISO |
Amitriptyline affects the expression of POR mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
|
|
G |
PROKR1 |
prokineticin receptor 1 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of PROKR1 mRNA |
CTD |
PMID:21820738 |
|
NCBI chr 2:68,643,579...68,658,251
Ensembl chr 2:68,643,579...68,658,251
|
|
G |
PYCARD |
PYD and CARD domain containing |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of PYCARD protein]; Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of PYCARD protein] |
CTD |
PMID:28633109 |
|
NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450
|
|
G |
RASD1 |
ras related dexamethasone induced 1 |
increases expression |
ISO |
Amitriptyline results in increased expression of RASD1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr17:17,494,437...17,496,395
Ensembl chr17:17,494,437...17,496,395
|
|
G |
RBL2 |
RB transcriptional corepressor like 2 |
affects expression |
ISO |
Amitriptyline affects the expression of RBL2 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr16:53,434,471...53,491,648
Ensembl chr16:53,433,977...53,491,648
|
|
G |
REG3A |
regenerating family member 3 alpha |
increases expression |
ISO |
Amitriptyline results in increased expression of REG3B mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 2:79,157,006...79,159,753
Ensembl chr 2:79,157,003...79,159,753
|
|
G |
RNF112 |
ring finger protein 112 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of RNF112 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr17:19,411,232...19,417,276
Ensembl chr17:19,411,125...19,417,276
|
|
G |
SCD |
stearoyl-CoA desaturase |
increases expression |
EXP |
Amitriptyline results in increased expression of SCD mRNA |
CTD |
PMID:16324787 |
|
NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826
|
|
G |
SCN11A |
sodium voltage-gated channel alpha subunit 11 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of SCN11A mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 3:38,845,764...39,051,944
Ensembl chr 3:38,845,764...39,052,157
|
|
G |
SEMA6A |
semaphorin 6A |
increases expression |
ISO |
Amitriptyline results in increased expression of SEMA6A mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 5:116,443,555...116,574,823
Ensembl chr 5:116,443,555...116,574,823
|
|
G |
SERPINA3 |
serpin family A member 3 |
increases expression |
EXP |
Amitriptyline results in increased expression of SERPINA3 mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr14:94,612,391...94,624,053
Ensembl chr14:94,612,384...94,624,055
|
|
G |
SH3GL3 |
SH3 domain containing GRB2 like 3, endophilin A3 |
affects expression |
ISO |
Amitriptyline affects the expression of SH3GL3 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr15:83,447,341...83,633,820
Ensembl chr15:83,447,228...83,618,743
|
|
G |
SLC22A1 |
solute carrier family 22 member 1 |
multiple interactions decreases activity |
EXP |
Amitriptyline inhibits the reaction [SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide] Amitriptyline results in decreased activity of SLC22A1 protein |
CTD |
PMID:30189235 PMID:31364238 |
|
NCBI chr 6:160,121,815...160,158,718
Ensembl chr 6:160,121,815...160,158,718
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions decreases activity |
EXP |
Amitriptyline inhibits the reaction [SLC22A2 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]; Amitriptyline inhibits the reaction [SLC22A2 protein results in increased import of Tetraethylammonium]; Amitriptyline inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Amitriptyline inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium] Amitriptyline results in decreased activity of SLC22A2 protein |
CTD |
PMID:21599003 PMID:23770354 PMID:28629854 PMID:30189235 PMID:31364238 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
G |
SLC22A6 |
solute carrier family 22 member 6 |
multiple interactions |
EXP |
Amitriptyline inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:21561794 |
|
NCBI chr11:62,976,597...62,984,967
Ensembl chr11:62,936,385...62,984,967
|
|
G |
SLC2A3 |
solute carrier family 2 member 3 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr12:7,919,230...7,936,187
Ensembl chr12:7,919,230...8,019,007
|
|
G |
SLC47A2 |
solute carrier family 47 member 2 |
multiple interactions |
EXP |
Amitriptyline inhibits the reaction [SLC47A2 protein results in increased import of Tetraethylammonium] |
CTD |
PMID:28629854 |
|
NCBI chr17:19,678,317...19,718,979
Ensembl chr17:19,678,288...19,718,979
|
|
G |
SLC6A6 |
solute carrier family 6 member 6 |
affects expression |
ISO |
Amitriptyline affects the expression of SLC6A6 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 3:14,402,576...14,489,349
Ensembl chr 3:14,402,576...14,489,349
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
affects expression |
ISO |
Amitriptyline affects the expression of SLCO1A4 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr12:21,264,600...21,419,634
Ensembl chr12:21,264,600...21,419,594
|
|
G |
SMAGP |
small cell adhesion glycoprotein |
increases expression |
ISO |
Amitriptyline results in increased expression of SMAGP mRNA |
CTD |
PMID:22341215 |
|
NCBI chr12:51,244,558...51,270,415
Ensembl chr12:51,244,558...51,270,415
|
|
G |
SMPD1 |
sphingomyelin phosphodiesterase 1 |
decreases activity increases response to substance multiple interactions |
EXP ISO |
Amitriptyline results in decreased activity of SMPD1 protein SMPD1 protein results in increased susceptibility to Amitriptyline [Amitriptyline results in decreased expression of and results in decreased activity of SMPD1 protein] which results in decreased abundance of Ceramides; Amitriptyline results in decreased expression of and results in decreased activity of SMPD1 protein |
CTD |
PMID:23770692 |
|
NCBI chr11:6,390,474...6,394,996
Ensembl chr11:6,390,440...6,394,998
|
|
G |
SOD1 |
superoxide dismutase 1 |
increases expression |
ISO |
Amitriptyline results in increased expression of SOD1 mRNA |
CTD |
PMID:10721683 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SORL1 |
sortilin related receptor 1 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of SORL1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr11:121,452,314...121,633,763
Ensembl chr11:121,452,314...121,633,763
|
|
G |
SOX11 |
SRY-box transcription factor 11 |
increases expression |
ISO |
Amitriptyline results in increased expression of SOX11 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 2:5,692,384...5,701,385
Ensembl chr 2:5,692,384...5,701,385
|
|
G |
SPRR1A |
small proline rich protein 1A |
increases expression |
ISO |
Amitriptyline results in increased expression of SPRR1A mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:152,984,081...152,985,814
Ensembl chr 1:152,984,081...152,985,814
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
Amitriptyline results in increased cleavage of and results in increased activity of SREBF1 protein |
CTD |
PMID:16324787 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
SREBF2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
EXP |
Amitriptyline results in increased cleavage of and results in increased activity of SREBF2 protein |
CTD |
PMID:16324787 |
|
NCBI chr22:41,833,105...41,907,305
Ensembl chr22:41,833,105...41,907,306
|
|
G |
SSTR1 |
somatostatin receptor 1 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of SSTR1 mRNA |
CTD |
PMID:21820738 |
|
NCBI chr14:38,207,904...38,213,067
Ensembl chr14:38,207,904...38,213,067
|
|
G |
ST13 |
ST13 Hsp70 interacting protein |
affects expression |
ISO |
Amitriptyline affects the expression of ST13 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr22:40,824,535...40,856,639
Ensembl chr22:40,824,535...40,856,639
|
|
G |
STAC2 |
SH3 and cysteine rich domain 2 |
increases expression |
ISO |
Amitriptyline results in increased expression of STAC2 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr17:39,210,541...39,225,945
Ensembl chr17:39,210,541...39,225,945
|
|
G |
STBD1 |
starch binding domain 1 |
affects expression |
ISO |
Amitriptyline affects the expression of STBD1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 4:76,306,733...76,311,130
Ensembl chr 4:76,306,733...76,311,130
|
|
G |
STMN1 |
stathmin 1 |
affects expression |
ISO |
Amitriptyline affects the expression of STMN1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 1:25,884,179...25,906,880
Ensembl chr 1:25,884,181...25,906,991
|
|
G |
STMN4 |
stathmin 4 |
increases expression |
ISO |
Amitriptyline results in increased expression of STMN4 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 8:27,235,308...27,258,404
Ensembl chr 8:27,235,308...27,258,420
|
|
G |
TAGLN |
transgelin |
decreases expression |
EXP |
Amitriptyline results in decreased expression of TAGLN mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr11:117,199,294...117,207,465
Ensembl chr11:117,199,370...117,207,464
|
|
G |
TEX261 |
testis expressed 261 |
affects expression |
ISO |
Amitriptyline affects the expression of TEX261 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 2:70,985,942...70,994,873
Ensembl chr 2:70,968,325...70,994,873
|
|
G |
TGM1 |
transglutaminase 1 |
increases expression |
ISO |
Amitriptyline results in increased expression of TGM1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr14:24,249,114...24,263,177
Ensembl chr14:24,249,114...24,264,432
|
|
G |
TIMM10B |
translocase of inner mitochondrial membrane 10B |
affects expression |
ISO |
Amitriptyline affects the expression of TIMM10B mRNA |
CTD |
PMID:18355885 |
|
NCBI chr11:6,481,501...6,484,681
Ensembl chr11:6,481,501...6,484,681
|
|
G |
TMPRSS2 |
transmembrane serine protease 2 |
increases expression |
EXP |
Amitriptyline results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr21:41,464,305...41,508,158
Ensembl chr21:41,464,300...41,531,116
|
|
G |
TRH |
thyrotropin releasing hormone |
multiple interactions |
EXP |
Amitriptyline inhibits the reaction [TRH protein results in decreased expression of TSHB protein] |
CTD |
PMID:6455462 |
|
NCBI chr 3:129,974,720...129,977,935
Ensembl chr 3:129,974,688...129,977,935
|
|
G |
TRPV1 |
transient receptor potential cation channel subfamily V member 1 |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased uptake of Calcium] |
CTD |
PMID:23264033 |
|
NCBI chr17:3,565,446...3,609,411
Ensembl chr17:3,565,444...3,609,411
|
|
G |
TSHB |
thyroid stimulating hormone subunit beta |
multiple interactions |
EXP |
Amitriptyline inhibits the reaction [TRH protein results in decreased expression of TSHB protein] |
CTD |
PMID:6455462 |
|
NCBI chr 1:115,029,826...115,034,309
Ensembl chr 1:115,029,826...115,034,302
|
|
G |
UBA52 |
ubiquitin A-52 residue ribosomal protein fusion product 1 |
affects expression |
ISO |
Amitriptyline affects the expression of UBA52 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr19:18,563,766...18,577,550
Ensembl chr19:18,571,730...18,577,550
|
|
G |
UGT1A1 |
UDP glucuronosyltransferase family 1 member A1 |
affects expression |
ISO |
Amitriptyline affects the expression of UGT1A1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300
|
|
G |
UGT2A1 |
UDP glucuronosyltransferase family 2 member A1 complex locus |
affects expression |
ISO |
Amitriptyline affects the expression of UGT2A1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 4:69,588,417...69,653,247
Ensembl chr 4:69,588,417...69,653,249
|
|
G |
UGT2B17 |
UDP glucuronosyltransferase family 2 member B17 |
affects expression |
ISO |
Amitriptyline affects the expression of UGT2B1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 4:68,537,173...68,576,322
Ensembl chr 4:68,537,173...68,576,413
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [Homocysteine results in decreased secretion of VEGFA protein] |
CTD |
PMID:23024785 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
WIPI1 |
WD repeat domain, phosphoinositide interacting 1 |
increases expression |
EXP |
Amitriptyline results in increased expression of WIPI1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr17:68,421,281...68,457,496
Ensembl chr17:68,420,948...68,457,513
|
|
|
G |
HRH1 |
histamine receptor H1 |
multiple interactions |
EXP |
azatadine binds to and results in decreased activity of HRH1 protein |
CTD |
PMID:2864258 |
|
NCBI chr 3:11,137,238...11,263,557
Ensembl chr 3:11,137,093...11,263,557
|
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
increases metabolic processing |
EXP |
CYP2B6 protein results in increased metabolism of Benzphetamine |
CTD |
PMID:12464242 PMID:15769884 |
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions |
EXP |
Benzphetamine inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] |
CTD |
PMID:19299527 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions |
EXP |
Bepridil inhibits the reaction [ABCB1 protein results in increased transport of Digoxin] |
CTD |
PMID:11895100 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ATF4 |
activating transcription factor 4 |
increases expression |
EXP |
Bepridil results in increased expression of ATF4 protein |
CTD |
PMID:21292685 |
|
NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,683
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
affects metabolic processing |
EXP |
CYP3A4 protein affects the metabolism of Bepridil |
CTD |
PMID:15286053 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression |
EXP |
Bepridil results in increased expression of DDIT3 protein |
CTD |
PMID:21292685 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
EIF2A |
eukaryotic translation initiation factor 2A |
increases phosphorylation |
EXP |
Bepridil results in increased phosphorylation of EIF2A protein |
CTD |
PMID:21292685 |
|
NCBI chr 3:150,546,787...150,586,016
Ensembl chr 3:150,546,678...150,586,016
|
|
G |
KCNA5 |
potassium voltage-gated channel subfamily A member 5 |
decreases activity |
EXP |
Bepridil results in decreased activity of KCNA5 protein |
CTD |
PMID:11711026 |
|
NCBI chr12:5,043,879...5,046,788
Ensembl chr12:5,043,879...5,046,788
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
EXP |
Bepridil binds to and results in decreased activity of KCNH2 protein; Bepridil inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Bepridil results in decreased activity of KCNH2 protein |
CTD |
PMID:15272206 PMID:15671647 PMID:21158687 PMID:24052561 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
SLC8A1 |
solute carrier family 8 member A1 |
multiple interactions |
EXP |
Bepridil inhibits the reaction [SLC8A1 protein results in increased susceptibility to Chlorodiphenyl (54% Chlorine)] |
CTD |
PMID:16009740 |
|
NCBI chr 2:40,097,270...40,512,435
Ensembl chr 2:40,097,270...40,611,053
|
|
G |
TNFRSF10B |
TNF receptor superfamily member 10b |
increases expression |
EXP |
Bepridil results in increased expression of TNFRSF10B protein |
CTD |
PMID:21292685 |
|
NCBI chr 8:23,020,133...23,069,031
Ensembl chr 8:23,020,133...23,069,031
|
|
G |
TNFSF10 |
TNF superfamily member 10 |
increases response to substance |
EXP |
Bepridil results in increased susceptibility to TNFSF10 protein |
CTD |
PMID:21292685 |
|
NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475
|
|
|
G |
CCL5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA] |
CTD |
PMID:23688403 |
|
NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
|
|
G |
CXCL10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
EXP |
4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [Biological Products results in increased expression of CXCL10 protein]]; butenafine inhibits the reaction [Biological Products results in increased expression of CXCL10 mRNA]; butenafine inhibits the reaction [Biological Products results in increased expression of CXCL10 protein] |
CTD |
PMID:24471457 |
|
NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA] |
CTD |
PMID:23688403 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
IL4 |
interleukin 4 |
multiple interactions |
EXP |
4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; butenafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone] |
CTD |
PMID:23688403 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions |
EXP |
butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein] |
CTD |
PMID:23688403 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
butenafine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
G |
STAT1 |
signal transducer and activator of transcription 1 |
multiple interactions |
EXP |
4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [Biological Products results in increased activity of STAT1 protein]]; butenafine inhibits the reaction [Biological Products results in increased phosphorylation of and results in increased activity of STAT1 protein] |
CTD |
PMID:24471457 |
|
NCBI chr 2:190,969,149...191,014,171
Ensembl chr 2:190,908,460...191,020,960
|
|
G |
TSLP |
thymic stromal lymphopoietin |
multiple interactions |
EXP |
4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein] |
CTD |
PMID:23688403 |
|
NCBI chr 5:111,070,062...111,078,026
Ensembl chr 5:111,070,062...111,078,026
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases expression decreases activity |
EXP |
Chlorpromazine analog results in increased expression of ABCB1 mRNA Chlorpromazine results in decreased activity of ABCB1 protein |
CTD |
PMID:15924885 PMID:16810505 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCB11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases expression |
EXP ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ABCB11 mRNA Chlorpromazine results in decreased expression of ABCB11 mRNA; Chlorpromazine results in decreased expression of ABCB11 protein |
CTD |
PMID:27344345 PMID:27765674 PMID:28391356 PMID:35708773 |
|
NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
|
|
G |
ABCB4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ABCB4 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435
|
|
G |
ABCB6 |
ATP binding cassette subfamily B member 6 (LAN blood group) |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of ABCB6 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:219,209,772...219,218,958
Ensembl chr 2:219,209,772...219,218,994
|
|
G |
ABCB9 |
ATP binding cassette subfamily B member 9 |
increases expression |
ISO |
Chlorpromazine results in increased expression of ABCB9 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:122,918,610...122,975,114
Ensembl chr12:122,920,951...122,981,649
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
increases expression multiple interactions |
ISO |
Chlorpromazine results in increased expression of ABCC2 mRNA [Bile Acids and Salts co-treated with Chlorpromazine] results in decreased expression of ABCC2 mRNA |
CTD |
PMID:27765674 PMID:35708773 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCC3 |
ATP binding cassette subfamily C member 3 |
increases expression multiple interactions decreases expression |
EXP ISO |
Chlorpromazine analog results in increased expression of ABCC3 mRNA [Bile Acids and Salts co-treated with Chlorpromazine] results in decreased expression of ABCC3 mRNA Chlorpromazine results in decreased expression of ABCC3 mRNA |
CTD |
PMID:15924885 PMID:25596134 PMID:35708773 |
|
NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
|
|
G |
ABCC4 |
ATP binding cassette subfamily C member 4 (PEL blood group) |
increases expression |
ISO |
Chlorpromazine results in increased expression of ABCC4 mRNA |
CTD |
PMID:35708773 |
|
NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
|
|
G |
ABCG2 |
ATP binding cassette subfamily G member 2 (JR blood group) |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
|
|
G |
ABCG8 |
ATP binding cassette subfamily G member 8 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ABCG8 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988
|
|
G |
ACACA |
acetyl-CoA carboxylase alpha |
decreases phosphorylation |
ISO |
Chlorpromazine results in decreased phosphorylation of ACACA protein |
CTD |
PMID:17512020 |
|
NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836
|
|
G |
ACE2 |
angiotensin converting enzyme 2 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236
|
|
G |
ACHE |
acetylcholinesterase (Yt blood group) |
decreases activity increases activity multiple interactions |
EXP ISO |
Chlorpromazine results in decreased activity of ACHE protein Chlorpromazine results in increased activity of ACHE protein Dichlorvos promotes the reaction [Chlorpromazine results in decreased activity of ACHE protein] |
CTD |
PMID:4859365 PMID:29614332 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
ACP5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr19:11,574,660...11,578,975
Ensembl chr19:11,574,653...11,579,993
|
|
G |
ADRA1A |
adrenoceptor alpha 1A |
decreases activity |
ISO |
Chlorpromazine results in decreased activity of ADRA1A protein |
CTD |
PMID:23611293 |
|
NCBI chr 8:26,748,150...26,867,379
Ensembl chr 8:26,748,150...26,867,278
|
|
G |
ADRA1B |
adrenoceptor alpha 1B |
decreases activity |
ISO |
Chlorpromazine results in decreased activity of ADRA1B protein |
CTD |
PMID:23611293 |
|
NCBI chr 5:159,865,086...159,989,205
Ensembl chr 5:159,865,080...159,973,012
|
|
G |
AFP |
alpha fetoprotein |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of AFP mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 4:73,436,221...73,456,174
Ensembl chr 4:73,431,138...73,456,174
|
|
G |
AGRN |
agrin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of AGRN mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:1,020,120...1,056,116
Ensembl chr 1:1,020,120...1,056,118
|
|
G |
AHR |
aryl hydrocarbon receptor |
affects activity |
ISO |
Chlorpromazine affects the activity of AHR protein |
CTD |
PMID:25596134 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
AK3 |
adenylate kinase 3 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of AK3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 9:4,709,556...4,742,043
Ensembl chr 9:4,709,556...4,742,043
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
Chlorpromazine results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:17512020 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
ALDH1A1 |
aldehyde dehydrogenase 1 family member A1 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ALDH1A1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442
|
|
G |
ALDOA |
aldolase, fructose-bisphosphate A |
increases expression |
ISO |
Chlorpromazine results in increased expression of ALDOA mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:30,064,279...30,070,420
Ensembl chr16:30,064,164...30,070,457
|
|
G |
ALPP |
alkaline phosphatase, placental |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]; Chlorpromazine inhibits the reaction [Isoproterenol results in increased expression of ALPP mRNA] |
CTD |
PMID:16036225 |
|
NCBI chr 2:232,378,751...232,382,889
Ensembl chr 2:232,378,724...232,382,889
|
|
G |
AP1S1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of AP1S1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 7:101,154,476...101,161,276
Ensembl chr 7:101,154,456...101,161,596
|
|
G |
APOC4 |
apolipoprotein C4 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of APOC4 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr19:44,942,237...44,945,496
Ensembl chr19:44,942,237...44,945,496
|
|
G |
APOF |
apolipoprotein F |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of APOF mRNA |
CTD |
PMID:27344345 |
|
NCBI chr12:56,360,568...56,362,857
Ensembl chr12:56,360,568...56,362,857
|
|
G |
AREG |
amphiregulin |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of AREG mRNA |
CTD |
PMID:15924885 PMID:30703373 |
|
NCBI chr 4:74,445,136...74,455,005
Ensembl chr 4:74,445,136...74,455,005
|
|
G |
ARFGEF2 |
ADP ribosylation factor guanine nucleotide exchange factor 2 |
increases expression |
ISO |
Chlorpromazine results in increased expression of ARFGEF2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:48,921,711...49,036,693
Ensembl chr20:48,921,711...49,036,693
|
|
G |
ARHGEF10 |
Rho guanine nucleotide exchange factor 10 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of ARHGEF10 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:1,823,300...1,958,641
Ensembl chr 8:1,823,926...1,958,641
|
|
G |
ASAH1 |
N-acylsphingosine amidohydrolase 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of ASAH1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 8:18,055,992...18,084,961
Ensembl chr 8:18,055,992...18,084,998
|
|
G |
ASNS |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
EXP |
Chlorpromazine results in increased expression of ASNS mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 7:97,851,677...97,928,441
Ensembl chr 7:97,851,677...97,872,542
|
|
G |
ATF4 |
activating transcription factor 4 |
affects activity multiple interactions |
ISO EXP |
Chlorpromazine affects the activity of ATF4 protein [Chlorpromazine co-treated with Cholic Acids] affects the expression of ATF4 mRNA |
CTD |
PMID:25596134 PMID:27344345 |
|
NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,683
|
|
G |
ATP6V1B2 |
ATPase H+ transporting V1 subunit B2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of ATP6V1B2 protein |
CTD |
PMID:19441803 |
|
NCBI chr 8:20,197,381...20,221,696
Ensembl chr 8:20,197,381...20,226,819
|
|
G |
AVP |
arginine vasopressin |
increases expression multiple interactions |
EXP ISO |
Chlorpromazine results in increased expression of AVP protein Chlorpromazine inhibits the reaction [Lithium results in increased expression of AVP protein] |
CTD |
PMID:3567260 PMID:3976404 |
|
NCBI chr20:3,082,556...3,084,724
Ensembl chr20:3,082,556...3,084,724
|
|
G |
BAG4 |
BAG cochaperone 4 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of BAG4 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 8:38,176,855...38,213,301
Ensembl chr 8:38,176,533...38,213,301
|
|
G |
BCL2L1 |
BCL2 like 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of BCL2L1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BDNF |
brain derived neurotrophic factor |
affects response to substance affects expression |
EXP ISO |
BDNF affects the susceptibility to Chlorpromazine Chlorpromazine affects the expression of BDNF mRNA |
CTD |
PMID:18408624 PMID:31324950 |
|
NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058
|
|
G |
BHLHE40 |
basic helix-loop-helix family member e40 |
increases expression |
EXP |
Chlorpromazine analog results in increased expression of BHLHE40 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 3:4,979,437...4,985,323
Ensembl chr 3:4,979,437...4,985,323
|
|
G |
BIRC2 |
baculoviral IAP repeat containing 2 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of BIRC2 mRNA |
CTD |
PMID:30703373 |
|
NCBI chr11:102,347,214...102,378,670
Ensembl chr11:102,347,211...102,378,670
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of BIRC5 mRNA; Chlorpromazine results in decreased expression of BIRC5 mRNA |
CTD |
PMID:15924885 PMID:30703373 |
|
NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
|
|
G |
BNIP3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
Chlorpromazine results in increased expression of BNIP3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:131,967,684...131,981,923
Ensembl chr10:131,967,684...131,981,967
|
|
G |
BTG2 |
BTG anti-proliferation factor 2 |
increases expression |
EXP |
Chlorpromazine analog results in increased expression of BTG2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 1:203,305,519...203,309,602
Ensembl chr 1:203,305,491...203,309,602
|
|
G |
BTG3 |
BTG anti-proliferation factor 3 |
increases expression |
EXP |
Chlorpromazine analog results in increased expression of BTG3 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr21:17,593,653...17,612,901
Ensembl chr21:17,593,653...17,612,945
|
|
G |
C3 |
complement C3 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of C3 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr19:6,677,704...6,720,650
Ensembl chr19:6,677,704...6,730,562
|
|
G |
C6 |
complement C6 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of C6 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 5:41,142,116...41,261,469
Ensembl chr 5:41,142,116...41,261,438
|
|
G |
CA2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CAR2 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 8:85,464,007...85,481,493
Ensembl chr 8:85,463,968...85,481,493
|
|
G |
CALCR |
calcitonin receptor |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 7:93,424,486...93,574,724
Ensembl chr 7:93,424,486...93,574,730
|
|
G |
CALR |
calreticulin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CALR mRNA |
CTD |
PMID:18246545 |
|
NCBI chr19:12,938,609...12,944,489
Ensembl chr19:12,938,578...12,944,489
|
|
G |
CAT |
catalase |
multiple interactions decreases expression decreases activity |
ISO EXP |
carvedilol inhibits the reaction [Chlorpromazine results in decreased expression of CAT protein]; zolpidem inhibits the reaction [Chlorpromazine results in decreased activity of CAT] |
CTD |
PMID:12010767 PMID:17513028 PMID:25449126 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCN2 |
cellular communication network factor 2 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of CCN2 mRNA; Chlorpromazine results in decreased expression of CCN2 protein |
CTD |
PMID:30703373 |
|
NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372
|
|
G |
CCN3 |
cellular communication network factor 3 |
affects expression |
ISO |
Chlorpromazine affects the expression of CCN3 mRNA |
CTD |
PMID:31324950 |
|
NCBI chr 8:119,416,446...119,424,434
Ensembl chr 8:119,416,446...119,424,434
|
|
G |
CCNB2 |
cyclin B2 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of CCNB2 mRNA; Chlorpromazine results in decreased expression of CCNB2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr15:59,105,146...59,125,045
Ensembl chr15:59,105,126...59,125,045
|
|
G |
CCND1 |
cyclin D1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CCND1 mRNA |
CTD |
PMID:17202759 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCND3 |
cyclin D3 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of CCND3 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 6:41,934,933...42,050,035
Ensembl chr 6:41,934,934...42,050,357
|
|
G |
CCNF |
cyclin F |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of CCNF mRNA |
CTD |
PMID:15924885 |
|
NCBI chr16:2,429,447...2,458,854
Ensembl chr16:2,429,394...2,458,854
|
|
G |
CD274 |
CD274 molecule |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [platycodin D results in decreased expression of and results in increased secretion of CD274 protein] |
CTD |
PMID:31150782 |
|
NCBI chr 9:5,450,542...5,470,554
Ensembl chr 9:5,450,503...5,470,566
|
|
G |
CD44 |
CD44 molecule (IN blood group) |
multiple interactions decreases expression |
ISO EXP |
Chlorpromazine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CD44 protein] Chlorpromazine results in decreased expression of CD44 protein |
CTD |
PMID:9929743 PMID:30703373 |
|
NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402
|
|
G |
CD86 |
CD86 molecule |
increases expression |
EXP |
Chlorpromazine results in increased expression of CD86 protein |
CTD |
PMID:19665512 |
|
NCBI chr 3:122,055,362...122,121,136
Ensembl chr 3:122,055,362...122,121,139
|
|
G |
CDK5 |
cyclin dependent kinase 5 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of CDK5 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 7:151,053,815...151,057,897
Ensembl chr 7:151,053,815...151,057,897
|
|
G |
CDK7 |
cyclin dependent kinase 7 |
increases expression |
EXP |
Chlorpromazine analog results in increased expression of CDK7 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 5:69,234,795...69,277,430
Ensembl chr 5:69,234,795...69,277,430
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[EGR1 binds to CDKN1A promoter] promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA]; EGR1 promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA] |
CTD |
PMID:20368687 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
|
|
G |
CDKN2C |
cyclin dependent kinase inhibitor 2C |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of CDKN2C mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 1:50,968,706...50,974,634
Ensembl chr 1:50,960,745...50,974,634
|
|
G |
CES2 |
carboxylesterase 2 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CES2 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr16:66,934,471...66,945,096
Ensembl chr16:66,934,444...66,945,096
|
|
G |
CFH |
complement factor H |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CFH mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 1:196,652,043...196,747,504
Ensembl chr 1:196,651,754...196,752,476
|
|
G |
CGREF1 |
cell growth regulator with EF-hand domain 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CGREF1 mRNA |
CTD |
PMID:17202759 |
|
NCBI chr 2:27,099,353...27,119,128
Ensembl chr 2:27,098,889...27,119,128
|
|
G |
CHTF18 |
chromosome transmission fidelity factor 18 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of CHTF18 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr16:788,620...798,074
Ensembl chr16:788,046...800,737
|
|
G |
CITED2 |
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CITED2 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 6:139,371,807...139,374,648
Ensembl chr 6:139,371,807...139,374,648
|
|
G |
CKS2 |
CDC28 protein kinase regulatory subunit 2 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of CKS2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 9:89,311,195...89,316,703
Ensembl chr 9:89,311,195...89,316,703
|
|
G |
CLCF1 |
cardiotrophin like cytokine factor 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of CLCF1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr11:67,364,168...67,374,177
Ensembl chr11:67,364,168...67,374,177
|
|
G |
COL18A1 |
collagen type XVIII alpha 1 chain |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of COL18A1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr21:45,405,165...45,513,720
Ensembl chr21:45,405,165...45,513,720
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Chlorpromazine results in increased expression of COL1A1 mRNA |
CTD |
PMID:35708773 |
|
NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632
|
|
G |
COL4A1 |
collagen type IV alpha 1 chain |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of COL4A1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr13:110,148,963...110,307,157
Ensembl chr13:110,148,963...110,307,157
|
|
G |
CORT |
cortistatin |
affects expression |
ISO |
Chlorpromazine affects the expression of CORT mRNA |
CTD |
PMID:31324950 |
|
NCBI chr 1:10,450,031...10,451,998
Ensembl chr 1:10,450,031...10,451,998
|
|
G |
COX8A |
cytochrome c oxidase subunit 8A |
affects expression increases expression |
ISO |
Chlorpromazine affects the expression of COX8A mRNA Chlorpromazine results in increased expression of COX8A mRNA |
CTD |
PMID:18246545 |
|
NCBI chr11:63,974,620...63,976,543
Ensembl chr11:63,974,620...63,976,543
|
|
G |
CRH |
corticotropin releasing hormone |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of CRH mRNA |
CTD |
PMID:16205782 |
|
NCBI chr 8:66,176,376...66,178,464
Ensembl chr 8:66,176,376...66,178,464
|
|
G |
CTH |
cystathionine gamma-lyase |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CTH mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:70,411,268...70,439,851
Ensembl chr 1:70,411,218...70,439,851
|
|
G |
CTSK |
cathepsin K |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 1:150,796,208...150,808,260
Ensembl chr 1:150,794,880...150,809,577
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
increases expression multiple interactions |
EXP |
Chlorpromazine results in increased expression of CXCL8 mRNA [Chlorpromazine co-treated with lipopolysaccharide, E. coli O26-B6] results in decreased expression of CXCL8 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions decreases activity decreases response to substance increases expression |
EXP ISO |
[Filipin co-treated with Chlorpromazine co-treated with Wortmannin] inhibits the reaction [Particulate Matter results in increased expression of CYP1A1 mRNA]; Chlorpromazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Chlorpromazine results in decreased activity of CYP1A1 protein CYP1A1 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in increased expression of CYP1A1 mRNA |
CTD |
PMID:17202759 PMID:18246545 PMID:18493746 PMID:25596134 PMID:26477383 PMID:29724254 PMID:33814510 More...
|
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
multiple interactions decreases response to substance increases expression increases oxidation affects expression decreases methylation |
EXP ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CYP1A2 mRNA; [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine; Chlorpromazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]; CYP1A2 protein results in increased metabolism of and results in increased activity of Chlorpromazine CYP1A2 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in increased expression of CYP1A2 mRNA CYP1A2 protein results in increased oxidation of Chlorpromazine Chlorpromazine affects the expression of CYP1A2 mRNA CYP1A2 protein results in decreased methylation of Chlorpromazine |
CTD |
PMID:18246545 PMID:18493746 PMID:19482014 PMID:20615392 PMID:23397584 PMID:25596134 PMID:26477383 PMID:27344345 More...
|
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases response to substance decreases activity multiple interactions |
EXP |
CYP1B1 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in decreased activity of CYP1B1 protein [Filipin co-treated with Chlorpromazine co-treated with Wortmannin] inhibits the reaction [Particulate Matter results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:26477383 PMID:29724254 PMID:33814510 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP2A6 |
cytochrome P450 family 2 subfamily A member 6 |
decreases activity decreases response to substance |
EXP |
Chlorpromazine results in decreased activity of CYP2A6 protein CYP2A6 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:15135088 PMID:26477383 |
|
NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
multiple interactions decreases response to substance |
EXP ISO |
[Chlorpromazine results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; Chlorpromazine inhibits the reaction [Androstenols inhibits the reaction [NR1I3 protein results in increased expression of CYP2B6 mRNA]] CYP2B6 protein results in decreased susceptibility to Chlorpromazine NR1I3 protein affects the reaction [Chlorpromazine results in increased expression of CYP2B10 mRNA] |
CTD |
PMID:10037683 PMID:12049174 PMID:17041008 PMID:26477383 |
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
CYP2C18 |
cytochrome P450 family 2 subfamily C member 18 |
decreases response to substance decreases expression |
EXP ISO |
CYP2C18 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in decreased expression of CYP2C mRNA; Chlorpromazine results in decreased expression of CYP2C11 mRNA |
CTD |
PMID:18246545 PMID:26477383 |
|
NCBI chr10:94,683,729...94,736,190
Ensembl chr10:94,683,729...94,736,190
|
|
G |
CYP2C19 |
cytochrome P450 family 2 subfamily C member 19 |
decreases activity decreases response to substance multiple interactions affects methylation |
EXP |
Chlorpromazine results in decreased activity of CYP2C19 protein CYP2C19 protein results in decreased susceptibility to Chlorpromazine [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine CYP2C19 protein affects the methylation of Chlorpromazine |
CTD |
PMID:15135088 PMID:20615392 PMID:23397584 PMID:26477383 |
|
NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
|
|
G |
CYP2C8 |
cytochrome P450 family 2 subfamily C member 8 |
decreases response to substance |
EXP |
CYP2C8 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:26477383 |
|
NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
decreases activity decreases response to substance multiple interactions |
EXP |
Chlorpromazine results in decreased activity of CYP2C9 protein CYP2C9 protein results in decreased susceptibility to Chlorpromazine [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine |
CTD |
PMID:15135088 PMID:23397584 PMID:26477383 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP2D6 |
cytochrome P450 family 2 subfamily D member 6 |
multiple interactions decreases response to substance |
EXP |
[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine; CYP2D6 protein results in increased metabolism of and results in increased activity of Chlorpromazine CYP2D6 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:19482014 PMID:23397584 PMID:26477383 |
|
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
decreases activity decreases response to substance |
EXP |
Chlorpromazine results in decreased activity of CYP2E1 protein CYP2E1 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:15135088 PMID:26477383 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
decreases activity decreases response to substance affects oxidation affects methylation multiple interactions |
EXP |
Chlorpromazine results in decreased activity of CYP3A4 protein CYP3A4 protein results in decreased susceptibility to Chlorpromazine CYP3A4 protein affects the oxidation of Chlorpromazine CYP3A4 protein affects the methylation of Chlorpromazine [Chlorpromazine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine |
CTD |
PMID:15135088 PMID:17041008 PMID:20615392 PMID:23397584 PMID:26477383 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
decreases response to substance |
EXP |
CYP3A5 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:26477383 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
|
|
G |
CYP3A7 |
cytochrome P450 family 3 subfamily A member 7 |
decreases response to substance |
EXP |
CYP3A7 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:26477383 |
|
NCBI chr 7:99,705,036...99,735,196
Ensembl chr 7:99,705,036...99,735,196
|
|
G |
CYP8B1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CYP8B1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898
|
|
G |
DAO |
D-amino acid oxidase |
decreases activity |
EXP |
Chlorpromazine results in decreased activity of DAO protein |
CTD |
PMID:18615285 |
|
NCBI chr12:108,880,092...108,901,043
Ensembl chr12:108,858,932...108,901,043
|
|
G |
DCSTAMP |
dendrocyte expressed seven transmembrane protein |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of DCSTAMP mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 8:104,339,796...104,356,689
Ensembl chr 8:104,339,087...104,356,689
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression |
ISO |
Chlorpromazine results in increased expression of DDIT3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
DEPP1 |
DEPP autophagy regulator 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of DEPP1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr10:44,976,128...44,978,809
Ensembl chr10:44,970,981...44,978,809
|
|
G |
DRD1 |
dopamine receptor D1 |
decreases activity |
EXP |
Chlorpromazine results in decreased activity of DRD1 protein |
CTD |
PMID:23611293 |
|
NCBI chr 5:175,440,036...175,444,182
Ensembl chr 5:175,440,036...175,444,182
|
|
G |
DRD2 |
dopamine receptor D2 |
decreases response to substance decreases activity |
EXP |
DRD2 polymorphism results in decreased susceptibility to Chlorpromazine Chlorpromazine results in decreased activity of DRD2 protein |
CTD |
PMID:15694263 PMID:23611293 |
|
NCBI chr11:113,409,605...113,475,398
Ensembl chr11:113,409,605...113,475,691
|
|
G |
DUSP1 |
dual specificity phosphatase 1 |
increases expression affects expression |
EXP ISO |
Chlorpromazine analog results in increased expression of DUSP1 mRNA Chlorpromazine affects the expression of DUSP1 mRNA |
CTD |
PMID:15924885 PMID:20843724 |
|
NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195
|
|
G |
DUSP9 |
dual specificity phosphatase 9 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of DUSP9 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr X:153,642,441...153,651,326
Ensembl chr X:153,642,492...153,651,326
|
|
G |
E2F1 |
E2F transcription factor 1 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of E2F1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385
|
|
G |
EGR1 |
early growth response 1 |
increases expression multiple interactions |
ISO |
Chlorpromazine results in increased expression of EGR1 [EGR1 binds to CDKN1A promoter] promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA]; EGR1 promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA]; MAPK1 affects the reaction [Chlorpromazine results in increased expression of EGR1]; MAPK3 affects the reaction [Chlorpromazine results in increased expression of EGR1] |
CTD |
PMID:20368687 |
|
NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
|
|
G |
EIF1 |
eukaryotic translation initiation factor 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of EIF1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:41,688,885...41,692,668
Ensembl chr17:41,688,885...41,692,668
|
|
G |
ENO2 |
enolase 2 |
increases expression |
ISO |
Chlorpromazine results in increased expression of ENO2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:6,914,580...6,923,697
Ensembl chr12:6,913,745...6,923,698
|
|
G |
ERO1A |
endoplasmic reticulum oxidoreductase 1 alpha |
increases expression |
ISO |
Chlorpromazine results in increased expression of ERO1A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr14:52,639,915...52,695,558
Ensembl chr14:52,639,915...52,695,900
|
|
G |
F2 |
coagulation factor II, thrombin |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of F2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr11:46,719,213...46,739,506
Ensembl chr11:46,719,196...46,739,506
|
|
G |
FABP1 |
fatty acid binding protein 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of FABP1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062
|
|
G |
FAS |
Fas cell surface death receptor |
increases expression |
EXP |
Chlorpromazine analog results in increased expression of FAS mRNA |
CTD |
PMID:15924885 |
|
NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605
|
|
G |
FBP1 |
fructose-bisphosphatase 1 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FBP1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 9:94,603,133...94,640,263
Ensembl chr 9:94,603,133...94,640,249
|
|
G |
FBXO22 |
F-box protein 22 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of FBXO22 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr15:75,903,878...75,942,511
Ensembl chr15:75,903,876...75,942,511
|
|
G |
FECH |
ferrochelatase |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of FECH mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:57,544,377...57,586,702
Ensembl chr18:57,544,377...57,586,732
|
|
G |
FETUB |
fetuin B |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FETUB mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 3:186,635,969...186,653,141
Ensembl chr 3:186,635,969...186,653,141
|
|
G |
FGA |
fibrinogen alpha chain |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FGA mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 4:154,583,126...154,590,742
Ensembl chr 4:154,583,126...154,590,742
|
|
G |
FGF2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FGF2 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236
|
|
G |
FGFR1 |
fibroblast growth factor receptor 1 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of FGFR1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 8:38,411,143...38,468,635
Ensembl chr 8:38,400,215...38,468,834
|
|
G |
FGR |
FGR proto-oncogene, Src family tyrosine kinase |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of FGR mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:27,612,064...27,635,185
Ensembl chr 1:27,612,064...27,635,185
|
|
G |
FKBP5 |
FKBP prolyl isomerase 5 |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [Lipopolysaccharides results in decreased expression of FKBP5 protein] |
CTD |
PMID:21034739 |
|
NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583
|
|
G |
FNDC4 |
fibronectin type III domain containing 4 |
increases expression |
EXP |
Chlorpromazine results in increased expression of FNDC4 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 2:27,491,883...27,495,200
Ensembl chr 2:27,491,883...27,495,200
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
affects expression |
ISO |
Chlorpromazine affects the expression of FOS mRNA |
CTD |
PMID:20843724 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
FOSB |
FosB proto-oncogene, AP-1 transcription factor subunit |
affects expression |
ISO |
Chlorpromazine affects the expression of FOSB mRNA |
CTD |
PMID:20843724 |
|
NCBI chr19:45,467,996...45,475,179
Ensembl chr19:45,467,995...45,475,179
|
|
G |
FOSL1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression affects expression |
EXP ISO |
Chlorpromazine analog results in increased expression of FOSL1 mRNA Chlorpromazine affects the expression of FOSL1 mRNA |
CTD |
PMID:15924885 PMID:20843724 |
|
NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
|
|
G |
FOSL2 |
FOS like 2, AP-1 transcription factor subunit |
affects expression |
ISO |
Chlorpromazine affects the expression of FOSL2 mRNA |
CTD |
PMID:20843724 |
|
NCBI chr 2:28,392,858...28,417,317
Ensembl chr 2:28,392,448...28,417,317
|
|
G |
FTH1 |
ferritin heavy chain 1 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FTH1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr11:61,964,285...61,967,634
Ensembl chr11:61,959,718...61,967,634
|
|
G |
G6PD |
glucose-6-phosphate dehydrogenase |
decreases expression decreases activity multiple interactions |
EXP ISO |
Chlorpromazine analog results in decreased expression of G6PD mRNA Chlorpromazine results in decreased activity of G6PD protein [Taurine co-treated with coenzyme Q10] inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein]; coenzyme Q10 inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein]; Taurine inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein] |
CTD |
PMID:15924885 PMID:33548410 |
|
NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572
|
|
G |
GAD1 |
glutamate decarboxylase 1 |
decreases methylation multiple interactions |
ISO |
Chlorpromazine results in decreased methylation of GAD1 promoter Valproic Acid promotes the reaction [Chlorpromazine results in decreased methylation of GAD1 promoter] |
CTD |
PMID:19110320 |
|
NCBI chr 2:170,813,210...170,861,151
Ensembl chr 2:170,813,213...170,861,151
|
|
G |
GCGR |
glucagon receptor |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of GCGR mRNA |
CTD |
PMID:27344345 |
|
NCBI chr17:81,804,150...81,814,008
Ensembl chr17:81,804,132...81,814,008
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of GCLC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
|
|
G |
GDF15 |
growth differentiation factor 15 |
increases expression |
ISO |
Chlorpromazine results in increased expression of GDF15 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr19:18,386,158...18,389,176
Ensembl chr19:18,374,731...18,389,176
|
|
G |
GDPD3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
increases expression |
EXP |
Chlorpromazine results in increased expression of GDPD3 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr16:30,104,810...30,113,537
Ensembl chr16:30,104,810...30,113,537
|
|
G |
GFAP |
glial fibrillary acidic protein |
affects expression |
ISO |
Chlorpromazine affects the expression of GFAP mRNA |
CTD |
PMID:31324950 |
|
NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937
|
|
G |
GPNMB |
glycoprotein nmb |
increases expression |
ISO |
Chlorpromazine results in increased expression of GPNMB mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:23,246,775...23,275,108
Ensembl chr 7:23,235,967...23,275,108
|
|
G |
GPT |
glutamic--pyruvic transaminase |
increases expression |
ISO |
Chlorpromazine results in increased expression of GPT protein |
CTD |
PMID:35722787 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
GSR |
glutathione-disulfide reductase |
decreases activity |
ISO |
Chlorpromazine results in decreased activity of GSR protein |
CTD |
PMID:6693892 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
GSTA1 |
glutathione S-transferase alpha 1 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of GSTA1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 6:52,791,371...52,803,816
Ensembl chr 6:52,791,371...52,803,860
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
affects activity |
ISO |
Chlorpromazine affects the activity of HIF1A protein |
CTD |
PMID:25596134 |
|
NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
EXP |
Chlorpromazine results in increased expression of HMGCR mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
HMGCS1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 5:43,287,470...43,313,412
Ensembl chr 5:43,287,470...43,313,512
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression affects expression |
EXP ISO |
Chlorpromazine results in increased expression of HMOX1 mRNA Chlorpromazine affects the expression of HMOX1 mRNA |
CTD |
PMID:15924885 PMID:25596134 PMID:31324950 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HPN |
hepsin |
increases expression |
EXP |
Chlorpromazine results in increased expression of HPN mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr19:35,040,506...35,066,573
Ensembl chr19:35,040,506...35,066,573
|
|
G |
HSPA2 |
heat shock protein family A (Hsp70) member 2 |
decreases expression increases expression |
ISO |
Chlorpromazine results in decreased expression of HSPA2 mRNA; Chlorpromazine results in decreased expression of HSPA2 protein Chlorpromazine results in increased expression of HSPA2 mRNA |
CTD |
PMID:36751017 |
|
NCBI chr14:64,535,905...64,543,237
Ensembl chr14:64,535,905...64,546,173
|
|
G |
HSPB1 |
heat shock protein family B (small) member 1 |
increases expression decreases expression |
ISO |
Chlorpromazine results in increased expression of HSPB1 mRNA Chlorpromazine results in decreased expression of HSPB1 mRNA |
CTD |
PMID:36751017 |
|
NCBI chr 7:76,302,673...76,304,292
Ensembl chr 7:76,302,673...76,304,295
|
|
G |
HSPD1 |
heat shock protein family D (Hsp60) member 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of HSPD1 mRNA |
CTD |
PMID:36751017 |
|
NCBI chr 2:197,486,584...197,500,274
Ensembl chr 2:197,486,584...197,516,737
|
|
G |
HSPE1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of HSPE1 mRNA |
CTD |
PMID:36751017 |
|
NCBI chr 2:197,500,379...197,503,449
Ensembl chr 2:197,500,140...197,503,449
|
|
G |
IBSP |
integrin binding sialoprotein |
decreases expression multiple interactions |
ISO |
Chlorpromazine results in decreased expression of IBSP mRNA herbimycin inhibits the reaction [Chlorpromazine results in decreased expression of IBSP mRNA]; U 0126 inhibits the reaction [Chlorpromazine results in decreased expression of IBSP mRNA] |
CTD |
PMID:16294319 |
|
NCBI chr 4:87,799,554...87,812,435
Ensembl chr 4:87,799,554...87,812,435
|
|
G |
IFNB1 |
interferon beta 1 |
multiple interactions |
EXP |
Chlorpromazine promotes the reaction [PAM2-CSK4 results in increased expression of IFNB1 mRNA] |
CTD |
PMID:32796029 |
|
NCBI chr 9:21,077,104...21,077,942
Ensembl chr 9:21,077,104...21,077,942
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA |
CTD |
PMID:29594315 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IFNLR1 |
interferon lambda receptor 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of IFNLR1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr 1:24,154,168...24,187,289
Ensembl chr 1:24,154,168...24,187,959
|
|
G |
IGFBP1 |
insulin like growth factor binding protein 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of IGFBP1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660
|
|
G |
IKBKG |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
increases expression |
EXP |
Chlorpromazine analog results in increased expression of IKBKG mRNA |
CTD |
PMID:15924885 |
|
NCBI chr X:154,541,238...154,565,046
Ensembl chr X:154,541,199...154,565,046
|
|
G |
IL1A |
interleukin 1 alpha |
multiple interactions |
EXP |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Chlorpromazine |
CTD |
PMID:19362101 |
|
NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493
|
|
G |
IL1B |
interleukin 1 beta |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of IL1B mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL2 |
interleukin 2 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein]; Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11014349 PMID:29594315 |
|
NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Chlorpromazine |
CTD |
PMID:19362101 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INHBE |
inhibin subunit beta E |
increases expression |
EXP |
Chlorpromazine results in increased expression of INHBE mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr12:57,455,307...57,458,025
Ensembl chr12:57,452,323...57,459,280
|
|
G |
INS-IGF2 |
INS-IGF2 readthrough |
decreases secretion |
ISO |
Chlorpromazine results in decreased secretion of INS1 protein |
CTD |
PMID:18308779 |
|
NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209
|
|
G |
INSIG2 |
insulin induced gene 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of INSIG2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:118,088,471...118,110,997
Ensembl chr 2:118,088,452...118,110,997
|
|
G |
IRS2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
Chlorpromazine results in decreased expression of and results in decreased phosphorylation of IRS2 protein; Chlorpromazine results in decreased expression of and results in increased degradation of IRS2 protein |
CTD |
PMID:17512020 PMID:18308779 |
|
NCBI chr13:109,752,695...109,786,583
Ensembl chr13:109,752,695...109,786,583
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
EXP |
Chlorpromazine inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Chlorpromazine results in decreased activity of KCNH2 protein |
CTD |
PMID:15071359 PMID:21158687 PMID:24052561 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
KCNN2 |
potassium calcium-activated channel subfamily N member 2 |
decreases activity |
ISO |
Chlorpromazine results in decreased activity of KCNN2 protein |
CTD |
PMID:10915830 |
|
NCBI chr 5:114,055,978...114,496,496
Ensembl chr 5:114,055,926...114,496,500
|
|
G |
KLF4 |
KLF transcription factor 4 |
multiple interactions decreases expression |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of KLF4 mRNA Chlorpromazine results in decreased expression of KLF4 mRNA |
CTD |
PMID:27344345 PMID:30703373 |
|
NCBI chr 9:107,484,852...107,489,769
Ensembl chr 9:107,484,852...107,490,482
|
|
G |
KLKB1 |
kallikrein B1 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of KLKB1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 4:186,210,853...186,258,471
Ensembl chr 4:186,226,438...186,258,471
|
|
G |
KNG1 |
kininogen 1 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of KNG1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 3:186,717,359...186,744,410
Ensembl chr 3:186,717,348...186,744,410
|
|
G |
LATS1 |
large tumor suppressor kinase 1 |
increases phosphorylation |
EXP |
Chlorpromazine results in increased phosphorylation of LATS1 protein |
CTD |
PMID:30703373 |
|
NCBI chr 6:149,658,153...149,718,101
Ensembl chr 6:149,658,153...149,718,105
|
|
G |
LDHC |
lactate dehydrogenase C |
decreases activity multiple interactions |
ISO |
Chlorpromazine results in decreased activity of LDHC protein [Taurine co-treated with coenzyme Q10] inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein]; coenzyme Q10 inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein]; Taurine inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein] |
CTD |
PMID:33548410 |
|
NCBI chr11:18,412,318...18,452,063
Ensembl chr11:18,412,318...18,452,063
|
|
G |
LDLR |
low density lipoprotein receptor |
increases expression |
EXP |
Chlorpromazine results in increased expression of LDLR mRNA |
CTD |
PMID:17052361 |
|
NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820
|
|
G |
LEP |
leptin |
increases expression |
ISO |
Chlorpromazine results in increased expression of LEP protein |
CTD |
PMID:17512020 |
|
NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629
|
|
G |
LSS |
lanosterol synthase |
increases expression |
EXP |
Chlorpromazine results in increased expression of LSS mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr21:46,188,446...46,228,774
Ensembl chr21:46,188,141...46,228,824
|
|
G |
MAP2 |
microtubule associated protein 2 |
increases expression |
ISO |
Chlorpromazine results in increased expression of MAP2 mRNA |
CTD |
PMID:15079866 |
|
NCBI chr 2:209,424,047...209,734,112
Ensembl chr 2:209,424,047...209,734,147
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP ISO |
Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein] MAPK1 affects the reaction [Chlorpromazine results in increased expression of EGR1] |
CTD |
PMID:11014349 PMID:20368687 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK14 |
mitogen-activated protein kinase 14 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of MAPK14 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 6:36,027,808...36,124,214
Ensembl chr 6:36,027,782...36,111,236
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
decreases expression multiple interactions |
EXP ISO |
Chlorpromazine analog results in decreased expression of MAPK3 mRNA MAPK3 affects the reaction [Chlorpromazine results in increased expression of EGR1] Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11014349 PMID:15924885 PMID:20368687 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with lipoteichoic acid] results in increased phosphorylation of MAPK8 protein; Chlorpromazine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased phosphorylation of MAPK8 protein]; TIRAP gene mutant form inhibits the reaction [Chlorpromazine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein]] |
CTD |
PMID:23238562 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPKAPK2 |
MAPK activated protein kinase 2 |
increases expression |
ISO |
Chlorpromazine results in increased expression of MAPKAPK2 mRNA |
CTD |
PMID:19441803 |
|
NCBI chr 1:206,684,905...206,734,281
Ensembl chr 1:206,684,905...206,734,281
|
|
G |
MCM3 |
minichromosome maintenance complex component 3 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of MCM3 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 6:52,264,015...52,284,742
Ensembl chr 6:52,264,014...52,284,881
|
|
G |
MCM5 |
minichromosome maintenance complex component 5 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of MCM5 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr22:35,400,140...35,455,031
Ensembl chr22:35,400,134...35,425,431
|
|
G |
MDM2 |
MDM2 proto-oncogene |
increases expression |
ISO |
Chlorpromazine results in increased expression of MDM2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:68,808,172...68,850,686
Ensembl chr12:68,808,177...68,845,544
|
|
G |
MITF |
melanocyte inducing transcription factor |
increases expression |
EXP |
Chlorpromazine results in increased expression of MITF protein |
CTD |
PMID:25449126 |
|
NCBI chr 3:69,739,464...69,968,332
Ensembl chr 3:69,739,456...69,968,336
|
|
G |
MKI67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of MKI67 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased expression of MMP9 mRNA]; Chlorpromazine inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased secretion of MMP9 protein] |
CTD |
PMID:25200491 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MSC |
musculin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of MSC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:71,841,560...71,844,412
Ensembl chr 8:71,841,560...71,844,412
|
|
G |
MSH2 |
mutS homolog 2 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of MSH2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 2:47,403,067...47,709,830
Ensembl chr 2:47,403,067...47,663,146
|
|
G |
MST1 |
macrophage stimulating 1 |
increases phosphorylation |
EXP |
Chlorpromazine results in increased phosphorylation of MST1 protein |
CTD |
PMID:30703373 |
|
NCBI chr 3:49,683,947...49,689,474
Ensembl chr 3:49,683,947...49,689,501
|
|
G |
MT1A |
metallothionein 1A |
increases expression |
ISO |
Chlorpromazine results in increased expression of MT1A mRNA |
CTD |
PMID:8128501 |
|
NCBI chr16:56,638,666...56,640,087
Ensembl chr16:56,638,666...56,640,087
|
|
G |
MYBL2 |
MYB proto-oncogene like 2 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of MYBL2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr20:43,667,114...43,716,482
Ensembl chr20:43,667,019...43,716,495
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of MYC mRNA |
CTD |
PMID:30703373 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
NAMPT |
nicotinamide phosphoribosyltransferase |
increases expression |
ISO |
Chlorpromazine results in increased expression of NAMPT mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:106,248,298...106,285,888
Ensembl chr 7:106,248,298...106,285,966
|
|
G |
NANOG |
Nanog homeobox |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of NANOG mRNA |
CTD |
PMID:30703373 |
|
NCBI chr12:7,789,402...7,799,146
Ensembl chr12:7,787,794...7,799,146
|
|
G |
NDUFS3 |
NADH:ubiquinone oxidoreductase core subunit S3 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of NDUFS3 protein |
CTD |
PMID:19441803 |
|
NCBI chr11:47,579,074...47,584,562
Ensembl chr11:47,565,336...47,584,562
|
|
G |
NECTIN2 |
nectin cell adhesion molecule 2 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Cadmium Chloride results in decreased expression of and affects the localization of NECTIN2 protein] |
CTD |
PMID:25046863 |
|
NCBI chr19:44,846,297...44,889,223
Ensembl chr19:44,846,175...44,889,223
|
|
G |
NEDD9 |
neural precursor cell expressed, developmentally down-regulated 9 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of NEDD9 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:11,183,298...11,382,348
Ensembl chr 6:11,183,298...11,382,348
|
|
G |
NEFH |
neurofilament heavy chain |
affects expression |
ISO |
Chlorpromazine affects the expression of NEFH mRNA |
CTD |
PMID:31324950 |
|
NCBI chr22:29,480,218...29,491,390
Ensembl chr22:29,480,218...29,491,390
|
|
G |
NFATC1 |
nuclear factor of activated T cells 1 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr18:79,395,930...79,529,323
Ensembl chr18:79,395,856...79,529,325
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
decreases expression affects activity |
ISO |
Chlorpromazine results in decreased expression of NFE2L2 mRNA Chlorpromazine affects the activity of NFE2L2 protein |
CTD |
PMID:25596134 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NINJ1 |
ninjurin 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of NINJ1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 9:93,121,496...93,134,251
Ensembl chr 9:93,121,496...93,134,251
|
|
G |
NPPB |
natriuretic peptide B |
increases expression |
ISO |
Chlorpromazine results in increased expression of NPPB protein |
CTD |
PMID:36751017 |
|
NCBI chr 1:11,857,464...11,858,945
Ensembl chr 1:11,857,464...11,858,945
|
|
G |
NR0B2 |
nuclear receptor subfamily 0 group B member 2 |
increases expression |
EXP |
Chlorpromazine results in increased expression of NR0B2 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975
|
|
G |
NR1H4 |
nuclear receptor subfamily 1 group H member 4 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of NR1H4 mRNA |
CTD |
PMID:27765674 PMID:28391356 |
|
NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases expression multiple interactions |
EXP |
Chlorpromazine analog results in increased expression of NR1I2 mRNA [Chlorpromazine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:15924885 PMID:17041008 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
increases activity increases expression multiple interactions |
ISO EXP |
Chlorpromazine results in increased activity of NR1I3 protein Chlorpromazine results in increased expression of NR1I3 mRNA [Chlorpromazine co-treated with Cholic Acids] affects the expression of NR1I3 mRNA; [Chlorpromazine results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; Chlorpromazine inhibits the reaction [Androstenols inhibits the reaction [NR1I3 protein results in increased expression of CYP2B6 mRNA]] NR1I3 protein affects the reaction [Chlorpromazine results in increased expression of CYP2B10 mRNA]; NR1I3 protein affects the reaction [Chlorpromazine results in increased expression of CYP3A11 mRNA] |
CTD |
PMID:10037683 PMID:12049174 PMID:12948398 PMID:17041008 PMID:22310298 PMID:27344345 More...
|
|
NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
|
|
G |
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein] |
CTD |
PMID:16581232 |
|
NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512
|
|
G |
NUPR1 |
nuclear protein 1, transcriptional regulator |
increases expression |
EXP |
Chlorpromazine results in increased expression of NUPR1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr16:28,532,708...28,538,974
Ensembl chr16:28,532,708...28,539,008
|
|
G |
ORC1 |
origin recognition complex subunit 1 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of ORC1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 1:52,372,829...52,409,503
Ensembl chr 1:52,372,829...52,404,423
|
|
G |
ORM1 |
orosomucoid 1 |
affects binding multiple interactions |
EXP |
Chlorpromazine binds to ORM1 protein alternative form Chlorpromazine inhibits the reaction [Warfarin binds to ORM1 protein alternative form] |
CTD |
PMID:8946472 |
|
NCBI chr 9:114,323,098...114,326,479
Ensembl chr 9:114,323,098...114,326,479
|
|
G |
ORM2 |
orosomucoid 2 |
affects binding multiple interactions |
EXP |
Chlorpromazine binds to ORM2 protein alternative form Chlorpromazine inhibits the reaction [Imipramine binds to ORM2 protein alternative form] |
CTD |
PMID:8946472 |
|
NCBI chr 9:114,329,869...114,333,251
Ensembl chr 9:114,329,869...114,333,251
|
|
G |
PDIA2 |
protein disulfide isomerase family A member 2 |
increases expression |
EXP |
Chlorpromazine analog results in increased expression of PDIA2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr16:283,164...287,215
Ensembl chr16:283,164...287,215
|
|
G |
PDIA5 |
protein disulfide isomerase family A member 5 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of PDIA5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:123,067,025...123,162,104
Ensembl chr 3:123,067,025...123,225,227
|
|
G |
PDK1 |
pyruvate dehydrogenase kinase 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of PDK1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:172,555,373...172,724,312
Ensembl chr 2:172,555,373...172,608,669
|
|
G |
PDK4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
ISO |
Chlorpromazine results in increased expression of PDK4 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:95,583,499...95,596,516
Ensembl chr 7:95,583,499...95,596,516
|
|
G |
PHYH |
phytanoyl-CoA 2-hydroxylase |
increases expression |
EXP |
Chlorpromazine results in increased expression of PHYH mRNA |
CTD |
PMID:15342952 |
|
NCBI chr10:13,277,799...13,300,064
Ensembl chr10:13,277,796...13,302,412
|
|
G |
PIAS1 |
protein inhibitor of activated STAT 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of PIAS1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr15:68,054,315...68,193,847
Ensembl chr15:68,054,309...68,198,603
|
|
G |
PIM1 |
Pim-1 proto-oncogene, serine/threonine kinase |
increases expression |
EXP |
Chlorpromazine analog results in increased expression of PIM1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 6:37,170,152...37,175,428
Ensembl chr 6:37,170,152...37,175,428
|
|
G |
PIR |
pirin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of PIR mRNA |
CTD |
PMID:25596134 |
|
NCBI chr X:15,384,799...15,493,333
Ensembl chr X:15,384,799...15,493,564
|
|
G |
PLIN2 |
perilipin 2 |
increases expression |
ISO |
Chlorpromazine results in increased expression of PLIN2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 9:19,108,388...19,127,492
Ensembl chr 9:19,108,375...19,149,290
|
|
G |
PMEPA1 |
prostate transmembrane protein, androgen induced 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of PMEPA1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:57,648,396...57,711,472
Ensembl chr20:57,648,392...57,711,536
|
|
G |
POLA1 |
DNA polymerase alpha 1, catalytic subunit |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of POLA1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr X:24,693,918...24,996,986
Ensembl chr X:24,693,873...24,996,986
|
|
G |
POLD4 |
DNA polymerase delta 4, accessory subunit |
increases expression |
EXP |
Chlorpromazine analog results in increased expression of POLD4 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr11:67,350,765...67,353,596
Ensembl chr11:67,350,772...67,356,972
|
|
G |
POU5F1 |
POU class 5 homeobox 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of POU5F1 mRNA |
CTD |
PMID:30703373 |
|
NCBI chr 6:31,164,337...31,170,682
Ensembl chr 6:31,164,337...31,180,731
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
affects activity |
ISO |
Chlorpromazine affects the activity of PPARG protein |
CTD |
PMID:25596134 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PPP1R15A |
protein phosphatase 1 regulatory subunit 15A |
increases expression |
ISO |
Chlorpromazine results in increased expression of PPP1R15A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr19:48,872,421...48,876,058
Ensembl chr19:48,872,212...48,876,059
|
|
G |
PRKAA1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
decreases phosphorylation |
ISO |
Chlorpromazine results in decreased phosphorylation of PRKAA1 protein |
CTD |
PMID:17512020 |
|
NCBI chr 5:40,759,389...40,798,374
Ensembl chr 5:40,759,389...40,798,374
|
|
G |
PRL |
prolactin |
increases expression |
EXP |
Chlorpromazine results in increased expression of PRL protein |
CTD |
PMID:718334 PMID:996201 |
|
NCBI chr 6:22,287,246...22,302,835
Ensembl chr 6:22,287,244...22,302,826
|
|
G |
RARA |
retinoic acid receptor alpha |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of RARA mRNA |
CTD |
PMID:18246545 |
|
NCBI chr17:40,309,180...40,357,643
Ensembl chr17:40,309,180...40,357,643
|
|
G |
RND1 |
Rho family GTPase 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of RND1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:48,857,145...48,865,870
Ensembl chr12:48,857,145...48,865,870
|
|
G |
RND3 |
Rho family GTPase 3 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of RND3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:150,468,193...150,487,695
Ensembl chr 2:150,468,195...150,539,011
|
|
G |
RNF121 |
ring finger protein 121 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of RNF121 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr11:71,929,046...71,997,597
Ensembl chr11:71,929,018...71,997,597
|
|
G |
RUNX1 |
RUNX family transcription factor 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of RUNX1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr21:34,787,801...35,049,302
Ensembl chr21:34,787,801...36,004,667
|
|
G |
RXRG |
retinoid X receptor gamma |
affects response to substance |
ISO |
RXRG protein affects the susceptibility to Chlorpromazine |
CTD |
PMID:10336693 |
|
NCBI chr 1:165,400,922...165,445,126
Ensembl chr 1:165,400,922...165,445,355
|
|
G |
SAT1 |
spermidine/spermine N1-acetyltransferase 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SAT1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr X:23,783,173...23,786,210
Ensembl chr X:23,783,173...23,786,210
|
|
G |
SC5D |
sterol-C5-desaturase |
increases expression |
EXP |
Chlorpromazine results in increased expression of SC5D mRNA |
CTD |
PMID:17052361 |
|
NCBI chr11:121,292,771...121,313,410
Ensembl chr11:121,292,681...121,313,410
|
|
G |
SERPINA3 |
serpin family A member 3 |
increases expression |
EXP |
Chlorpromazine results in increased expression of SERPINA3 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr14:94,612,391...94,624,053
Ensembl chr14:94,612,384...94,624,055
|
|
G |
SERPINH1 |
serpin family H member 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SERPINH1 mRNA |
CTD |
PMID:35708773 |
|
NCBI chr11:75,562,253...75,572,783
Ensembl chr11:75,562,056...75,572,783
|
|
G |
SESN1 |
sestrin 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of SESN1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:108,984,309...109,094,846
Ensembl chr 6:108,984,309...109,094,846
|
|
G |
SIK1 |
salt inducible kinase 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of SIK1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr21:43,414,483...43,427,131
Ensembl chr21:43,414,483...43,427,131
|
|
G |
SLC10A1 |
solute carrier family 10 member 1 |
decreases expression increases expression |
ISO |
Chlorpromazine results in decreased expression of SLC10A1 mRNA Chlorpromazine results in increased expression of SLC10A1 mRNA |
CTD |
PMID:27765674 PMID:28391356 PMID:35708773 |
|
NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
|
|
G |
SLC12A8 |
solute carrier family 12 member 8 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SLC12A8 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:125,082,644...125,212,748
Ensembl chr 3:125,082,636...125,212,864
|
|
G |
SLC19A1 |
solute carrier family 19 member 1 |
multiple interactions decreases activity |
ISO |
Chlorpromazine inhibits the reaction [SLC19A1 protein results in increased uptake of Methotrexate] Chlorpromazine results in decreased activity of SLC19A1 protein |
CTD |
PMID:17482559 |
|
NCBI chr21:45,502,517...45,563,025
Ensembl chr21:45,493,572...45,573,365
|
|
G |
SLC1A5 |
solute carrier family 1 member 5 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SLC1A5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr19:46,774,883...46,788,594
Ensembl chr19:46,774,883...46,788,594
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
G |
SLC22A7 |
solute carrier family 22 member 7 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of SLC22A7 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 6:43,295,714...43,305,538
Ensembl chr 6:43,295,694...43,305,538
|
|
G |
SLC2A3 |
solute carrier family 2 member 3 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:15342952 |
|
NCBI chr12:7,919,230...7,936,187
Ensembl chr12:7,919,230...8,019,007
|
|
G |
SLC31A1 |
solute carrier family 31 member 1 |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [Copper affects the localization of SLC31A1 protein] |
CTD |
PMID:12501239 |
|
NCBI chr 9:113,221,544...113,264,492
Ensembl chr 9:113,221,544...113,264,492
|
|
G |
SLC3A2 |
solute carrier family 3 member 2 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SLC3A2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr11:62,856,109...62,888,860
Ensembl chr11:62,856,004...62,888,880
|
|
G |
SLC51B |
SLC51 subunit beta |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of SLC51B mRNA |
CTD |
PMID:27344345 |
|
NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
|
|
G |
SLC6A6 |
solute carrier family 6 member 6 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SLC6A6 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:14,402,576...14,489,349
Ensembl chr 3:14,402,576...14,489,349
|
|
G |
SLCO2B1 |
solute carrier organic anion transporter family member 2B1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of SLCO2B1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr11:75,151,107...75,206,549
Ensembl chr11:75,100,563...75,206,549
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Copper inhibits the reaction [Trientine results in decreased activity of SOD1 protein]] |
CTD |
PMID:22362149 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SOX2 |
SRY-box transcription factor 2 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of SOX2 mRNA |
CTD |
PMID:30703373 |
|
NCBI chr 3:181,711,925...181,714,436
Ensembl chr 3:181,711,925...181,714,436
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of SPP1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532
|
|
G |
SPSB1 |
splA/ryanodine receptor domain and SOCS box containing 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SPSB1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:9,292,894...9,369,532
Ensembl chr 1:9,292,894...9,369,532
|
|
G |
SRC |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of SRC protein] |
CTD |
PMID:29702141 |
|
NCBI chr20:37,344,699...37,406,050
Ensembl chr20:37,344,685...37,406,050
|
|
G |
SREBF2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
EXP |
Chlorpromazine results in increased cleavage of and results in increased activity of SREBF2 protein |
CTD |
PMID:17052361 |
|
NCBI chr22:41,833,105...41,907,305
Ensembl chr22:41,833,105...41,907,306
|
|
G |
STRBP |
spermatid perinuclear RNA binding protein |
increases expression |
ISO |
Chlorpromazine results in increased expression of STRBP mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 9:123,109,494...123,268,586
Ensembl chr 9:123,109,500...123,268,586
|
|
G |
STS |
steroid sulfatase |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [Tretinoin results in increased activity of STS protein] |
CTD |
PMID:16178010 |
|
NCBI chr X:7,147,290...7,354,641
Ensembl chr X:7,147,237...7,804,358
|
|
G |
TAGLN |
transgelin |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of TAGLN mRNA |
CTD |
PMID:17175557 |
|
NCBI chr11:117,199,294...117,207,465
Ensembl chr11:117,199,370...117,207,464
|
|
G |
TF |
transferrin |
affects localization |
EXP |
Chlorpromazine affects the localization of TF protein |
CTD |
PMID:12501239 |
|
NCBI chr 3:133,661,998...133,796,641
Ensembl chr 3:133,746,040...133,796,641
|
|
G |
TFDP1 |
transcription factor Dp-1 |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of TFDP1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr13:113,584,688...113,641,473
Ensembl chr13:113,584,721...113,641,473
|
|
G |
TIPARP |
TCDD inducible poly(ADP-ribose) polymerase |
increases expression |
ISO |
Chlorpromazine results in increased expression of TIPARP mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:156,674,590...156,706,770
Ensembl chr 3:156,673,235...156,706,770
|
|
G |
TIRAP |
TIR domain containing adaptor protein |
multiple interactions |
ISO |
TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased expression of TNF protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased phosphorylation of MAPK8 protein]; TIRAP gene mutant form inhibits the reaction [Chlorpromazine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein]]; TIRAP protein results in increased susceptibility to [Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4]; TIRAP protein results in increased susceptibility to [Chlorpromazine co-treated with lipoteichoic acid] |
CTD |
PMID:23238562 |
|
NCBI chr11:126,283,093...126,294,933
Ensembl chr11:126,282,497...126,298,845
|
|
G |
TMPRSS2 |
transmembrane serine protease 2 |
increases expression |
EXP |
Chlorpromazine results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr21:41,464,305...41,508,158
Ensembl chr21:41,464,300...41,531,116
|
|
G |
TNF |
tumor necrosis factor |
decreases expression increases response to substance multiple interactions |
EXP ISO |
Chlorpromazine analog results in decreased expression of TNF protein; Chlorpromazine results in decreased expression of TNF mRNA TNF protein results in increased susceptibility to Chlorpromazine [Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein; [Chlorpromazine co-treated with lipoteichoic acid] results in increased expression of TNF protein; Chlorpromazine inhibits the reaction [[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride]; Chlorpromazine inhibits the reaction [hydroquinone results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased susceptibility to Chlorpromazine]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased expression of TNF protein] [IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Chlorpromazine; Chlorpromazine results in decreased expression of and results in decreased activity of TNF protein |
CTD |
PMID:8550079 PMID:15052360 PMID:19362101 PMID:20371967 PMID:22414385 PMID:23238562 More...
|
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFAIP8 |
TNF alpha induced protein 8 |
increases expression |
ISO |
Chlorpromazine results in increased expression of TNFAIP8 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:119,268,759...119,399,688
Ensembl chr 5:119,268,692...119,399,688
|
|
G |
TNFRSF14 |
TNF receptor superfamily member 14 |
increases expression |
EXP |
Chlorpromazine analog results in increased expression of TNFRSF14 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 1:2,554,234...2,563,829
Ensembl chr 1:2,555,639...2,565,382
|
|
G |
TNFSF11 |
TNF superfamily member 11 |
decreases activity multiple interactions |
ISO |
Chlorpromazine results in decreased activity of TNFSF11; Chlorpromazine results in decreased activity of TNFSF11 protein Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CAR2 mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of DCSTAMP mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
|
|
G |
TP53 |
tumor protein p53 |
affects activity |
ISO |
Chlorpromazine affects the activity of TP53 protein |
CTD |
PMID:25596134 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
|
|
G |
TRAFD1 |
TRAF-type zinc finger domain containing 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of TRAFD1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:112,125,560...112,153,604
Ensembl chr12:112,125,538...112,153,604
|
|
G |
TUBA1A |
tubulin alpha 1a |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of TUBA1A mRNA |
CTD |
PMID:27015953 |
|
NCBI chr12:49,184,795...49,189,080
Ensembl chr12:49,184,686...49,189,080
|
|
G |
TXN |
thioredoxin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of TXN1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 9:110,243,810...110,256,507
Ensembl chr 9:110,243,810...110,256,507
|
|
G |
TXNRD1 |
thioredoxin reductase 1 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of TXNRD1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307
|
|
G |
TYR |
tyrosinase |
increases expression |
EXP |
Chlorpromazine results in increased expression of TYR protein |
CTD |
PMID:25449126 |
|
NCBI chr11:89,177,875...89,295,759
Ensembl chr11:89,177,875...89,295,759
|
|
G |
UNG |
uracil DNA glycosylase |
decreases expression |
EXP |
Chlorpromazine analog results in decreased expression of UNG mRNA |
CTD |
PMID:15924885 |
|
NCBI chr12:109,097,597...109,110,992
Ensembl chr12:109,097,597...109,126,725
|
|
G |
UNKL |
unk like zinc finger |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of UNKL mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:1,363,205...1,414,704
Ensembl chr16:1,363,205...1,414,751
|
|
G |
VEGFA |
vascular endothelial growth factor A |
increases expression |
EXP |
Chlorpromazine analog results in increased expression of VEGFA mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
VEGFB |
vascular endothelial growth factor B |
increases expression |
ISO |
Chlorpromazine results in increased expression of VEGFB mRNA |
CTD |
PMID:25596134 |
|
NCBI chr11:64,234,584...64,239,264
Ensembl chr11:64,234,584...64,239,264
|
|
G |
WARS1 |
tryptophanyl-tRNA synthetase 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of WARS1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr14:100,333,790...100,376,327
Ensembl chr14:100,333,790...100,376,805
|
|
G |
WIPI1 |
WD repeat domain, phosphoinositide interacting 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of WIPI1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr17:68,421,281...68,457,496
Ensembl chr17:68,420,948...68,457,513
|
|
G |
XBP1 |
X-box binding protein 1 |
affects activity decreases expression |
ISO |
Chlorpromazine affects the activity of XBP1 protein Chlorpromazine results in decreased expression of XBP1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597
|
|
G |
XPC |
XPC complex subunit, DNA damage recognition and repair factor |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of XPC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:14,145,147...14,178,601
Ensembl chr 3:14,145,147...14,178,621
|
|
G |
XRCC4 |
X-ray repair cross complementing 4 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of XRCC4 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 5:83,077,547...83,374,473
Ensembl chr 5:83,077,498...83,353,787
|
|
G |
YAP1 |
Yes1 associated transcriptional regulator |
multiple interactions |
EXP |
Chlorpromazine results in decreased expression of and results in increased phosphorylation of and affects the localization of YAP1 protein |
CTD |
PMID:30703373 |
|
NCBI chr11:102,110,447...102,233,424
Ensembl chr11:102,110,447...102,233,424
|
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
clidinium inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
|
G |
ABHD2 |
abhydrolase domain containing 2, acylglycerol lipase |
decreases expression |
EXP |
Clomiphene results in decreased expression of ABHD2 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr15:89,040,998...89,202,355
Ensembl chr15:89,087,459...89,202,355
|
|
G |
AR |
androgen receptor |
affects binding multiple interactions |
ISO EXP |
Clomiphene binds to AR protein Clomiphene binds to and results in decreased activity of AR protein; Clomiphene inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein] |
CTD |
PMID:14565775 PMID:25752796 PMID:33049310 |
|
NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619
|
|
G |
CA12 |
carbonic anhydrase 12 |
decreases expression |
EXP |
Clomiphene results in decreased expression of CA12 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr15:63,321,378...63,381,846
Ensembl chr15:63,321,378...63,381,846
|
|
G |
CCND1 |
cyclin D1 |
decreases expression |
EXP |
Clomiphene results in decreased expression of CCND1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCNG2 |
cyclin G2 |
increases expression |
EXP |
Clomiphene results in increased expression of CCNG2 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 4:77,157,207...77,170,060
Ensembl chr 4:77,157,207...77,433,388
|
|
G |
CXCL12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
EXP |
Clomiphene results in decreased expression of CXCL12 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr10:44,370,165...44,385,097
Ensembl chr10:44,370,165...44,386,493
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
decreases activity |
EXP |
Clomiphene results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases activity |
EXP |
Clomiphene results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions |
EXP |
[Clomiphene results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25455453 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
DKK1 |
dickkopf WNT signaling pathway inhibitor 1 |
decreases expression |
EXP |
Clomiphene results in decreased expression of DKK1 protein |
CTD |
PMID:21851939 |
|
NCBI chr10:52,314,281...52,317,657
Ensembl chr10:52,314,281...52,318,042
|
|
G |
EFNA1 |
ephrin A1 |
increases expression |
EXP |
Clomiphene results in increased expression of EFNA1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 1:155,127,876...155,134,899
Ensembl chr 1:155,127,876...155,134,899
|
|
G |
EGR3 |
early growth response 3 |
decreases expression |
EXP |
Clomiphene results in decreased expression of EGR3 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 8:22,687,659...22,693,480
Ensembl chr 8:22,687,659...22,693,480
|
|
G |
ESR1 |
estrogen receptor 1 |
multiple interactions affects binding |
EXP |
Clomiphene binds to and results in decreased activity of ESR1 protein; Clomiphene inhibits the reaction [16 alpha-iodoestradiol binds to ESR1 protein]; Clomiphene promotes the reaction [ESR1 protein alternative form binds to ESR1 protein alternative form] Clomiphene binds to ESR1 protein |
CTD |
PMID:9048584 PMID:15521089 PMID:19233257 PMID:25012808 PMID:25752796 PMID:26865669 PMID:33049310 More...
|
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
ESR2 |
estrogen receptor 2 |
increases activity affects binding multiple interactions |
ISO EXP |
Clomiphene results in increased activity of ESR2 protein Clomiphene binds to Esr2 protein Clomiphene binds to and results in decreased activity of ESR2 protein Clomiphene binds to ESR2 protein Clomiphene inhibits the reaction [16 alpha-iodoestradiol binds to ESR2 protein] |
CTD RGD |
PMID:9048584 PMID:12224631 PMID:19211805 PMID:25752796 PMID:9048584 |
RGD:8694130 |
NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
EXP |
Clomiphene results in increased expression of F3 protein |
CTD |
PMID:25569083 |
|
NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
|
|
G |
F5 |
coagulation factor V |
affects response to substance |
EXP |
F5 gene polymorphism affects the susceptibility to Clomiphene |
CTD |
PMID:19371211 |
|
NCBI chr 1:169,511,951...169,586,481
Ensembl chr 1:169,511,951...169,586,588
|
|
G |
FOXC1 |
forkhead box C1 |
decreases expression |
EXP |
Clomiphene results in decreased expression of FOXC1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 6:1,609,915...1,613,897
Ensembl chr 6:1,609,915...1,613,897
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
multiple interactions increases expression |
EXP |
Clomiphene promotes the reaction [Alcohols results in increased expression of FSHB protein] Clomiphene results in increased expression of FSHB protein |
CTD |
PMID:1915937 PMID:8590623 |
|
NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,014...30,235,261
|
|
G |
GNRH1 |
gonadotropin releasing hormone 1 |
multiple interactions |
EXP |
Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]] |
CTD |
PMID:17054466 |
|
NCBI chr 8:25,419,258...25,425,040
Ensembl chr 8:25,419,258...25,424,654
|
|
G |
HOXA10 |
homeobox A10 |
decreases expression |
ISO |
Clomiphene results in decreased expression of HOXA10 mRNA; Clomiphene results in decreased expression of HOXA10 protein |
CTD |
PMID:26603317 |
|
NCBI chr 7:27,170,605...27,179,861
Ensembl chr 7:27,170,605...27,180,261
|
|
G |
ID3 |
inhibitor of DNA binding 3 |
increases expression |
EXP |
Clomiphene results in increased expression of ID3 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 1:23,557,926...23,559,501
Ensembl chr 1:23,557,926...23,559,501
|
|
G |
ITGB3 |
integrin subunit beta 3 |
decreases expression |
EXP ISO |
Clomiphene results in decreased expression of ITGB3 protein Clomiphene results in decreased expression of ITGB3 mRNA; Clomiphene results in decreased expression of ITGB3 protein |
CTD |
PMID:15749485 PMID:26603317 |
|
NCBI chr17:47,253,827...47,313,743
Ensembl chr17:47,253,827...47,313,743
|
|
G |
IYD |
iodotyrosine deiodinase |
multiple interactions |
EXP |
Clomiphene inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 6:150,369,012...150,405,969
Ensembl chr 6:150,368,892...150,405,969
|
|
G |
JAK2 |
Janus kinase 2 |
decreases expression |
EXP |
Clomiphene results in decreased expression of JAK2 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 9:4,984,390...5,129,948
Ensembl chr 9:4,984,390...5,129,948
|
|
G |
KYNU |
kynureninase |
increases expression |
EXP |
Clomiphene results in increased expression of KYNU mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 2:142,877,664...143,055,833
Ensembl chr 2:142,877,657...143,055,833
|
|
G |
LHB |
luteinizing hormone subunit beta |
increases secretion multiple interactions |
EXP |
Clomiphene results in increased secretion of LHB protein Clomiphene promotes the reaction [Alcohols results in increased expression of LHB protein]; PRL protein inhibits the reaction [Clomiphene results in increased secretion of LHB protein] |
CTD |
PMID:3891423 PMID:8590623 |
|
NCBI chr19:49,015,980...49,019,498
Ensembl chr19:49,015,980...49,017,091
|
|
G |
LIF |
LIF interleukin 6 family cytokine |
increases expression decreases expression |
EXP ISO |
Clomiphene results in increased expression of LIF mRNA Clomiphene results in decreased expression of LIF mRNA; Clomiphene results in decreased expression of LIF protein |
CTD |
PMID:21851939 PMID:26603317 |
|
NCBI chr22:30,240,453...30,246,759
Ensembl chr22:30,240,453...30,246,759
|
|
G |
MYB |
MYB proto-oncogene, transcription factor |
decreases expression |
EXP |
Clomiphene results in decreased expression of MYB mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 6:135,181,308...135,219,172
Ensembl chr 6:135,181,308...135,219,173
|
|
G |
MYBL1 |
MYB proto-oncogene like 1 |
decreases expression |
EXP |
Clomiphene results in decreased expression of MYBL1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 8:66,562,175...66,613,218
Ensembl chr 8:66,562,175...66,614,247
|
|
G |
NMRK1 |
nicotinamide riboside kinase 1 |
decreases expression |
EXP |
Clomiphene results in decreased expression of NMRK1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 9:75,060,577...75,088,155
Ensembl chr 9:75,060,573...75,088,217
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity multiple interactions |
EXP ISO |
Clomiphene results in increased activity of NR1I2 protein Clomiphene binds to and results in increased activity of NR1I2 protein [Clomiphene results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Clomiphene binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 PMID:33049310 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
OLFM1 |
olfactomedin 1 |
decreases expression |
EXP |
Clomiphene results in decreased expression of OLFM1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 9:135,075,505...135,121,184
Ensembl chr 9:135,075,422...135,121,180
|
|
G |
PDZK1 |
PDZ domain containing 1 |
decreases expression |
EXP |
Clomiphene results in decreased expression of PDZK1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 1:145,670,852...145,707,400
Ensembl chr 1:145,670,852...145,708,148
|
|
G |
PGR |
progesterone receptor |
increases expression multiple interactions |
EXP |
Clomiphene results in increased expression of PGR protein Clomiphene binds to and results in decreased activity of PGR protein |
CTD |
PMID:15749485 PMID:25752796 |
|
NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813
|
|
G |
PIK3R3 |
phosphoinositide-3-kinase regulatory subunit 3 |
increases expression |
EXP |
Clomiphene results in increased expression of PIK3R3 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 1:46,040,140...46,174,901
Ensembl chr 1:46,040,140...46,133,036
|
|
G |
PRKCE |
protein kinase C epsilon |
affects localization |
EXP |
Clomiphene affects the localization of PRKCE protein |
CTD |
PMID:9714066 |
|
NCBI chr 2:45,651,279...46,187,990
Ensembl chr 2:45,651,345...46,187,990
|
|
G |
PRL |
prolactin |
multiple interactions |
EXP |
Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]; Clomiphene inhibits the reaction [Estradiol results in increased secretion of PRL protein]; PRL protein inhibits the reaction [Clomiphene results in increased secretion of LHB protein] |
CTD |
PMID:3891423 PMID:17054466 |
|
NCBI chr 6:22,287,246...22,302,835
Ensembl chr 6:22,287,244...22,302,826
|
|
G |
PRSS23 |
serine protease 23 |
decreases expression |
EXP |
Clomiphene results in decreased expression of PRSS23 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr11:86,791,071...86,952,910
Ensembl chr11:86,791,059...86,952,910
|
|
G |
PTGES |
prostaglandin E synthase |
decreases expression |
EXP |
Clomiphene results in decreased expression of PTGES mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042
|
|
G |
RBBP8 |
RB binding protein 8, endonuclease |
decreases expression |
EXP |
Clomiphene results in decreased expression of RBBP8 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr18:22,914,139...23,026,486
Ensembl chr18:22,798,261...23,026,488
|
|
G |
RCL1 |
RNA terminal phosphate cyclase like 1 |
decreases expression |
EXP |
Clomiphene results in decreased expression of RCL1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 9:4,792,944...4,861,066
Ensembl chr 9:4,792,944...4,885,917
|
|
G |
RET |
ret proto-oncogene |
decreases expression |
EXP |
Clomiphene results in decreased expression of RET mRNA |
CTD |
PMID:26865669 |
|
NCBI chr10:43,077,069...43,130,351
Ensembl chr10:43,077,064...43,130,351
|
|
G |
SGK1 |
serum/glucocorticoid regulated kinase 1 |
decreases expression |
EXP |
Clomiphene results in decreased expression of SGK1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 6:134,169,256...134,318,112
Ensembl chr 6:134,169,248...134,318,112
|
|
G |
SGK3 |
serum/glucocorticoid regulated kinase family member 3 |
decreases expression |
EXP |
Clomiphene results in decreased expression of SGK3 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 8:66,712,781...66,862,022
Ensembl chr 8:66,712,734...66,862,022
|
|
G |
SHBG |
sex hormone binding globulin |
affects binding |
EXP |
Clomiphene binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr17:7,614,064...7,633,372
Ensembl chr17:7,613,946...7,633,382
|
|
G |
SIAH2 |
siah E3 ubiquitin protein ligase 2 |
decreases expression |
EXP |
Clomiphene results in decreased expression of SIAH2 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 3:150,741,125...150,763,169
Ensembl chr 3:150,741,125...150,763,477
|
|
G |
SMOX |
spermine oxidase |
decreases expression |
EXP |
Clomiphene results in decreased expression of SMOX mRNA |
CTD |
PMID:26865669 |
|
NCBI chr20:4,148,828...4,187,727
Ensembl chr20:4,120,980...4,187,747
|
|
G |
SSBP2 |
single stranded DNA binding protein 2 |
increases expression |
EXP |
Clomiphene results in increased expression of SSBP2 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 5:81,412,804...81,751,807
Ensembl chr 5:81,412,804...81,751,797
|
|
G |
SVIL |
supervillin |
decreases expression |
EXP |
Clomiphene results in decreased expression of SVIL mRNA |
CTD |
PMID:26865669 |
|
NCBI chr10:29,457,338...29,736,936
Ensembl chr10:29,457,338...29,736,959
|
|
G |
TFAP2A |
transcription factor AP-2 alpha |
increases expression |
EXP |
Clomiphene results in increased expression of TFAP2A mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 6:10,396,677...10,419,659
Ensembl chr 6:10,393,186...10,419,659
|
|
G |
TFAP2C |
transcription factor AP-2 gamma |
decreases expression |
EXP |
Clomiphene results in decreased expression of TFAP2C mRNA |
CTD |
PMID:26865669 |
|
NCBI chr20:56,629,306...56,639,283
Ensembl chr20:56,629,306...56,639,283
|
|
G |
TFPI |
tissue factor pathway inhibitor |
increases expression |
EXP |
Clomiphene results in increased expression of TFPI mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 2:187,464,230...187,554,435
Ensembl chr 2:187,464,230...187,565,760
|
|
G |
THRA |
thyroid hormone receptor alpha |
multiple interactions |
EXP |
Clomiphene binds to and results in increased activity of THRA protein |
CTD |
PMID:33049310 |
|
NCBI chr17:40,062,193...40,093,867
Ensembl chr17:40,058,290...40,093,867
|
|
G |
THRB |
thyroid hormone receptor beta |
multiple interactions |
EXP |
Clomiphene binds to and results in increased activity of THRB protein |
CTD |
PMID:33049310 |
|
NCBI chr 3:24,117,153...24,495,708
Ensembl chr 3:24,117,153...24,495,756
|
|
|
G |
CASP3 |
caspase 3 |
increases expression |
ISO |
Cyproheptadine results in increased expression of CASP3 protein |
CTD |
PMID:33675893 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
decreases activity |
EXP |
Cyproheptadine results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
GH1 |
growth hormone 1 |
increases expression |
EXP |
Cyproheptadine results in increased expression of GH1 protein |
CTD |
PMID:642945 |
|
NCBI chr17:63,917,203...63,918,839
Ensembl chr17:63,917,200...63,918,839
|
|
G |
HSF1 |
heat shock transcription factor 1 |
increases activity |
EXP |
Cyproheptadine results in increased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 8:144,291,604...144,314,720
Ensembl chr 8:144,291,591...144,314,720
|
|
G |
HTR2A |
5-hydroxytryptamine receptor 2A |
multiple interactions |
EXP |
Cyproheptadine binds to and results in decreased activity of HTR2A protein |
CTD |
PMID:17031071 |
|
NCBI chr13:46,831,546...46,898,082
Ensembl chr13:46,831,546...46,897,076
|
|
G |
HTR7 |
5-hydroxytryptamine receptor 7 |
affects binding multiple interactions |
EXP |
Cyproheptadine binds to HTR7 protein Cyproheptadine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein] |
CTD |
PMID:20827463 |
|
NCBI chr10:90,740,823...90,858,039
Ensembl chr10:90,740,823...90,858,039
|
|
G |
IL6 |
interleukin 6 |
decreases expression |
ISO |
Cyproheptadine results in decreased expression of IL6 protein |
CTD |
PMID:33675893 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
KCNN2 |
potassium calcium-activated channel subfamily N member 2 |
decreases activity |
ISO |
Cyproheptadine results in decreased activity of KCNN2 protein |
CTD |
PMID:10915830 |
|
NCBI chr 5:114,055,978...114,496,496
Ensembl chr 5:114,055,926...114,496,500
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
decreases expression |
ISO |
Cyproheptadine results in decreased expression of NFKB1 protein |
CTD |
PMID:33675893 |
|
NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302
|
|
G |
POMC |
proopiomelanocortin |
decreases secretion |
EXP |
Cyproheptadine results in decreased secretion of POMC protein |
CTD |
PMID:642945 |
|
NCBI chr 2:25,160,860...25,168,580
Ensembl chr 2:25,160,853...25,168,903
|
|
G |
PRL |
prolactin |
decreases secretion |
EXP |
Cyproheptadine results in decreased secretion of PRL protein |
CTD |
PMID:642945 |
|
NCBI chr 6:22,287,246...22,302,835
Ensembl chr 6:22,287,244...22,302,826
|
|
G |
SIRT1 |
sirtuin 1 |
increases expression |
ISO |
Cyproheptadine results in increased expression of SIRT1 protein |
CTD |
PMID:33675893 |
|
NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
Cyproheptadine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
G |
SLC22A5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
Cyproheptadine affects the reaction [SLC22A5 gene mutant form affects the transport of and affects the abundance of Pyrilamine] |
CTD |
PMID:19821448 |
|
NCBI chr 5:132,369,710...132,395,612
Ensembl chr 5:132,369,710...132,395,613
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
affects response to substance |
ISO |
ABCB1A protein affects the susceptibility to Dextropropoxyphene |
CTD |
PMID:15502009 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
CES1 |
carboxylesterase 1 |
affects binding |
EXP |
Dextropropoxyphene binds to CES1 protein |
CTD |
PMID:10381793 |
|
NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337
|
|
G |
CES2 |
carboxylesterase 2 |
affects binding |
EXP |
Dextropropoxyphene binds to CES2 protein |
CTD |
PMID:10381793 |
|
NCBI chr16:66,934,471...66,945,096
Ensembl chr16:66,934,444...66,945,096
|
|
G |
OPRD1 |
opioid receptor delta 1 |
multiple interactions affects binding |
ISO |
[Dextropropoxyphene binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRD1 protein] which results in decreased uptake of Serotonin |
CTD |
PMID:7562497 |
|
NCBI chr 1:28,812,170...28,871,267
Ensembl chr 1:28,812,170...28,871,267
|
|
G |
OPRK1 |
opioid receptor kappa 1 |
multiple interactions affects binding |
ISO |
[Dextropropoxyphene binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRK1 protein] which results in decreased uptake of Serotonin |
CTD |
PMID:7562497 |
|
NCBI chr 8:53,225,724...53,251,637
Ensembl chr 8:53,225,724...53,251,637
|
|
G |
OPRM1 |
opioid receptor mu 1 |
multiple interactions affects binding |
ISO |
[Dextropropoxyphene binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRM1 protein] which results in decreased uptake of Serotonin |
CTD |
PMID:7562497 |
|
NCBI chr 6:154,010,496...154,246,867
Ensembl chr 6:154,010,496...154,246,867
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
Dextropropoxyphene inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
Dicyclomine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
|
G |
TP53 |
tumor protein p53 |
affects activity |
EXP |
Diphenoxylate affects the activity of TP53 protein |
CTD |
PMID:35435491 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
|
|
|
G |
HRH1 |
histamine receptor H1 |
multiple interactions |
EXP |
diphenylpyraline binds to and results in increased activity of HRH1 protein; diphenylpyraline inhibits the reaction [Pyrilamine binds to HRH1 protein] |
CTD |
PMID:1912125 |
|
NCBI chr 3:11,137,238...11,263,557
Ensembl chr 3:11,137,093...11,263,557
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
EXP |
diphenylpyraline results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
|
G |
ABCB4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
EXP |
Doxylamine results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
multiple interactions |
EXP |
Doxylamine binds to and results in increased activity of NR1I3 protein alternative form |
CTD |
PMID:20869355 |
|
NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
|
|
|
G |
ACHE |
acetylcholinesterase (Yt blood group) |
decreases activity |
ISO |
EPTC results in decreased activity of ACHE protein |
CTD |
PMID:14644616 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
ALDH2 |
aldehyde dehydrogenase 2 family member |
decreases activity |
ISO |
EPTC metabolite results in decreased activity of ALDH2 protein |
CTD |
PMID:10513990 |
|
NCBI chr12:111,766,933...111,817,532
Ensembl chr12:111,766,887...111,817,532
|
|
G |
ALOX15 |
arachidonate 15-lipoxygenase |
affects response to substance |
EXP |
ALOX15 gene SNP affects the susceptibility to EPTC |
CTD |
PMID:22919386 |
|
NCBI chr17:4,630,919...4,641,678
Ensembl chr17:4,630,919...4,642,294
|
|
G |
CHRNA3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
ISO |
EPTC results in decreased activity of [CHRNA3 protein binds to CHRNB2 protein]; EPTC results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein] |
CTD |
PMID:14644616 |
|
NCBI chr15:78,593,052...78,620,996
Ensembl chr15:78,593,052...78,621,295
|
|
G |
CHRNA4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO |
EPTC results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; EPTC results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein] |
CTD |
PMID:14644616 |
|
NCBI chr20:63,343,223...63,361,349
Ensembl chr20:63,343,223...63,378,401
|
|
G |
CHRNB2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
EPTC results in decreased activity of [CHRNA3 protein binds to CHRNB2 protein]; EPTC results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] |
CTD |
PMID:14644616 |
|
NCBI chr 1:154,567,778...154,580,013
Ensembl chr 1:154,567,778...154,580,013
|
|
G |
CHRNB4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
EPTC results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]; EPTC results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein] |
CTD |
PMID:14644616 |
|
NCBI chr15:78,624,111...78,661,641
Ensembl chr15:78,624,111...78,727,754
|
|
|
G |
ALDH1A2 |
aldehyde dehydrogenase 1 family member A2 |
increases expression |
ISO |
fenpropidine results in increased expression of ALDH1A2 mRNA |
CTD |
PMID:34737147 |
|
NCBI chr15:57,953,429...58,065,711
Ensembl chr15:57,953,424...58,497,866
|
|
G |
CYP26A1 |
cytochrome P450 family 26 subfamily A member 1 |
increases expression |
ISO |
fenpropidine results in increased expression of CYP26A1 mRNA |
CTD |
PMID:34737147 |
|
NCBI chr10:93,073,475...93,077,885
Ensembl chr10:93,073,475...93,077,885
|
|
G |
MSMO1 |
methylsterol monooxygenase 1 |
increases expression |
ISO |
fenpropidine results in increased expression of MSMO1 mRNA |
CTD |
PMID:34737147 |
|
NCBI chr 4:165,327,669...165,343,164
Ensembl chr 4:165,327,667...165,343,164
|
|
G |
MYH14 |
myosin heavy chain 14 |
decreases expression |
ISO |
fenpropidine results in decreased expression of MYH14 protein |
CTD |
PMID:34737147 |
|
NCBI chr19:50,203,622...50,310,540
Ensembl chr19:50,188,186...50,310,542
|
|
G |
MYH6 |
myosin heavy chain 6 |
decreases expression |
ISO |
fenpropidine results in decreased expression of MYH6 mRNA |
CTD |
PMID:34737147 |
|
NCBI chr14:23,381,987...23,408,273
Ensembl chr14:23,381,982...23,408,273
|
|
G |
NES |
nestin |
increases expression |
ISO |
fenpropidine results in increased expression of NES mRNA |
CTD |
PMID:34737147 |
|
NCBI chr 1:156,668,763...156,677,407
Ensembl chr 1:156,668,763...156,677,407
|
|
G |
NKX2-5 |
NK2 homeobox 5 |
decreases expression |
ISO |
fenpropidine results in decreased expression of NKX2-5 mRNA |
CTD |
PMID:34737147 |
|
NCBI chr 5:173,232,109...173,235,206
Ensembl chr 5:173,232,109...173,235,311
|
|
G |
TFAP2A |
transcription factor AP-2 alpha |
increases expression |
ISO |
fenpropidine results in increased expression of TFAP2A protein |
CTD |
PMID:34737147 |
|
NCBI chr 6:10,396,677...10,419,659
Ensembl chr 6:10,393,186...10,419,659
|
|
G |
TUBB3 |
tubulin beta 3 class III |
increases expression |
ISO |
fenpropidine results in increased expression of TUBB3 mRNA |
CTD |
PMID:34737147 |
|
NCBI chr16:89,921,925...89,936,097
Ensembl chr16:89,921,392...89,938,761
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions |
EXP |
ferric nitrilotriacetate inhibits the reaction [Asbestos, Crocidolite results in increased expression of ABCB1 protein]; ferric nitrilotriacetate inhibits the reaction [Razoxane results in increased expression of ABCB1 protein] |
CTD |
PMID:18385176 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 (ABCC1 blood group) |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of ABCC1 mRNA |
CTD |
PMID:18617210 |
|
NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of ABCC2 mRNA |
CTD |
PMID:18617210 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCC4 |
ATP binding cassette subfamily C member 4 (PEL blood group) |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of ABCC4 mRNA |
CTD |
PMID:18617210 |
|
NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
|
|
G |
ANXA2 |
annexin A2 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of ANXA2 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr15:60,347,151...60,397,986
Ensembl chr15:60,347,134...60,402,883
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of BAX mRNA |
CTD |
PMID:23208426 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BBC3 |
BCL2 binding component 3 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of BBC3 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr19:47,220,824...47,232,860
Ensembl chr19:47,220,822...47,232,766
|
|
G |
BIK |
BCL2 interacting killer |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of BIK mRNA |
CTD |
PMID:23208426 |
|
NCBI chr22:43,110,750...43,129,712
Ensembl chr22:43,110,750...43,129,712
|
|
G |
CALD1 |
caldesmon 1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of CALD1 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 7:134,745,467...134,970,729
Ensembl chr 7:134,744,252...134,970,729
|
|
G |
CANX |
calnexin |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of CANX protein |
CTD |
PMID:16908007 |
|
NCBI chr 5:179,678,656...179,731,641
Ensembl chr 5:179,678,628...179,731,641
|
|
G |
CASP12 |
caspase 12 (gene/pseudogene) |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of CASP12 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr11:104,883,286...104,898,460
Ensembl chr11:104,885,718...104,898,670
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP3 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP3 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP3 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP3 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
ISO |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP8 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP8 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
ISO |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP9 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP9 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP9 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP9 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions decreases activity |
ISO |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of CAT protein; chrysin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein]; geraniol inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of CAT protein]; Quercetin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein] |
CTD |
PMID:9667754 PMID:15198074 PMID:18684806 PMID:21907755 PMID:23194824 PMID:30098279 More...
|
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCND1 |
cyclin D1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of CCND1 mRNA; ferric nitrilotriacetate results in increased expression of CCND1 protein |
CTD |
PMID:18055543 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CD44 |
CD44 molecule (IN blood group) |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of CD44 mRNA; ferric nitrilotriacetate results in increased expression of CD44 protein |
CTD |
PMID:18055543 |
|
NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402
|
|
G |
CD47 |
CD47 molecule |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of CD47 mRNA |
CTD |
PMID:9119739 |
|
NCBI chr 3:108,043,091...108,091,031
Ensembl chr 3:108,043,091...108,091,862
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of CDKN1A mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
|
|
G |
CHRM1 |
cholinergic receptor muscarinic 1 |
decreases expression |
ISO |
ferric nitrilotriacetate results in decreased expression of CHRM1 mRNA |
CTD |
PMID:19490752 |
|
NCBI chr11:62,908,679...62,921,878
Ensembl chr11:62,908,679...62,921,807
|
|
G |
CHRM2 |
cholinergic receptor muscarinic 2 |
decreases expression |
ISO |
ferric nitrilotriacetate results in decreased expression of CHRM2 mRNA |
CTD |
PMID:19490752 |
|
NCBI chr 7:136,868,652...137,020,213
Ensembl chr 7:136,868,652...137,020,255
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
increases expression multiple interactions |
ISO |
ferric nitrilotriacetate results in increased expression of COL1A1 protein ethylisopropylamiloride inhibits the reaction [ferric nitrilotriacetate results in increased expression of COL1A1 protein] |
CTD |
PMID:11159895 |
|
NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632
|
|
G |
CYGB |
cytoglobin |
multiple interactions |
ISO |
CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]; CYGB protein results in decreased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid] |
CTD |
PMID:16581302 |
|
NCBI chr17:76,527,356...76,551,193
Ensembl chr17:76,527,356...76,551,175
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions |
EXP |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein; [Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein; allyl sulfide inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]; Ditiocarb inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]] |
CTD |
PMID:12086689 PMID:17034788 PMID:21352821 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of FOS mRNA |
CTD |
PMID:10381381 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
FOSL1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of FOSL1 mRNA; ferric nitrilotriacetate results in increased expression of FOSL1 protein |
CTD |
PMID:18055543 |
|
NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
|
|
G |
G6PD |
glucose-6-phosphate dehydrogenase |
decreases activity |
ISO |
ferric nitrilotriacetate results in decreased activity of G6PD protein |
CTD |
PMID:9667754 |
|
NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of GCLC mRNA |
CTD |
PMID:18617210 |
|
NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
|
|
G |
GSR |
glutathione-disulfide reductase |
decreases activity multiple interactions |
ISO |
ferric nitrilotriacetate results in decreased activity of GSR protein [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of GSR protein; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of GSR protein]; Quercetin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of GSR protein] |
CTD |
PMID:9667754 PMID:15198074 PMID:30098279 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
GTSE1 |
G2 and S-phase expressed 1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of GTSE1 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr22:46,296,870...46,330,810
Ensembl chr22:46,296,870...46,330,810
|
|
G |
HAVCR1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased secretion of HAVCR1 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 protein; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased secretion of HAVCR1 protein] |
CTD |
PMID:21907755 PMID:30098279 |
|
NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
ferric nitrilotriacetate inhibits the reaction [Asbestos, Crocidolite results in increased activity of HIF1A protein]; ferric nitrilotriacetate inhibits the reaction [Razoxane results in increased activity of HIF1A protein] |
CTD |
PMID:18385176 |
|
NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of HMOX1 mRNA |
CTD |
PMID:18617210 PMID:19490752 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HSP90AA1 |
heat shock protein 90 alpha family class A member 1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of HSP90AA1 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr14:102,080,742...102,139,749
Ensembl chr14:102,080,742...102,139,699
|
|
G |
IL24 |
interleukin 24 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of IL24 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 1:206,897,443...206,904,139
Ensembl chr 1:206,897,443...206,904,139
|
|
G |
IL6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
ferric nitrilotriacetate results in increased expression of IL6 protein ferric nitrilotriacetate results in increased expression of IL6 mRNA [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of IL6 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of IL6 protein] |
CTD |
PMID:15781289 PMID:19490752 PMID:23194824 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of JUN mRNA; ferric nitrilotriacetate results in increased expression of JUN protein |
CTD |
PMID:18055543 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
KRT18 |
keratin 18 |
multiple interactions |
EXP |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein |
CTD |
PMID:17034788 |
|
NCBI chr12:52,948,855...52,952,906
Ensembl chr12:52,948,871...52,952,906
|
|
G |
KRT8 |
keratin 8 |
multiple interactions |
EXP |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein |
CTD |
PMID:17034788 |
|
NCBI chr12:52,897,191...52,949,860
Ensembl chr12:52,897,187...52,949,954
|
|
G |
MCM3 |
minichromosome maintenance complex component 3 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of MCM3 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 6:52,264,015...52,284,742
Ensembl chr 6:52,264,014...52,284,881
|
|
G |
MT1X |
metallothionein 1X |
multiple interactions |
ISO |
[ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT1 protein binds to Cadmium]; [ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT1 protein binds to Zinc]; ferric nitrilotriacetate results in increased oxidation of [MT1 protein binds to Zinc] |
CTD |
PMID:22001350 |
|
NCBI chr16:56,682,470...56,684,196
Ensembl chr16:56,682,470...56,684,196
|
|
G |
MT2A |
metallothionein 2A |
multiple interactions |
ISO |
[ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT2 protein binds to Cadmium] |
CTD |
PMID:22001350 |
|
NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497
|
|
G |
MT3 |
metallothionein 3 |
decreases response to substance |
EXP |
MT3 protein results in decreased susceptibility to ferric nitrilotriacetate |
CTD |
PMID:12383939 |
|
NCBI chr16:56,589,528...56,591,085
Ensembl chr16:56,589,074...56,591,088
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of MYC mRNA; ferric nitrilotriacetate results in increased expression of MYC protein |
CTD |
PMID:18055543 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
affects localization |
ISO |
ferric nitrilotriacetate affects the localization of NFE2L2 protein |
CTD |
PMID:18617210 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of NFKB1 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of NFKB1 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO |
ferric nitrilotriacetate inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; ferric nitrilotriacetate inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein]; ferric nitrilotriacetate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] ferric nitrilotriacetate results in increased expression of NOS2 protein [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of NOS2 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of NOS2 protein]; chrysin inhibits the reaction [ferric nitrilotriacetate results in increased expression of NOS2 protein]; ferric nitrilotriacetate promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; ferric nitrilotriacetate promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] |
CTD |
PMID:11461780 PMID:11746204 PMID:12490132 PMID:23194824 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of NQO1 mRNA; ferric nitrilotriacetate results in increased expression of NQO1 protein |
CTD |
PMID:18617210 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
ODC1 |
ornithine decarboxylase 1 |
multiple interactions increases activity |
ISO |
[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein; Active Hexose Correlated Compound inhibits the reaction [[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein]; Vitamin E inhibits the reaction [ferric nitrilotriacetate results in increased activity of ODC1 protein] |
CTD |
PMID:9667754 PMID:14623030 PMID:15949125 |
|
NCBI chr 2:10,439,968...10,448,327
Ensembl chr 2:10,439,968...10,448,327
|
|
G |
PCK1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of PCK1 mRNA |
CTD |
PMID:16960379 |
|
NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121
|
|
G |
PCNA |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PCNA protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PCNA protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA protein] |
CTD |
PMID:21907755 PMID:23194824 |
|
NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
|
|
G |
PHLDA3 |
pleckstrin homology like domain family A member 3 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of PHLDA3 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 1:201,464,278...201,469,188
Ensembl chr 1:201,464,278...201,469,237
|
|
G |
PLAU |
plasminogen activator, urokinase |
multiple interactions increases expression increases activity |
EXP |
Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased activity of PLAU mRNA]; Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased expression of PLAU mRNA] |
CTD |
PMID:17571974 |
|
NCBI chr10:73,909,164...73,917,494
Ensembl chr10:73,909,177...73,917,496
|
|
G |
PLK2 |
polo like kinase 2 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of PLK2 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 5:58,453,982...58,460,086
Ensembl chr 5:58,453,982...58,460,139
|
|
G |
POLA1 |
DNA polymerase alpha 1, catalytic subunit |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of POLA1 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr X:24,693,918...24,996,986
Ensembl chr X:24,693,873...24,996,986
|
|
G |
PPIA |
peptidylprolyl isomerase A |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of PPIA protein |
CTD |
PMID:16908007 |
|
NCBI chr 7:44,796,681...44,803,117
Ensembl chr 7:44,796,680...44,824,564
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein]; chrysin inhibits the reaction [ferric nitrilotriacetate results in increased expression of PTGS2 protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein] |
CTD |
PMID:23194824 PMID:30098279 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
PTPRB |
protein tyrosine phosphatase receptor type B |
decreases expression |
ISO |
ferric nitrilotriacetate results in decreased expression of PTPRB mRNA |
CTD |
PMID:10854235 |
|
NCBI chr12:70,515,870...70,637,429
Ensembl chr12:70,515,870...70,637,440
|
|
G |
PTPRZ1 |
protein tyrosine phosphatase receptor type Z1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of PTPRZ1 mRNA; ferric nitrilotriacetate results in increased expression of PTPRZ1 protein |
CTD |
PMID:18055543 |
|
NCBI chr 7:121,873,161...122,062,036
Ensembl chr 7:121,873,089...122,062,036
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased localization of RELA protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased localization of RELA protein] |
CTD |
PMID:23194824 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RPL19 |
ribosomal protein L19 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of RPL19 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr17:39,200,283...39,204,732
Ensembl chr17:39,200,283...39,204,840
|
|
G |
RPRM |
reprimo, TP53 dependent G2 arrest mediator homolog |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of RPRM mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 2:153,477,338...153,478,762
Ensembl chr 2:153,477,338...153,478,762
|
|
G |
RPS13 |
ribosomal protein S13 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of RPS13 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr11:17,074,388...17,077,667
Ensembl chr11:17,074,388...17,077,715
|
|
G |
RPS15 |
ribosomal protein S15 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of RPS15 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr19:1,438,396...1,440,495
Ensembl chr19:1,438,358...1,440,495
|
|
G |
SLC11A2 |
solute carrier family 11 member 2 |
decreases expression |
EXP |
ferric nitrilotriacetate results in decreased expression of SLC11A2 mRNA |
CTD |
PMID:11925462 |
|
NCBI chr12:50,952,263...51,028,886
Ensembl chr12:50,979,401...51,028,566
|
|
G |
SLC40A1 |
solute carrier family 40 member 1 |
decreases expression |
EXP |
ferric nitrilotriacetate results in decreased expression of SLC40A1 mRNA |
CTD |
PMID:11925462 |
|
NCBI chr 2:189,560,590...189,580,786
Ensembl chr 2:189,560,590...189,583,758
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
ferric nitrilotriacetate inhibits the reaction [Dimethylnitrosamine results in decreased expression of SOD1 protein] |
CTD |
PMID:15842777 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SSRP1 |
structure specific recognition protein 1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of SSRP1 mRNA |
CTD |
PMID:8844983 |
|
NCBI chr11:57,325,988...57,335,892
Ensembl chr11:57,325,986...57,335,892
|
|
G |
TGFA |
transforming growth factor alpha |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of TGFA mRNA; ferric nitrilotriacetate results in increased expression of TGFA protein |
CTD |
PMID:8340253 |
|
NCBI chr 2:70,447,284...70,553,826
Ensembl chr 2:70,447,284...70,554,193
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions |
ISO |
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA] |
CTD |
PMID:16581302 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TGFB2 |
transforming growth factor beta 2 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of TGFB2 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 1:218,345,336...218,444,619
Ensembl chr 1:218,345,336...218,444,619
|
|
G |
TIMP1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16581302 |
|
NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789
|
|
G |
TNF |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
ferric nitrilotriacetate results in increased expression of TNF protein [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of TNF protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of TNF protein] |
CTD |
PMID:15781289 PMID:23194824 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
ISO |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein] |
CTD |
PMID:21907755 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
|
|
G |
TXN |
thioredoxin |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of TXN protein |
CTD |
PMID:15834431 |
|
NCBI chr 9:110,243,810...110,256,507
Ensembl chr 9:110,243,810...110,256,507
|
|
G |
TXNIP |
thioredoxin interacting protein |
decreases expression increases methylation |
ISO |
ferric nitrilotriacetate results in decreased expression of TXNIP protein ferric nitrilotriacetate results in increased methylation of TXNIP promoter |
CTD |
PMID:15834431 |
|
NCBI chr 1:145,992,435...145,996,579
Ensembl chr 1:145,992,435...145,996,579
|
|
G |
UBD |
ubiquitin D |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of UBD mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 6:29,555,515...29,559,732
Ensembl chr 6:29,555,515...29,559,732
|
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
decreases secretion |
ISO |
Lumefantrine results in decreased secretion of FSHB protein |
CTD |
PMID:26811345 |
|
NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,014...30,235,261
|
|
G |
PRL |
prolactin |
increases secretion |
ISO |
Lumefantrine results in increased secretion of PRL protein |
CTD |
PMID:26811345 |
|
NCBI chr 6:22,287,246...22,302,835
Ensembl chr 6:22,287,244...22,302,826
|
|
|
G |
A2M |
alpha-2-macroglobulin |
multiple interactions |
ISO |
N(6),N(6)-dimethyladenine inhibits the reaction [Cadmium Chloride results in increased expression of A2M protein] |
CTD |
PMID:15618353 |
|
NCBI chr12:9,067,708...9,116,229
Ensembl chr12:9,067,664...9,116,229
|
|
G |
CDH1 |
cadherin 1 |
multiple interactions |
ISO |
N(6),N(6)-dimethyladenine promotes the reaction [Cadmium Chloride results in decreased expression of CDH1 protein] |
CTD |
PMID:15618353 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
CDH2 |
cadherin 2 |
multiple interactions |
ISO |
N(6),N(6)-dimethyladenine promotes the reaction [Cadmium Chloride results in decreased expression of CDH2 protein] |
CTD |
PMID:15618353 |
|
NCBI chr18:27,932,879...28,177,130
Ensembl chr18:27,932,879...28,177,946
|
|
G |
CTNNB1 |
catenin beta 1 |
multiple interactions |
ISO |
N(6),N(6)-dimethyladenine promotes the reaction [Cadmium Chloride results in decreased expression of CTNNB1 protein] |
CTD |
PMID:15618353 |
|
NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096
|
|
G |
LIG1 |
DNA ligase 1 |
multiple interactions |
EXP |
N(6),N(6)-dimethyladenine inhibits the reaction [2-chloroethyl ethyl sulfide results in increased phosphorylation of LIG1 protein] |
CTD |
PMID:16700562 |
|
NCBI chr19:48,115,445...48,170,344
Ensembl chr19:48,115,445...48,170,603
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
N(6),N(6)-dimethyladenine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK8 protein] |
CTD |
PMID:15618353 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
N(6),N(6)-dimethyladenine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK9 protein] |
CTD |
PMID:15618353 |
|
NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
|
|
G |
OCLN |
occludin |
multiple interactions |
ISO |
N(6),N(6)-dimethyladenine promotes the reaction [Cadmium Chloride results in decreased expression of OCLN protein] |
CTD |
PMID:15618353 |
|
NCBI chr 5:69,492,547...69,558,104
Ensembl chr 5:69,492,292...69,558,104
|
|
G |
TJP1 |
tight junction protein 1 |
multiple interactions |
ISO |
N(6),N(6)-dimethyladenine promotes the reaction [Cadmium Chloride results in decreased expression of TJP1 protein] |
CTD |
PMID:15618353 |
|
NCBI chr15:29,699,367...29,969,049
Ensembl chr15:29,699,367...29,968,915
|
|
|
G |
AXIN2 |
axin 2 |
decreases expression |
EXP |
N,N-dimethylaniline analog results in decreased expression of AXIN2 protein |
CTD |
PMID:21291235 |
|
NCBI chr17:65,528,563...65,561,648
Ensembl chr17:65,528,563...65,561,648
|
|
G |
CYP2A13 |
cytochrome P450 family 2 subfamily A member 13 |
multiple interactions increases metabolic processing |
EXP |
CYP2A13 gene polymorphism inhibits the reaction [CYP2A13 protein results in increased metabolism of N,N-dimethylaniline] |
CTD |
PMID:18669584 |
|
NCBI chr19:41,088,451...41,096,195
Ensembl chr19:41,088,451...41,096,195
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
EXP |
N,N-dimethylaniline analog results in decreased expression of MYC protein |
CTD |
PMID:21291235 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
PYGO2 |
pygopus family PHD finger 2 |
decreases expression |
EXP |
N,N-dimethylaniline analog results in decreased expression of PYGO2 protein |
CTD |
PMID:21291235 |
|
NCBI chr 1:154,957,026...154,961,782
Ensembl chr 1:154,957,026...154,963,853
|
|
G |
TCF7L2 |
transcription factor 7 like 2 |
decreases expression |
EXP |
N,N-dimethylaniline analog results in decreased expression of TCF7L2 mRNA; N,N-dimethylaniline analog results in decreased expression of TCF7L2 protein |
CTD |
PMID:21291235 |
|
NCBI chr10:112,950,247...113,167,678
Ensembl chr10:112,950,247...113,167,678
|
|
|
G |
AR |
androgen receptor |
multiple interactions |
EXP |
Deanol inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:18324785 |
|
NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619
|
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
EXP |
naftifine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
affects response to substance increases transport |
EXP ISO |
ABCB1 exon SNP affects the susceptibility to Nortriptyline ABCB1A protein results in increased transport of Nortriptyline; ABCB1A protein results in increased transport of Nortriptyline metabolite |
CTD |
PMID:10700657 PMID:12082591 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCB4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
EXP |
Nortriptyline results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435
|
|
G |
CASP3 |
caspase 3 |
decreases activity increases activity multiple interactions |
ISO EXP |
Nortriptyline results in decreased activity of CASP3 protein Nortriptyline results in increased activity of CASP3 protein Palmitic Acid promotes the reaction [Nortriptyline results in increased activity of CASP3 protein] |
CTD |
PMID:17686041 PMID:18174477 PMID:22700542 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP7 |
caspase 7 |
multiple interactions increases activity |
EXP |
Palmitic Acid promotes the reaction [Nortriptyline results in increased activity of CASP7 protein] |
CTD |
PMID:22700542 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CYCS |
cytochrome c, somatic |
decreases secretion |
ISO |
Nortriptyline results in decreased secretion of CYCS protein |
CTD |
PMID:17686041 |
|
NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
increases metabolic processing |
EXP |
Nortriptyline results in increased metabolism of CYP1A2 protein |
CTD |
PMID:18359012 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP2C8 |
cytochrome P450 family 2 subfamily C member 8 |
decreases activity multiple interactions |
EXP |
Nortriptyline results in decreased activity of CYP2C8 protein torsemide inhibits the reaction [Nortriptyline results in decreased activity of CYP2C8 protein] |
CTD |
PMID:15304522 |
|
NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497
|
|
G |
CYP2D6 |
cytochrome P450 family 2 subfamily D member 6 |
decreases response to substance increases metabolic processing multiple interactions increases hydroxylation |
EXP |
CYP2D6 gene mutant form results in decreased susceptibility to Nortriptyline Nortriptyline results in increased metabolism of CYP2D6 protein Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in decreased susceptibility to Nortriptyline] CYP2D6 protein results in increased hydroxylation of Nortriptyline |
CTD |
PMID:11673748 PMID:17470523 PMID:18359012 |
|
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
increases metabolic processing |
EXP |
Nortriptyline results in increased metabolism of CYP3A4 protein |
CTD |
PMID:18359012 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
increases metabolic processing |
EXP |
Nortriptyline results in increased metabolism of CYP3A5 protein |
CTD |
PMID:18359012 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
|
|
G |
GNB3 |
G protein subunit beta 3 |
decreases response to substance increases response to substance |
EXP |
GNB3 gene polymorphism results in decreased susceptibility to Nortriptyline GNB3 protein results in increased susceptibility to Nortriptyline |
CTD |
PMID:14604448 |
|
NCBI chr12:6,840,925...6,847,393
Ensembl chr12:6,839,954...6,847,393
|
|
G |
HTR2C |
5-hydroxytryptamine receptor 2C |
decreases expression |
EXP |
Nortriptyline results in decreased expression of HTR2C protein |
CTD |
PMID:8131152 |
|
NCBI chr X:114,584,086...114,910,061
Ensembl chr X:114,584,078...114,910,061
|
|
G |
IL1A |
interleukin 1 alpha |
multiple interactions |
EXP |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Nortriptyline |
CTD |
PMID:19362101 |
|
NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Nortriptyline |
CTD |
PMID:19362101 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
EXP |
Nortriptyline inhibits the reaction [KCNH2 protein results in increased transport of Thallium] |
CTD |
PMID:21158687 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
PF4 |
platelet factor 4 |
affects expression |
EXP |
Nortriptyline affects the expression of PF4 protein |
CTD |
PMID:10770450 |
|
NCBI chr 4:73,980,811...73,982,124
Ensembl chr 4:73,980,811...73,982,027
|
|
G |
PPBP |
pro-platelet basic protein |
affects expression |
EXP |
Nortriptyline affects the expression of PPBP protein |
CTD |
PMID:10770450 |
|
NCBI chr 4:73,986,439...73,988,190
Ensembl chr 4:73,986,439...73,988,190
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
Nortriptyline inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
G |
SLC6A2 |
solute carrier family 6 member 2 |
affects response to substance |
EXP |
SLC6A2 gene polymorphism affects the susceptibility to Nortriptyline |
CTD |
PMID:17018806 |
|
NCBI chr16:55,655,988...55,706,192
Ensembl chr16:55,655,988...55,707,645
|
|
G |
SLC6A4 |
solute carrier family 6 member 4 |
affects response to substance increases response to substance decreases response to substance |
EXP |
SLC6A4 polymorphism affects the susceptibility to Nortriptyline; SLC6A4 promoter polymorphism affects the susceptibility to Nortriptyline SLC6A4 protein results in increased susceptibility to Nortriptyline SLC6A4 gene polymorphism results in decreased susceptibility to Nortriptyline |
CTD |
PMID:14604448 PMID:17018806 PMID:21658141 |
|
NCBI chr17:30,194,319...30,235,697
Ensembl chr17:30,194,319...30,236,002
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Nortriptyline |
CTD |
PMID:19362101 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
|
G |
AIFM1 |
apoptosis inducing factor mitochondria associated 1 |
increases expression |
EXP |
benoxinate results in increased expression of AIFM1 protein |
CTD |
PMID:27590991 |
|
NCBI chr X:130,129,362...130,165,841
Ensembl chr X:130,124,666...130,165,879
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
benoxinate results in increased expression of BAX protein |
CTD |
PMID:27590991 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2L1 |
BCL2 like 1 |
decreases expression |
EXP |
benoxinate results in decreased expression of BCL2L1 protein |
CTD |
PMID:27590991 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
CASP2 |
caspase 2 |
increases activity |
EXP |
benoxinate results in increased activity of CASP2 protein |
CTD |
PMID:27590991 |
|
NCBI chr 7:143,288,351...143,307,696
Ensembl chr 7:143,288,215...143,307,696
|
|
G |
CASP3 |
caspase 3 |
increases activity |
EXP |
benoxinate results in increased activity of CASP3 protein |
CTD |
PMID:27590991 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP9 |
caspase 9 |
increases activity |
EXP |
benoxinate results in increased activity of CASP9 protein |
CTD |
PMID:27590991 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
EXP |
benoxinate results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
benoxinate results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
benoxinate inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
EXP |
HRH1 protein affects the reaction [Procaine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:32061592 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
ALPL |
alkaline phosphatase, biomineralization associated |
increases expression |
EXP |
Procaine results in increased expression of ALPL mRNA |
CTD |
PMID:22083529 |
|
NCBI chr 1:21,508,984...21,578,410
Ensembl chr 1:21,509,397...21,578,410
|
|
G |
CALCA |
calcitonin related polypeptide alpha |
increases secretion |
ISO |
Procaine results in increased secretion of CALCA protein |
CTD |
PMID:18172555 |
|
NCBI chr11:14,966,668...14,972,351
Ensembl chr11:14,966,622...14,972,354
|
|
G |
CAPN1 |
calpain 1 |
multiple interactions |
ISO |
Procaine inhibits the reaction [Paraoxon results in increased expression of CAPN1 protein] |
CTD |
PMID:26998625 |
|
NCBI chr11:65,181,373...65,212,006
Ensembl chr11:65,180,566...65,212,006
|
|
G |
CAPN2 |
calpain 2 |
multiple interactions |
ISO |
Procaine inhibits the reaction [Paraoxon results in increased expression of CAPN2 protein] |
CTD |
PMID:26998625 |
|
NCBI chr 1:223,701,597...223,776,018
Ensembl chr 1:223,701,593...223,776,018
|
|
G |
CASP12 |
caspase 12 (gene/pseudogene) |
multiple interactions |
ISO |
Procaine inhibits the reaction [Paraoxon results in increased expression of and affects the activity of CASP12 protein]; Procaine inhibits the reaction [Paraoxon results in increased expression of CASP12 protein] |
CTD |
PMID:20079824 PMID:26998625 |
|
NCBI chr11:104,883,286...104,898,460
Ensembl chr11:104,885,718...104,898,670
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
Procaine inhibits the reaction [Paraoxon results in increased expression of and affects the activity of CASP3 protein] |
CTD |
PMID:26998625 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CDH5 |
cadherin 5 |
decreases expression multiple interactions |
EXP |
Procaine results in decreased expression of CDH5 protein HRH1 protein affects the reaction [Procaine results in decreased expression of CDH5 protein] |
CTD |
PMID:32061592 |
|
NCBI chr16:66,366,691...66,404,784
Ensembl chr16:66,366,690...66,404,784
|
|
G |
CES2 |
carboxylesterase 2 |
increases hydrolysis |
EXP |
CES2 protein results in increased hydrolysis of Procaine |
CTD |
PMID:9300133 PMID:15475733 |
|
NCBI chr16:66,934,471...66,945,096
Ensembl chr16:66,934,444...66,945,096
|
|
G |
ESR1 |
estrogen receptor 1 |
increases expression |
EXP |
Procaine results in increased expression of ESR1 mRNA |
CTD |
PMID:22083529 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
HRH1 |
histamine receptor H1 |
affects binding multiple interactions |
EXP |
HRH1 protein binds to Procaine [HRH1 protein binds to Procaine] which results in increased import of Calcium; HRH1 protein affects the reaction [Procaine results in decreased expression of CDH5 protein]; HRH1 protein affects the reaction [Procaine results in increased phosphorylation of AKT1 protein]; HRH1 protein affects the reaction [Procaine results in increased phosphorylation of ITPR1 protein]; HRH1 protein affects the reaction [Procaine results in increased phosphorylation of MAPK1 protein]; HRH1 protein affects the reaction [Procaine results in increased phosphorylation of MAPK3 protein]; HRH1 protein affects the reaction [Procaine results in increased phosphorylation of PLCG1 protein]; HRH1 protein affects the reaction [Procaine results in increased transport of fluorescein isothiocyanate bovine serum albumin] |
CTD |
PMID:32061592 |
|
NCBI chr 3:11,137,238...11,263,557
Ensembl chr 3:11,137,093...11,263,557
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[Procaine co-treated with Paraoxon] results in increased expression of HSPA5 protein |
CTD |
PMID:26998625 |
|
NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382
|
|
G |
ITPR1 |
inositol 1,4,5-trisphosphate receptor type 1 |
multiple interactions increases phosphorylation |
EXP |
HRH1 protein affects the reaction [Procaine results in increased phosphorylation of ITPR1 protein] |
CTD |
PMID:32061592 |
|
NCBI chr 3:4,493,348...4,847,506
Ensembl chr 3:4,493,345...4,847,506
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP |
Procaine results in increased phosphorylation of MAPK1 protein HRH1 protein affects the reaction [Procaine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:32061592 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
HRH1 protein affects the reaction [Procaine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:32061592 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
Procaine results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
PLCG1 |
phospholipase C gamma 1 |
multiple interactions increases phosphorylation |
EXP |
HRH1 protein affects the reaction [Procaine results in increased phosphorylation of PLCG1 protein] |
CTD |
PMID:32061592 |
|
NCBI chr20:41,137,543...41,177,626
Ensembl chr20:41,136,960...41,196,801
|
|
G |
TRPV1 |
transient receptor potential cation channel subfamily V member 1 |
increases activity |
ISO |
Procaine results in increased activity of TRPV1 protein |
CTD |
PMID:18172555 |
|
NCBI chr17:3,565,446...3,609,411
Ensembl chr17:3,565,444...3,609,411
|
|
|
G |
BCHE |
butyrylcholinesterase |
decreases activity |
EXP |
Promazine results in decreased activity of BCHE protein |
CTD |
PMID:236606 |
|
NCBI chr 3:165,772,904...165,837,423
Ensembl chr 3:165,772,904...165,837,462
|
|
G |
CRH |
corticotropin releasing hormone |
decreases expression |
EXP |
Promazine results in decreased expression of CRH mRNA |
CTD |
PMID:16205782 |
|
NCBI chr 8:66,176,376...66,178,464
Ensembl chr 8:66,176,376...66,178,464
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
EXP |
Promazine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
Promazine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
|
G |
AMBRA1 |
autophagy and beclin 1 regulator 1 |
decreases expression |
EXP |
Promethazine results in decreased expression of AMBRA1 protein |
CTD |
PMID:31682805 |
|
NCBI chr11:46,396,412...46,594,023
Ensembl chr11:46,396,414...46,594,125
|
|
G |
ATG5 |
autophagy related 5 |
decreases expression |
EXP |
Promethazine results in decreased expression of ATG5 protein |
CTD |
PMID:31682805 |
|
NCBI chr 6:106,184,476...106,325,760
Ensembl chr 6:106,045,423...106,325,791
|
|
G |
ATG7 |
autophagy related 7 |
decreases expression |
EXP |
Promethazine results in decreased expression of ATG7 protein |
CTD |
PMID:31682805 |
|
NCBI chr 3:11,272,397...11,576,353
Ensembl chr 3:11,272,309...11,557,665
|
|
G |
ATM |
ATM serine/threonine kinase |
decreases expression |
ISO |
Promethazine results in decreased expression of ATM mRNA |
CTD |
PMID:26011634 |
|
NCBI chr11:108,223,067...108,369,102
Ensembl chr11:108,222,823...108,369,102
|
|
G |
ATP5F1B |
ATP synthase F1 subunit beta |
decreases expression |
ISO |
Promethazine results in decreased expression of ATP5F1B mRNA |
CTD |
PMID:28903497 |
|
NCBI chr12:56,638,175...56,645,984
Ensembl chr12:56,638,175...56,645,984
|
|
G |
AURKA |
aurora kinase A |
decreases expression |
ISO |
Promethazine results in decreased expression of AURKA mRNA |
CTD |
PMID:26011634 |
|
NCBI chr20:56,369,390...56,392,215
Ensembl chr20:56,369,389...56,392,337
|
|
G |
AURKB |
aurora kinase B |
decreases expression |
ISO |
Promethazine results in decreased expression of AURKB mRNA |
CTD |
PMID:26011634 |
|
NCBI chr17:8,204,731...8,210,575
Ensembl chr17:8,204,733...8,210,600
|
|
G |
BAK1 |
BCL2 antagonist/killer 1 |
increases expression |
EXP |
Promethazine results in increased expression of BAK1 protein |
CTD |
PMID:31682805 |
|
NCBI chr 6:33,572,552...33,580,276
Ensembl chr 6:33,572,547...33,580,293
|
|
G |
BCHE |
butyrylcholinesterase |
decreases activity |
EXP ISO |
Promethazine results in decreased activity of BCHE protein |
CTD |
PMID:236606 |
|
NCBI chr 3:165,772,904...165,837,423
Ensembl chr 3:165,772,904...165,837,462
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression |
EXP |
Promethazine results in decreased expression of BCL2 protein |
CTD |
PMID:31682805 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
decreases expression |
EXP |
Promethazine results in decreased expression of BCL2L1 protein |
CTD |
PMID:31682805 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BECN1 |
beclin 1 |
multiple interactions |
EXP |
Promethazine affects the expression of and results in increased phosphorylation of BECN1 protein |
CTD |
PMID:31682805 |
|
NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
|
|
G |
BRCA1 |
BRCA1 DNA repair associated |
decreases expression |
ISO |
Promethazine results in decreased expression of BRCA1 mRNA |
CTD |
PMID:26011634 |
|
NCBI chr17:43,044,295...43,170,327
Ensembl chr17:43,044,295...43,170,245
|
|
G |
BRCA2 |
BRCA2 DNA repair associated |
decreases expression |
ISO |
Promethazine results in decreased expression of BRCA2 mRNA |
CTD |
PMID:26011634 |
|
NCBI chr13:32,315,508...32,400,268
Ensembl chr13:32,315,086...32,400,268
|
|
G |
BRCC3 |
BRCA1/BRCA2-containing complex subunit 3 |
decreases expression |
ISO |
Promethazine results in decreased expression of BRCC3 mRNA |
CTD |
PMID:26011634 |
|
NCBI chr X:155,071,508...155,123,077
Ensembl chr X:155,071,420...155,123,077
|
|
G |
BUB1 |
BUB1 mitotic checkpoint serine/threonine kinase |
decreases expression |
ISO |
Promethazine results in decreased expression of BUB1 mRNA |
CTD |
PMID:26011634 |
|
NCBI chr 2:110,637,528...110,678,063
Ensembl chr 2:110,637,528...110,678,063
|
|
G |
CASP3 |
caspase 3 |
decreases cleavage |
ISO |
Promethazine results in decreased cleavage of CASP3 protein |
CTD |
PMID:26011634 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression increases phosphorylation decreases expression |
ISO |
Promethazine results in increased expression of CDKN1A protein Promethazine results in increased phosphorylation of CDKN1A protein Promethazine results in decreased expression of CDKN1A mRNA |
CTD |
PMID:26011634 PMID:26558467 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
|
|
G |
CDKN2A |
cyclin dependent kinase inhibitor 2A |
decreases expression |
ISO |
Promethazine results in decreased expression of CDKN2A mRNA |
CTD |
PMID:26011634 |
|
NCBI chr 9:21,967,752...21,995,324
Ensembl chr 9:21,967,752...21,995,301
|
|
G |
CHEK1 |
checkpoint kinase 1 |
increases expression decreases expression |
ISO |
Promethazine results in increased expression of CHEK1 mRNA Promethazine results in decreased expression of CHEK1 mRNA |
CTD |
PMID:26011634 PMID:26558467 |
|
NCBI chr11:125,625,136...125,681,124
Ensembl chr11:125,625,163...125,676,255
|
|
G |
CHEK2 |
checkpoint kinase 2 |
decreases expression |
ISO |
Promethazine results in decreased expression of CHEK2 mRNA |
CTD |
PMID:26011634 |
|
NCBI chr22:28,687,743...28,741,834
Ensembl chr22:28,687,743...28,742,422
|
|
G |
CYP2D6 |
cytochrome P450 family 2 subfamily D member 6 |
decreases metabolic processing |
EXP |
CYP2D6 gene polymorphism results in decreased metabolism of Promethazine |
CTD |
PMID:19814645 |
|
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865
|
|
G |
ESCO1 |
establishment of sister chromatid cohesion N-acetyltransferase 1 |
decreases expression |
ISO |
Promethazine results in decreased expression of ESCO1 mRNA |
CTD |
PMID:26011634 |
|
NCBI chr18:21,529,284...21,600,704
Ensembl chr18:21,529,284...21,600,884
|
|
G |
G6PD |
glucose-6-phosphate dehydrogenase |
increases expression |
ISO |
Promethazine results in increased expression of G6PD mRNA |
CTD |
PMID:28903497 |
|
NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572
|
|
G |
GADD45A |
growth arrest and DNA damage inducible alpha |
affects expression |
ISO |
Promethazine affects the expression of GADD45A mRNA |
CTD |
PMID:26011634 |
|
NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334
|
|
G |
GAPDH |
glyceraldehyde-3-phosphate dehydrogenase |
decreases expression |
ISO |
Promethazine results in decreased expression of GAPDH mRNA |
CTD |
PMID:28903497 |
|
NCBI chr12:6,534,517...6,538,371
Ensembl chr12:6,534,512...6,538,374
|
|
G |
H2AX |
H2A.X variant histone |
decreases expression |
ISO |
Promethazine results in decreased expression of H2AX protein |
CTD |
PMID:26011634 |
|
NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
decreases expression |
ISO |
Promethazine results in decreased expression of HIF1A mRNA |
CTD |
PMID:28903497 |
|
NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HK2 |
hexokinase 2 |
decreases expression |
ISO |
Promethazine results in decreased expression of HK2 mRNA |
CTD |
PMID:28903497 |
|
NCBI chr 2:74,834,127...74,893,359
Ensembl chr 2:74,834,127...74,893,359
|
|
G |
HRH1 |
histamine receptor H1 |
multiple interactions |
EXP |
Promethazine binds to and results in decreased activity of HRH1 protein; Promethazine binds to and results in increased activity of HRH1 protein; Promethazine inhibits the reaction [Pyrilamine binds to HRH1 protein] |
CTD |
PMID:1377455 PMID:1912125 |
|
NCBI chr 3:11,137,238...11,263,557
Ensembl chr 3:11,137,093...11,263,557
|
|
G |
HRH2 |
histamine receptor H2 |
multiple interactions |
EXP |
Promethazine binds to and results in decreased activity of HRH2 protein |
CTD |
PMID:1377455 |
|
NCBI chr 5:175,658,071...175,710,756
Ensembl chr 5:175,658,030...175,710,756
|
|
G |
HSF1 |
heat shock transcription factor 1 |
decreases activity |
EXP |
Promethazine results in decreased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 8:144,291,604...144,314,720
Ensembl chr 8:144,291,591...144,314,720
|
|
G |
IL1A |
interleukin 1 alpha |
increases expression |
EXP |
Promethazine results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493
|
|
G |
IL1B |
interleukin 1 beta |
increases expression |
ISO |
Promethazine results in increased expression of IL1B protein |
CTD |
PMID:15265675 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
increases expression |
ISO |
Promethazine results in increased expression of IL6 protein |
CTD |
PMID:15265675 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
MAD1L1 |
mitotic arrest deficient 1 like 1 |
decreases expression |
ISO |
Promethazine results in decreased expression of MAD1L1 mRNA |
CTD |
PMID:26011634 |
|
NCBI chr 7:1,815,795...2,232,945
Ensembl chr 7:1,815,793...2,233,243
|
|
G |
MAD2L1 |
mitotic arrest deficient 2 like 1 |
increases expression decreases expression |
ISO |
Promethazine results in increased expression of MAD2L1 mRNA Promethazine results in decreased expression of MAD2L1 mRNA |
CTD |
PMID:26011634 PMID:26558467 |
|
NCBI chr 4:120,055,623...120,066,848
Ensembl chr 4:120,055,623...120,066,858
|
|
G |
MCL1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
EXP |
Promethazine results in decreased expression of MCL1 protein |
CTD |
PMID:31682805 |
|
NCBI chr 1:150,574,558...150,579,610
Ensembl chr 1:150,560,895...150,579,738
|
|
G |
MDM2 |
MDM2 proto-oncogene |
increases phosphorylation |
ISO |
Promethazine results in increased phosphorylation of MDM2 protein |
CTD |
PMID:26558467 |
|
NCBI chr12:68,808,172...68,850,686
Ensembl chr12:68,808,177...68,845,544
|
|
G |
MKI67 |
marker of proliferation Ki-67 |
increases expression affects expression |
ISO |
Promethazine results in increased expression of MKI67 protein Promethazine affects the expression of MKI67 protein |
CTD |
PMID:26011634 PMID:26558467 |
|
NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
Promethazine results in decreased expression of and results in decreased phosphorylation of MTOR protein |
CTD |
PMID:31682805 |
|
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Promethazine results in decreased expression of MYC mRNA |
CTD |
PMID:28903497 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
NCR3LG1 |
natural killer cell cytotoxicity receptor 3 ligand 1 |
increases expression |
EXP |
Promethazine results in increased expression of NCR3LG1 mRNA; Promethazine results in increased expression of NCR3LG1 protein |
CTD |
PMID:32060585 |
|
NCBI chr11:17,351,800...17,381,661
Ensembl chr11:17,351,800...17,377,341
|
|
G |
NGF |
nerve growth factor |
multiple interactions |
ISO |
Promethazine inhibits the reaction [Capsaicin results in increased expression of NGF protein] |
CTD |
PMID:15265675 |
|
NCBI chr 1:115,285,917...115,338,249
Ensembl chr 1:115,285,904...115,338,770
|
|
G |
PGAM1 |
phosphoglycerate mutase 1 |
increases expression |
ISO |
Promethazine results in increased expression of PGAM1 mRNA |
CTD |
PMID:28903497 |
|
NCBI chr10:97,426,191...97,433,444
Ensembl chr10:97,426,191...97,433,444
|
|
G |
PID1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
EXP |
Promethazine results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:229,023,973...229,271,287
Ensembl chr 2:228,850,526...229,271,287
|
|
G |
PKM |
pyruvate kinase M1/2 |
decreases expression |
ISO |
Promethazine results in decreased expression of PKM mRNA |
CTD |
PMID:28903497 |
|
NCBI chr15:72,199,029...72,231,591
Ensembl chr15:72,199,029...72,231,819
|
|
G |
PLK1 |
polo like kinase 1 |
decreases expression |
ISO |
Promethazine results in decreased expression of PLK1 mRNA |
CTD |
PMID:26011634 |
|
NCBI chr16:23,678,889...23,690,367
Ensembl chr16:23,677,656...23,690,367
|
|
G |
PMAIP1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
EXP |
Promethazine results in increased expression of PMAIP1 protein |
CTD |
PMID:31682805 |
|
NCBI chr18:59,899,996...59,904,305
Ensembl chr18:59,899,996...59,904,305
|
|
G |
RAD17 |
RAD17 checkpoint clamp loader component |
decreases expression |
ISO |
Promethazine results in decreased expression of RAD17 mRNA |
CTD |
PMID:26011634 |
|
NCBI chr 5:69,369,293...69,414,801
Ensembl chr 5:69,369,293...69,414,801
|
|
G |
RB1 |
RB transcriptional corepressor 1 |
decreases expression |
ISO |
Promethazine results in decreased expression of RB1 mRNA |
CTD |
PMID:26011634 |
|
NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436
|
|
G |
RBL2 |
RB transcriptional corepressor like 2 |
decreases expression |
ISO |
Promethazine results in decreased expression of RBL2 mRNA |
CTD |
PMID:26011634 PMID:26558467 |
|
NCBI chr16:53,434,471...53,491,648
Ensembl chr16:53,433,977...53,491,648
|
|
G |
SLC22A5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
Promethazine affects the reaction [SLC22A5 gene mutant form affects the transport of and affects the abundance of Pyrilamine]; Promethazine inhibits the reaction [SLC22A5 gene mutant form affects the transport of and affects the abundance of Pyrilamine] |
CTD |
PMID:19821448 |
|
NCBI chr 5:132,369,710...132,395,612
Ensembl chr 5:132,369,710...132,395,613
|
|
G |
SLC2A1 |
solute carrier family 2 member 1 |
decreases expression |
ISO |
Promethazine results in decreased expression of SLC2A1 mRNA |
CTD |
PMID:28903497 |
|
NCBI chr 1:42,925,353...42,958,868
Ensembl chr 1:42,925,353...42,958,893
|
|
G |
SLC2A2 |
solute carrier family 2 member 2 |
decreases expression |
ISO |
Promethazine results in decreased expression of SLC2A2 mRNA |
CTD |
PMID:28903497 |
|
NCBI chr 3:170,996,347...171,026,720
Ensembl chr 3:170,996,347...171,026,743
|
|
G |
SQSTM1 |
sequestosome 1 |
increases expression |
EXP |
Promethazine results in increased expression of SQSTM1 protein |
CTD |
PMID:31682805 |
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
G |
TMPRSS2 |
transmembrane serine protease 2 |
increases expression |
EXP |
Promethazine results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr21:41,464,305...41,508,158
Ensembl chr21:41,464,300...41,531,116
|
|
G |
TNF |
tumor necrosis factor |
increases expression |
ISO |
Promethazine results in increased expression of TNF protein |
CTD |
PMID:15265675 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFSF11 |
TNF superfamily member 11 |
decreases activity |
ISO |
Promethazine results in decreased activity of TNFSF11 |
CTD |
PMID:21869564 |
|
NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
|
|
G |
TOP2A |
DNA topoisomerase II alpha |
affects expression |
ISO |
Promethazine affects the expression of TOP2A protein |
CTD |
PMID:26011634 |
|
NCBI chr17:40,388,525...40,417,896
Ensembl chr17:40,388,525...40,417,896
|
|
G |
TP53 |
tumor protein p53 |
decreases expression |
ISO |
Promethazine results in decreased expression of TP53 mRNA |
CTD |
PMID:26011634 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
|
|
G |
UBD |
ubiquitin D |
decreases expression |
ISO |
Promethazine results in decreased expression of UBD protein |
CTD |
PMID:26011634 |
|
NCBI chr 6:29,555,515...29,559,732
Ensembl chr 6:29,555,515...29,559,732
|
|
G |
ULK1 |
unc-51 like autophagy activating kinase 1 |
increases expression |
EXP |
Promethazine results in increased expression of ULK1 protein |
CTD |
PMID:31682805 |
|
NCBI chr12:131,894,622...131,923,150
Ensembl chr12:131,894,622...131,923,150
|
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
increases expression |
EXP |
ropinirole results in increased expression of BCL2 protein |
CTD |
PMID:18242171 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
ropinirole inhibits the reaction [Rotenone results in increased cleavage of CASP3 protein] |
CTD |
PMID:18242171 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
EXP |
ropinirole inhibits the reaction [Rotenone results in increased cleavage of CASP9 protein] |
CTD |
PMID:18242171 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]] |
CTD |
PMID:25053526 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
DRD2 |
dopamine receptor D2 |
multiple interactions |
EXP |
ropinirole binds to and results in increased activity of DRD2 protein |
CTD |
PMID:18393062 |
|
NCBI chr11:113,409,605...113,475,398
Ensembl chr11:113,409,605...113,475,691
|
|
G |
DRD3 |
dopamine receptor D3 |
multiple interactions |
EXP |
ropinirole binds to and results in increased activity of DRD3 protein |
CTD |
PMID:18242171 PMID:18393062 |
|
NCBI chr 3:114,127,580...114,199,407
Ensembl chr 3:114,127,580...114,199,407
|
|
G |
DRD4 |
dopamine receptor D4 |
multiple interactions |
EXP |
ropinirole binds to and results in increased activity of DRD4 protein |
CTD |
PMID:18393062 |
|
NCBI chr11:637,269...640,706
Ensembl chr11:637,269...640,706
|
|
G |
EGR1 |
early growth response 1 |
decreases expression |
ISO |
ropinirole results in decreased expression of EGR1 mRNA |
CTD |
PMID:20452347 |
|
NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]] |
CTD |
PMID:25053526 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
ropinirole inhibits the reaction [Rotenone results in increased phosphorylation of JUN protein] |
CTD |
PMID:18242171 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
increases phosphorylation |
EXP |
ropinirole results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:18242171 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
increases phosphorylation |
EXP |
ropinirole results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:18242171 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]] |
CTD |
PMID:25053526 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; PTGER2 protein promotes the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; PTGER3 protein promotes the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein] |
CTD |
PMID:16784723 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
|
|
G |
CCL27 |
C-C motif chemokine ligand 27 |
multiple interactions |
EXP |
Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 mRNA]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; PTGER2 protein promotes the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; PTGER3 protein promotes the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 mRNA]; terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein] |
CTD |
PMID:16784723 |
|
NCBI chr 9:34,661,890...34,662,657
Ensembl chr 9:34,661,880...34,664,048
|
|
G |
CCL5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; PTGER2 protein promotes the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; PTGER3 protein promotes the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein] |
CTD |
PMID:16784723 PMID:23688403 |
|
NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
|
|
G |
CXCL10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
EXP |
Terbinafine inhibits the reaction [Biological Products results in increased expression of CXCL10 mRNA]; Terbinafine inhibits the reaction [Biological Products results in increased expression of CXCL10 protein] |
CTD |
PMID:24471457 |
|
NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
increases expression multiple interactions |
EXP |
terbinafine results in increased expression of CXCL8 protein terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; U 0126 inhibits the reaction [terbinafine results in increased expression of CXCL8 protein] |
CTD |
PMID:20816994 PMID:23688403 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
decreases activity |
EXP |
Terbinafine results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases activity |
EXP |
Terbinafine results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP2D6 |
cytochrome P450 family 2 subfamily D member 6 |
multiple interactions decreases activity |
EXP |
[terbinafine results in decreased activity of CYP2D6 protein] inhibits the reaction [CYP2D6 protein results in increased metabolism of Metoprolol] |
CTD |
PMID:24894748 |
|
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
increases response to substance increases expression |
EXP |
CYP3A4 protein results in increased susceptibility to terbinafine Terbinafine results in increased expression of CYP3A4 mRNA |
CTD |
PMID:21540358 PMID:36356836 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
GSTP1 |
glutathione S-transferase pi 1 |
multiple interactions |
EXP |
terbinafine inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
|
|
G |
HLA-A |
major histocompatibility complex, class I, A |
affects response to substance |
EXP |
HLA-A gene polymorphism affects the susceptibility to terbinafine |
CTD |
PMID:28043905 |
|
NCBI chr 6:29,942,532...29,945,870
Ensembl chr 6:29,941,260...29,949,572
|
|
G |
IL4 |
interleukin 4 |
multiple interactions decreases secretion decreases expression |
EXP |
1-Methyl-3-isobutylxanthine inhibits the reaction [Terbinafine results in decreased expression of IL4 mRNA]; 1-Methyl-3-isobutylxanthine inhibits the reaction [Terbinafine results in decreased secretion of IL4 protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; Bucladesine inhibits the reaction [Terbinafine results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Terbinafine results in decreased secretion of IL4 protein]; Colforsin inhibits the reaction [Terbinafine results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [Terbinafine results in decreased secretion of IL4 protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; Terbinafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone] terbinafine results in decreased secretion of IL4 protein terbinafine results in decreased expression of IL4 mRNA |
CTD |
PMID:11886533 PMID:15284827 PMID:23688403 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
IL5 |
interleukin 5 |
multiple interactions decreases expression decreases secretion |
EXP |
1-Methyl-3-isobutylxanthine inhibits the reaction [terbinafine results in decreased expression of IL5 mRNA]; 1-Methyl-3-isobutylxanthine inhibits the reaction [terbinafine results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL5 protein]; Colforsin inhibits the reaction [terbinafine results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [terbinafine results in decreased secretion of IL5 protein] |
CTD |
PMID:11886533 PMID:15284827 |
|
NCBI chr 5:132,541,445...132,556,815
Ensembl chr 5:132,541,445...132,556,838
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
EXP |
terbinafine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
increases phosphorylation |
EXP |
terbinafine results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:20816994 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
increases phosphorylation |
EXP |
terbinafine results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:20816994 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
decreases expression |
EXP |
terbinafine results in decreased expression of MMP2 mRNA |
CTD |
PMID:17172416 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
decreases expression |
EXP |
terbinafine results in decreased expression of MMP9 mRNA |
CTD |
PMID:17172416 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
affects response to substance |
EXP |
NFE2L2 protein affects the susceptibility to terbinafine |
CTD |
PMID:21540358 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions |
EXP |
terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein] |
CTD |
PMID:23688403 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749
|
|
G |
PTGER2 |
prostaglandin E receptor 2 |
multiple interactions increases response to substance |
EXP |
PTGER2 protein promotes the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; PTGER2 protein promotes the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; PTGER2 protein promotes the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]] PTGER2 protein results in increased susceptibility to terbinafine |
CTD |
PMID:16784723 |
|
NCBI chr14:52,314,312...52,328,598
Ensembl chr14:52,314,305...52,328,598
|
|
G |
PTGER3 |
prostaglandin E receptor 3 |
multiple interactions increases response to substance |
EXP |
PTGER3 protein promotes the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; PTGER3 protein promotes the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; PTGER3 protein promotes the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]] PTGER3 protein results in increased susceptibility to terbinafine |
CTD |
PMID:16784723 |
|
NCBI chr 1:70,852,358...71,047,816
Ensembl chr 1:70,852,353...71,047,816
|
|
G |
PTK2 |
protein tyrosine kinase 2 |
decreases phosphorylation |
EXP |
terbinafine results in decreased phosphorylation of PTK2 protein |
CTD |
PMID:17172416 |
|
NCBI chr 8:140,657,900...141,002,079
Ensembl chr 8:140,657,900...141,002,216
|
|
G |
PXN |
paxillin |
decreases phosphorylation |
EXP |
terbinafine results in decreased phosphorylation of PXN protein |
CTD |
PMID:17172416 |
|
NCBI chr12:120,210,447...120,265,730
Ensembl chr12:120,210,439...120,265,771
|
|
G |
RHOA |
ras homolog family member A |
increases localization |
EXP |
terbinafine results in increased localization of RHOA protein |
CTD |
PMID:17172416 |
|
NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,139...49,412,998
|
|
G |
RHOB |
ras homolog family member B |
decreases expression |
EXP |
terbinafine results in decreased expression of RHOB protein |
CTD |
PMID:17172416 |
|
NCBI chr 2:20,447,074...20,449,440
Ensembl chr 2:20,447,074...20,449,440
|
|
G |
RHOC |
ras homolog family member C |
increases localization |
EXP |
terbinafine results in increased localization of RHOC protein |
CTD |
PMID:17172416 |
|
NCBI chr 1:112,701,131...112,707,408
Ensembl chr 1:112,701,127...112,707,434
|
|
G |
STAT1 |
signal transducer and activator of transcription 1 |
multiple interactions |
EXP |
terbinafine inhibits the reaction [Biological Products results in increased phosphorylation of and results in increased activity of STAT1 protein] |
CTD |
PMID:24471457 |
|
NCBI chr 2:190,969,149...191,014,171
Ensembl chr 2:190,908,460...191,020,960
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions increases expression |
EXP |
Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 mRNA]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; PTGER2 protein promotes the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; PTGER2 protein promotes the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; PTGER2 protein promotes the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; PTGER3 protein promotes the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; PTGER3 protein promotes the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; PTGER3 protein promotes the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 mRNA]; Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein]; Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; Terbinafine inhibits the reaction [TNF protein results in increased secretion of Thromboxane B2]; Terbinafine promotes the reaction [TNF protein results in increased secretion of Dinoprostone]; U 0126 inhibits the reaction [Terbinafine results in increased expression of TNF protein] terbinafine results in increased expression of TNF protein |
CTD |
PMID:16784723 PMID:20816994 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TSLP |
thymic stromal lymphopoietin |
multiple interactions |
EXP |
4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein] |
CTD |
PMID:23688403 |
|
NCBI chr 5:111,070,062...111,078,026
Ensembl chr 5:111,070,062...111,078,026
|
|
|
G |
ABCB4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
EXP |
Tolterodine Tartrate results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435
|
|
G |
AHR |
aryl hydrocarbon receptor |
decreases expression |
EXP |
Tolterodine Tartrate results in decreased expression of AHR mRNA |
CTD |
PMID:24316275 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
CHRM2 |
cholinergic receptor muscarinic 2 |
multiple interactions |
EXP |
Tolterodine Tartrate binds to and results in decreased activity of CHRM2 protein |
CTD |
PMID:15140916 |
|
NCBI chr 7:136,868,652...137,020,213
Ensembl chr 7:136,868,652...137,020,255
|
|
G |
CHRM3 |
cholinergic receptor muscarinic 3 |
multiple interactions |
EXP |
Tolterodine Tartrate binds to and results in decreased activity of CHRM3 protein |
CTD |
PMID:15140916 |
|
NCBI chr 1:239,386,568...239,915,450
Ensembl chr 1:239,386,565...239,915,452
|
|
G |
CYP2D6 |
cytochrome P450 family 2 subfamily D member 6 |
increases metabolic processing affects metabolic processing multiple interactions |
EXP |
CYP2D6 protein results in increased metabolism of Tolterodine Tartrate CYP2D6 polymorphism affects the metabolism of Tolterodine Tartrate Fluoxetine inhibits the reaction [CYP2D6 protein results in increased metabolism of Tolterodine Tartrate] |
CTD |
PMID:10583026 PMID:28087463 |
|
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865
|
|
G |
IL1B |
interleukin 1 beta |
decreases expression |
EXP |
Tolterodine Tartrate results in decreased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
multiple interactions decreases expression |
EXP |
Tolterodine Tartrate inhibits the reaction [Dexamethasone results in increased expression of NR3C1 mRNA] Tolterodine Tartrate results in decreased expression of NR3C1 mRNA |
CTD |
PMID:24316275 |
|
NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
Tolterodine Tartrate inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
G |
SLPI |
secretory leukocyte peptidase inhibitor |
increases expression |
EXP |
Tolterodine Tartrate results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr20:45,252,239...45,254,564
Ensembl chr20:45,252,239...45,254,564
|
|
|
G |
AR |
androgen receptor |
decreases activity |
EXP |
Toremifene results in decreased activity of AR protein |
CTD |
PMID:15316697 |
|
NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619
|
|
G |
ESR1 |
estrogen receptor 1 |
multiple interactions |
ISO EXP |
Toremifene inhibits the reaction [Estradiol results in increased expression of ESR1 mRNA]; Toremifene inhibits the reaction [Estradiol results in increased expression of ESR1 protein] Toremifene binds to and results in decreased activity of ESR1 protein |
CTD |
PMID:12079510 PMID:25752796 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
ESR2 |
estrogen receptor 2 |
increases expression multiple interactions |
ISO EXP |
Toremifene results in increased expression of ESR2 mRNA Toremifene binds to and results in decreased activity of ESR2 protein |
CTD |
PMID:12079510 PMID:25752796 |
|
NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Toremifene inhibits the reaction [Estradiol results in increased expression of FOS mRNA]; Toremifene inhibits the reaction [Estradiol results in increased expression of FOS protein] |
CTD |
PMID:12079510 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
GSTA1 |
glutathione S-transferase alpha 1 |
decreases expression |
ISO |
Toremifene results in decreased expression of GSTA1 mRNA |
CTD |
PMID:9744569 |
|
NCBI chr 6:52,791,371...52,803,816
Ensembl chr 6:52,791,371...52,803,860
|
|
G |
IL1A |
interleukin 1 alpha |
multiple interactions |
ISO |
Toremifene inhibits the reaction [Estradiol results in increased expression of IL1A mRNA]; Toremifene inhibits the reaction [Estradiol results in increased expression of IL1A protein] |
CTD |
PMID:12079510 |
|
NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
EXP |
Toremifene results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
SERPINC1 |
serpin family C member 1 |
decreases expression |
EXP |
Toremifene results in decreased expression of SERPINC1 protein |
CTD |
PMID:14692654 |
|
NCBI chr 1:173,903,800...173,917,327
Ensembl chr 1:173,903,800...173,917,327
|
|
G |
SHBG |
sex hormone binding globulin |
increases expression affects binding |
EXP |
Toremifene results in increased expression of SHBG protein Toremifene binds to SHBG protein |
CTD |
PMID:14692654 PMID:25349334 |
|
NCBI chr17:7,614,064...7,633,372
Ensembl chr17:7,613,946...7,633,382
|
|
|
G |
PARK7 |
Parkinsonism associated deglycase |
decreases activity |
EXP |
Triallate results in decreased activity of PARK7 protein |
CTD |
PMID:36842454 |
|
NCBI chr 1:7,961,711...7,985,505
Ensembl chr 1:7,954,291...7,985,505
|
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
increases expression |
EXP |
triethanolamine results in increased expression of CXCL8 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
EXP |
[triethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA |
CTD |
PMID:29594315 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IL2 |
interleukin 2 |
multiple interactions |
EXP |
[triethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725
|
|
G |
KCNK18 |
potassium two pore domain channel subfamily K member 18 |
multiple interactions |
EXP |
triethanolamine inhibits the reaction [KCNK18 protein results in increased transport of Potassium] |
CTD |
PMID:12754259 |
|
NCBI chr10:117,197,489...117,210,299
Ensembl chr10:117,197,489...117,210,299
|
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
EXP |
Triflupromazine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
|
G |
FMO3 |
flavin containing dimethylaniline monoxygenase 3 |
affects metabolic processing increases metabolic processing multiple interactions increases oxidation |
EXP ISO |
FMO3 gene polymorphism affects the metabolism of trimethylamine FMO3 protein results in increased metabolism of trimethylamine trimethylamine inhibits the reaction [FMO3 protein results in increased oxidation of Methimazole] FMO3 protein results in increased oxidation of trimethylamine FMO3 protein results in increased oxidation of trimethylamine; FMO3 results in increased oxidation of trimethylamine |
CTD |
PMID:11414682 PMID:12214664 PMID:16601883 PMID:17050781 PMID:17142560 |
|
NCBI chr 1:171,090,905...171,117,819
Ensembl chr 1:171,090,901...171,117,819
|
|
G |
MTARC1 |
mitochondrial amidoxime reducing component 1 |
multiple interactions increases chemical synthesis |
EXP |
[MTARC1 protein results in increased reduction of trimethyloxamine] which results in increased chemical synthesis of trimethylamine MTARC1 protein results in increased chemical synthesis of trimethylamine |
CTD |
PMID:29856598 |
|
NCBI chr 1:220,786,913...220,819,659
Ensembl chr 1:220,786,352...220,819,659
|
|
G |
TAAR5 |
trace amine associated receptor 5 |
increases activity |
EXP |
trimethylamine results in increased activity of TAAR5 protein |
CTD |
PMID:23393561 |
|
NCBI chr 6:132,588,592...132,616,747
Ensembl chr 6:132,588,592...132,589,741
|
|
|
G |
ATF4 |
activating transcription factor 4 |
multiple interactions |
EXP |
trimethyloxamine inhibits the reaction [Tobacco Smoke Pollution analog results in increased expression of ATF4 protein] |
CTD |
PMID:25568320 |
|
NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,683
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
trimethyloxamine inhibits the reaction [Tobacco Smoke Pollution analog results in increased cleavage of CASP3 protein] |
CTD |
PMID:25568320 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions |
EXP |
trimethyloxamine inhibits the reaction [Tobacco Smoke Pollution analog results in increased expression of DDIT3 protein] |
CTD |
PMID:25568320 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
MBP |
myelin basic protein |
multiple interactions |
ISO |
trimethyloxamine promotes the reaction [MBP protein binds to MBP protein]; trimethyloxamine promotes the reaction [MBP protein mutant form binds to MBP protein mutant form] |
CTD |
PMID:12372316 |
|
NCBI chr18:76,978,833...77,133,708
Ensembl chr18:76,978,827...77,133,683
|
|
G |
MTARC1 |
mitochondrial amidoxime reducing component 1 |
increases reduction multiple interactions |
EXP |
MTARC1 protein results in increased reduction of trimethyloxamine [MTARC1 protein results in increased reduction of trimethyloxamine] which results in increased chemical synthesis of trimethylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine] |
CTD |
PMID:29856598 |
|
NCBI chr 1:220,786,913...220,819,659
Ensembl chr 1:220,786,352...220,819,659
|
|
G |
VAMP2 |
vesicle associated membrane protein 2 |
multiple interactions |
ISO |
trimethyloxamine promotes the reaction [rimabotulinumtoxinB results in increased cleavage of VAMP2 protein modified form] |
CTD |
PMID:27032463 |
|
NCBI chr17:8,159,147...8,162,948
Ensembl chr17:8,159,149...8,163,546
|
|